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Abstract 
Thyroid cancer represents the most common endocrine malignancy, and its incidence 
has increased significantly over the last few decades. Papillary thyroid carcinoma (PTC), 
the most frequent neoplasia originating from the thyroid epithelium, accounts for about 
80% of aU thyroid cancers. PTC is characterized by rearrangements of RET and NTRKl 
receptor tyrosine kinases, or by activating point mutations in the BRAF serine/threonine 
kinase or in the RAS genes. Even though the identification of PTC-associated oncogenes 
has provided a great contribution to the understanding of PTC pathogenesis, the molecular 
mechanisms underlying the development of this neoplasia, including the role of tumour 
suppressor genes, are still far from being completely elucidated. 
Recently, global gene expression analyses have provided new findings contributing 
to the dissection of thyroid tumour pathogenesis, through the identification of genes 
discriminating among different histotypes, candidates as new therapeutic targets and 
possible tumour suppressor genes. Despite the numerous gene expression studies, there are 
few data addressing the role of differentially expressed genes in the pathogenesis of 
thyroid tumours. A microarray gene expression profile previ~usly determined in our 
laboratory identified a list of genes differentially expressed in PTC versus normal thyroid; 
among those, we selected TIMP3, SlOOAll and CITEDl genes for which a role in the 
pathogenesis of PTC was also suggested by recently published gene and protein expression 
data. In this PhD project, we performed functional studies in order to assess the role of 
TIMP3, SlOOAll and CITEDl genes in thyroid carcinogenesis, with the aim of unveiling 
novel mechanisms and identifying novel therapeutic targets in thyroid tumours. 
TIMP3 (Tissue Inhibitor of Metalloproteinases-3) is a secreted protein able to inhibit 
extracellular matrix metalloproteinases. TIMP3 gene promoter has been found 
hypermethylated in thyroid cancer and its downregulation was associated with several 
aggressive tumour features. To investigate the role of TIMP3 in the pathogenesis of PTC 
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we used an integrated approach including analysis of several gene expression data sets and 
functional studies. TIMP3 was found to be downregulated in a consistent fraction in PTCs, 
with respect to normal thyroid. Restoration of TIMP3 in the PTC-derived NIMI cell line 
had no effect on growth rate; however, it reduced migration, invasion and anchorage 
independent growth. The striking effect was observed in vivo, as TIMP3 reduced the 
tumourigenicity ofNIMI cells by repressing angiogenesis and macrophage infiltration. All 
these observations suggest a tumour suppressor role in thyroid carcinogenesis. 
S100All (calgizzarin) is a member of the S100 Ca2+-binding protein family, which 
includes at least 20 proteins. Its role in tumour is not well known, and it appears to have 
distinct functions in different tumour types. Our microarray analysis showed that S I OOA 11 
is overexpressed in PTC compared to normal thyroid. In order to study the role of 
S 1 OOA II in thyroid carcinogenesis, we performed functional in vitro and in vivo analysis. 
Analysis of cellular localization in PTC-derived K 1 cell line, revealed that S I OOA 11 was 
mainly cytoplasmic and was able to trans locate into the nucleus after Ca2+ and TGF-p 
stimulation. We also found that this translocation did not increase p21 level, a negative 
regulator of cell growth. Moreover, we found that S 100A 11 did not alter the activation 
level of the EGFIEGFR pathway. We then investigated the effect ofS100All silencing on 
tumourigenic properties of K 1 cells. We found that S 100A 11 silencing did not affect cell 
proliferation, but it exerted a role on the anchorage-independent growth. Analysis of mouse 
tumour xenografts showed that S 1 OOA II was not involved in the in vivo tumourigenicity 
of KI cells. Concomitantly, we assessed the effect of SlOOAll gene modulation on the 
transforming potential of PTC-associated oncogenes. Cotransfection experiments in 
NIH3T3 cells, which represent a useful model for studying in vitro oncogene activity, 
showed that SlOOAll gene was able to enhance the transforming capability of the PTC-
associated TRK-T3 oncogene. Stable NIH3T3 foci expressing TRK-T3 and S100All 
concomitantly to TRK -T3 were produced. Functional studies showed that S I OOA 11 was 
not involved in the regulation of cell proliferation, whereas it was able to promote 
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invasion, anchorage independent growth and in vivo tumourigenicity of these transformed 
foci. 
CITED! (CBP/p300-Interacting Transactivators with glutamic acid (E) and aspartic 
acid (D)-rich C-terminal domain !) is part of a family of transcriptional cofactors that 
regulates diverse CBP/p300 transcriptional responses. In different microarray studies· 
CITED 1 was found overexpressed in PTC. It was also proposed as a highly sensitive and 
specific diagnostic marker, useful in differentiating PTC from benign and malignant 
thyroid tumours. For this reason, we are interested in the functional role of CITED! in this 
histotype. Preliminary experiments involved the analysis of CITED 1 expression in a 
collection of PTC-derived cell lines and the construction of CITED I cDNA expression 
vectors. Further analysis will involve the investigation of its effect on transforming activity 
of PTC-associated oncogenes and the effect of its gene silencing on the phenotype of a 
PTC-derived cellular model. 
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1: Thyroid cancer 
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J.lntroduction 
1.1. Thyroid cancer 
Thyroid cancer (TC) is the most common malignancy of endocrine organs (Parkin et 
aI., 2005); it represents 1.7% of total estimated new cancer cases, and its incidence has 
been increasing and has almost tripled over the past 30 years in the US and other 
industrialized countries (ColoMa et aI., 2007). An high incidence of TC has also been 
reported in Italy, where it represents the second and the fifth most common cancer among 
women and men (below age 45 years), respectively. In particular, referring to 2001-2005 
time period, the incidence rate was 18 per 100 000 women and 6 per 100 000 men, twofold 
higher than 1991-1995(Dal et aI., 2011). 
TCs could derive from epithelial follicular or parafollicular cells. The first, which are 
by far the most common, comprise papillary thyroid carcinoma (PTC) (about 80% of 
cases), follicular thyroid carcinoma (FTC) (10%), poorly differentiated thyroid carcinoma 
(PDTC) (4-6%), Hiirthle cell (oxyphil) carcinoma (HCC) (3%) and anaplastic thyroid 
carcinoma (ATC) (2-5%). The second, originating from parafollicular cells, are known as 
medullary thyroid carcinomas (MTC) (5-10%). Papillary and follicular carcinoma and their 
variants are also defined differentiated thyroid cancers (DTCs). Follicular adenoma (FA) is 
a benign tumour that may represent a precursor for some follicular carcinomas. Less 
differentiated thyroid cancers, PDTC and ATC, could arise de-novo from thyrocyte or from 
de-differentiation of the differentiated papillary and follicular tumours (Figure 1.1) 
The above reported increase in TC incidence is, in general, associated with increased 
access to high-resolution imaging and increased use of fine-needle aspiration (FNA) 
biopsy of small nodules, as well as progressively decreasing stringency of 
histopathological criteria applied to the diagnosis of papillary cancer over the past 10-15 
years. No significant change has been observed in the incidence of the less common 
histological types: follicular, medullary and anaplastic carcinoma (Davies and Welch, 
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2006). However, in addition to the improvement in diagnostic tools, other factors could 
contribute to the increase of this incidence such as exposure to radiation during medical 
procedures (Mettler, Jf. et al., 2009), obesity (Kit ahara et al., 2011) as well as the increase 
in pathological detection of incidental papillary thyroid cancer (Grodski et al. , 2008). 
At variance with the incidence rate, mortality rate is stable or decreasing both in the 
United States (Davies and Welch, 2006) and in Europe (La et al., 2010). Differentiate TCs 
and MTCs display a very good lO-year relative survival rate, ranging from 90% (Hundahl 
et al., 1998) to 74% , respectively; while it is dramatically short (less than 1 year) in the 
case of ATC which represents one of the most aggressive malignant tumours in humans. In 
at least the 20% of patients with differentiated TC, metastatic disease can occur (Durante et 
al. , 2006), thus the 10-year survival rate decreases to 42% for metastatic differentiated TC 
patients (Haq and Harmer, 2005)and to 24% in the case of MTC. The prolonged survival 
of metastatic patients is a peculiar characteristic that distinguishes these particular cancers 
from the large majority of advanced malignant tumours. 
BenIQ10 neClpl SIn W l!-differentl ted Poorly differentiated 
cancer cancer 
Anaplastic 
carcinoma 
Undfftrentlatedl 
cancer 
Figure 1.1 Scheme of development of follicular cell-derived thyroid cancer The most frequent type of 
thyroid cancers, papillary carcinoma, originates fro m thyroid follicular cell. Follicular carcinomas can 
develop either from pre-existing benign follicular adenomas or directly bypassing the stage of adenoma. 
Poorly di fferentiated and anaplastic carcinomas can arise de novo or from pre-existing well-differentiated 
papillary or follicular carcinomas (from (Nikiforov and Nikiforova, 2011) 
1.2 Histological classification of follicular cell-derived thyroid tumours 
1.2.1 Papillary thyroid carcinoma (PTC) 
PTC, accounting for 80% of thyroid malignancies, affects females more frequently 
than males (4:1) and the mean age at diagnosis is 40 years (Sheils, 2005). Although PTC 
usually grows slowly and is clinically indolent, rare aggressive forms with local invasion 
or distant metastasis can occur. Lymphatic vessels are the main pathway of diffusion of 
PTC and cervical lymph node metastases are very frequent at the time of diagnosis. Distant 
metastasis is uncommon, but when present, is most commonly found in the lung and bone. 
"Classical" PTC is microscopically characterized by a papillary architecture and a 
population of follicular cells with "ground glass" nuclei and irregularities of the nuclear 
. contours, including grooves and nuclear pseudoinclusions. Psammoma bodies, which 
represent a typical PTC feature, are found in at least 50% of cases. They are relatively 
specific for papillary carcinoma and are thought to represent necrosis of tumour cells or 
tips of papillae. PTC cells express cytokeratins, thyroglobulin and thyroid transcription 
factor-l (TTF -1). 
A series of histological variants (15-20% of PTC) have been described that, for the 
most part, are based upon morphologic pattern. Papillary thyroid microcarcinoma (PTMC) 
is generally applied to tumours measuring lcm or less in diameter. It is the most commonly 
occurring type of PTC and its prognosis is generally excellent, and while it may be 
associated with cervical metastases, distant metastases are rare. The other most common 
histological PTC variants are follicular, oncocytic, clear cell, diffuse sclerosing, tall cell, 
columnar cell, solid, and cribriform. Although the prognosis is similar to classic PTC for 
most of these variants, some histotypes, such as tall cell, columnar cell and solid variant, 
have a worse outcome. The tall cell variant, in particular, has a poorer prognosis than other 
variants. Extra-thyroid extension is common and there is a greater incidence of vascular 
invasion. The papillae are well formed and covered by cells that are at least twice as tall as 
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they are wide. Immunohistochemistry has shown that c-Met expression is significantly 
associated with tall cell histology, thus suggesting a role for its use in the early 
identification of patients with tall cell variant thyroid disease (Nardone et aI., 2003). 
1.2.2 Follicular thyroid carcinoma (FTC) 
FTC, accounting for approximately 10% of all thyroid malignancy, is more common 
in women over 50 years of age. It is rare in children, and more prevalent in iodine-deficient 
areas. It is characterized by follicular cell differentiation but lacking the above described 
nuclear features of PTC. Haematogenous diffusion is more frequent than lymphatic spread. 
At variance with PTC, cervical lymph node involvement is less common at diagnosis , 
while 20% of cases can present distant metastasis, mainly in the lung and bone sites. The 
risk of metastatic spread is higher in those cases with widespread vascular invasion. FTC 
cells commonly express thyroglobulin, TTF-I, and low molecular weight cytokeratin. 
Hiirthle cell carcinoma (HCC) or "oncocytic or oxyphilic" variant is a rare variant of 
FTC or (less commonly) of PTC. HCC are defined as tumours composed of 75% or more 
Hilrthle cells and exhibiting complete capsular- and/or vascular- invasion. The tumour cells 
are typically characterized by an abundant granular, eosinophilic cytoplasm derived from 
the presence of a large number of mitochondria. HCCs differ from the conventional FTCs 
in biological and clinical behaviour, for example involving cervical nodes (30% of cases) 
and developing distant metastasis. For these reasons, some groups have classified them as 
as a distinct pathologic entity. 
Fifty percent of patients with widely invasive FTC die of their disease, whereas 
patients with minimally invasive FTC have an expectancy of survival similar to that of a 
normal population when matched for age and sex. 
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1.2.3 Poorly differentiated thyroid carcinoma (PDTC) 
PDTC is a rare and controversial entity (4-6% of TC), more commonly seen in 
women and patients over 50 years of age. These tumours appeared to confer a survival rate 
between that of differentiated thyroid cancers and ATC. The aetiology of PDTC is 
unknown. It can be the terminal stage of the de-differentiation process of PTC or FTC or 
can arises de novo (Pilotti et aI., 1997). On presentation, it can appear as a unique thyroid 
mass, often rapidly growing, with or without cervical node involvement. Distant 
metastases can also be present. Three different histological patterns, insular, trabecular and 
solid, have been described (Sobrinho-Simoes et aI., 2002). The infiltrative pattern of 
growth, necrosis, vascular invasion, along with the identification of the patterns described 
above should allow PDTC to be recognized. Expression of TTF-l and thyroglobulin is 
common, although staining may be patchy and restricted to isolated tumour cells or poorly 
developed follicles. 
1.2.4 Anaplastic thyroid carcinoma (ATC) 
ATC is a relatively rare thyroid tumour (2-5% of TCs) with a mean age of 65 years at 
presentation. Like PDTC, it can be derived from DTC or can arise de novo. ATC is 
composed of undifferentiated cells that show the immunohistochemical features of 
epithelial differentiation. At the clinical level, ATC is characterized by a large thyroid 
mass, rapidly growing and infiltrating the surrounding tissues and muscles. The clinical 
course of the disease can be so rapid that surgical procedures, such as tracheotomy and 
gastrostomy, performed as supportive care, are often useless. 
Microscopically, there are two main patterns. 1) Squamoid: these tumours are 
undifferentiated but, nonetheless, epithelial with occasional focal keratinisation; 2) The 
second pattern is comprised of large, pleomorphic giant cells resembling osteocIasts and 
spindle cells resembling sarcoma. Cytokeratins are frequently expressed while 
thyroglobulin and TTF -1 tend to be absent in the tumour cells. Overexpression of cell 
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cycle regulatory protein such as cyclin Dl, along with decreased expression of p27 and 
mutations of p53 leading to increased staining patterns are frequent in undifferentiated 
carcinoma (Fagin et aI., 1993; Pickett et aI., 2005). 
1.3 Genetic alterations in TC 
IC represents a type of neoplasia in which critical genes are frequently mutated via 
two distinct molecular mechanisms: point mutation or chromosomal rearrangement. A 
growing body of evidence suggests that these two distinct mutational mechanisms are 
associated with specific aetiologic factors involved in thyroid carcinogenesis. In addition to 
these genetic variations, IC initiation and progression could also occur through 
accumulations of epigenetic alterations, including alterations in gene expression patterns, 
the presence of microRNAs, aberrant gene methylation and the dysregulation of oncogenic 
proteins. An outline summary of genetic abnormalities associated with IC is shown in 
Table 1.1 and in Figure 1.2. These will be discussed in more detail below. 
1.3.1 v-Rafmurine sarcoma viral oncogene homolog B1 (BRAF) oncogene 
BRAF is a serine-threonine kinase that is translocated to the cell membrane after 
being bound and activated by RAS. This results in the phosphorylation and activation of 
mitogen-activatd protein kinase (MAPK) and other downstream targets of the MAPK 
signalling pathway. BRAF is the commonest human oncogene, mutated in 7-9% of all 
malignant solid tumours, with the highest prevalence (60%) in melanoma. After 
melanoma, PTC is the second human malignancy where BRAF mutations are especially 
frequent, being found in 29-87% (with a mean frequency of about 45%) of cases (Kim et 
aI., 2006). 
Although more than 40 mutations have been identified in the BRAF gene, the most 
significant hot spot for mutation, accounting for over 90% of all BRAF mutations, is a 
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thymidine to adenine transversion at nucleotide 1799 (TI799A) in ex on 15. This 
substitution leads to a valine to glutamate transversion at residue 600 near the catalytic 
centre of the protein (BRAFV600E) and is believed to produce a constitutively active 
kinase by disrupting hydrophobic interactions between residues in the ATP binding site 
(Wan et aI., 2004). This is the most frequent mutation found in PTC, highly prevalent in 
PTC with classical histology and in tall cell variant. Other rare mechanisms, alternative to 
the BRAFV600E mutation, contribute to BRAF oncogenic mutation in PTC. The 
Lys601 Glu point mutation and small in- frame-insertions or deletions surrounding codon 
600 have been reported (Hou et aI., 2007b; Trovisco et aI., 2004). The presence of an 
AKAP91BRAF rearrangement has also been described (Ciampi et aI., 2005). This 
rearrangement is a paracentric inversion of chromosome 7q that leads to the fusion 
between the portion of the BRAF gene that encodes the protein kinase domain and the 
AKAP9 gene. 
BRAF mutations are also present in PTMC, suggesting that they can occur early in 
tumour development (Adeniran et aI., 2006). Transgenic mice with thyroid-specific 
expression of BRAFV600E developed PTC closely recapitulating those seen in human 
tumours (Knauf et aI., 2005) and thus supporting the role of BRAF oncogene in tumour 
initiation and differentiation, as well as its correlation with tumour characteristics. BRAF 
mutations are not found exclusively in PTC, but also in ATC (20-26% of cases), 
supporting the notion that the latter may originate from PTC de-differentiation. (Nikiforova 
et aI., 2003a; Smallridge et aI., 2009). 
Based on molecular results, numerous studies have investigated the clinical 
significance of BRAF mutation in PTC. The general tendency of the studies is to show an 
association of this mutation with factors related to poor prognosis, in particular advanced 
tumour stage on presentation, tumour recurrence and metastasis. BRAFV600E has been 
proposed as an independent predictor of tumour recurrence (Xing, 2007a). PTC carrying 
the BRAFV600E mutation exhibit decreased expression of genes involved in thyroid 
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hormone biosynthesis, including the sodium iodide symporter (NIS), the decreased ability 
to trap radioiodine and consequent treatment failure (Riesco-Eizaguirre et aI., 2006; Xing 
et aI., 2005). 
1.3.2 REarranged during Transfection (RET) oncogenes 
RET is a transmembrane thyrosine kinase receptor, known to be the signalling 
component of a multimolecular complex that includes the glial cell line-derived 
neurothrophic factor (GDNF) a co-receptor u (GFRu 1-4). Upon interaction with one of the 
four GFR u co-receptors, RET binds with high affinity to the GDNF family peptides 
including GDNF, neurturin, persephin and artemin (Airaksinen and Saarma, 2002). RET 
proto-oncogene, located at chromosome 1 Oq 11.2, is essential for development of the 
sympathetic, parasympathetic and enteric neurons, kidney and male germ cells (Arighi et 
aI., 2005). The germ line loss of function mutations of RET cause impaired formation of 
the enteric nervous system and congenital aganglionosis of the colon (Hirschsprung's 
disease), while germ line activating point mutations are causally related to the hereditary 
forms of MTC, Multiple endocrine neoplasia type 2A and 2B (MEN2A, MEN2B) and 
Familial MTC ( FMTC) (Arighi et aI., 2005). 
Oncogenic rearrangements of RET, producing the RETIPTCs, were the first genetic 
lesion identified in PTC. RETIPTCs oncogenes, present in a significant fraction of PTC 
(20-30%), are chimeric oncoproteins containing the intracellular domain (including TK 
and C terminal tail) of RET fused in frame to the 5' end of different donor genes. The 
donor genes are responsible for: i ) the expression of chimeric RET/PTC oncogenes in 
thyrocytes; and, ii) constitutive, ligand-independent activation of RETIPTC oncoproteins 
leading to chronic stimulation of MAPK signalling which triggers tumourigenesis (Jhiang 
et aI., 1996a; Santoro et aI., 1992). 
At least 12 different genes that are involved in the generation of RET/PTC oncogenes 
have been identified (Greco et aI., 2009). Two of the most common rearrangement types 
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are RET/PTC1 and RET/PTC3, in which RET is fused to either CCDC6 (also known as H4) 
or NCOA4 (also known as ELE1 or RFG), respectively (Grieco et aI., 1990; Santoro et aI., 
1994). Both of these rearrangements are paracentric intrachromosomal inversions, as all 
the fusion partners reside on the long arm of chromosome 10. By contrast, RET/PTC2 and 
nine more recently discovered types of RET/PTC rearrangements are all interchromosomal 
(Bongarzone et aI., 1993; Ciampi et aI., 2007; Klugbauer et aI., 1998; Klugbauer et aI., 
2000). The frequent occurrence of RET/PTC rearrangements in papillary microcarcinoma 
suggests that such rearrangements are an early event in thyroid carcinogenesis. Other 
reasons to support this are: 1) RETIPTC expression is present in microscopic and occult 
PTCs (Viglietto et aI., 1995); 2) RETIPTCI expression is sufficient to cause PTC-
diagnostic alteration in the nuclear envelope and chromatin structure of human normal 
primary thyrocytes (Fischer et aI., 1998); 3) RETIPTCs induce morphological 
transformation of PC-C 13 rat thyroid epithelial cells (Jhiang et aI., 1996b). RET/PTC 
rearrangements are listed in Table 1.1. 
RET IPTC is found on average in approximately 20% of adult sporadic papillary 
carcinomas, although its prevalence is highly variable between different observations due 
to either geographic variability or different sensitivity of the detection. RET/PTC is 
typically more common in tumours from patients with a history of radiation exposure (50-
80%) and its prevalence is higher in young patients (40-70%) (Collins et aI., 2002; Fenton 
et aI., 2000). Radiation exposure after the Chernobyl accident particularly increased the 
frequency of prc carrying RET/PTe3 or BRAF/AKAP9 rearrangement (Ciampi et aI., 
2005; Smida et aI., 1999). In particular, in post-Chernobyl prcs the presence of 
RET/PTe3 is associated-with the solid/follicular variant, while the less frequent RET/PTe] 
rearrangement is associated with the classical and diffuse sclerosing variant (Nikiforov, 
2006). The role of radiation exposure in the generation of RET/PTC is also supported by 
the experimental induction of RET/PTC by irradiating human cultured thyroid cells 
(Caudill et aI., 2005; Ito et aI., 1993). 
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1.3.3 TRK oncogenes 
The neurotrophin tyrosine kinase receptor, type 1 (NTRK1) gene (also known as 
TRKA) located at chromosome I, encodes the high affinity receptor for neural growth 
factor (NGF). It regulates growth, differentiation and apoptosis in the peripheral and 
central nervous system, and stimulates the proliferation of a number of non-neural cell 
types such as lymphocytes, keratinocytes and prostate cells. 
In PTC NTRK1 gene undergoes oncogenic rearrangements similar to those described 
above for RET. Several TRK oncogenes differing in the activating regions have been 
isolated from PTC. The most frequent oncogene is TRK (Butti et aI., 1995) and is identical 
to that first isolated from colon carcinoma containing sequences from the non-muscle 
Tropomyosin gene (TPM3) on chromosome Iq22-23. TRK-T1 and TRK-T2 oncogenes both 
derive from a rearrangement between the NTRK1 and Translocated Promoter Region 
(l'PR) genes on chromosome lq25, but each one displays a different structure. TRK-T3 is 
activated by TRK Fused Gene (TFG) , a novel gene on chromosome 3qll-12, first 
identified in this rearranged version (Greco et aI., 2004). The TRK oncogenes are listed in 
Table 1.1. 
Somatic rearrangements of the NTRK1 gene in PTC are less common than those 
involving the RET gene and their frequency does not exceed 12%. The association of 
NTRKI rearrangements with radiation is not clearly defined since their frequency in PTC 
associated with therapeutic or accidental (Chernobyl) radiations was similar to that of 
sporadic tumours (Bounacer et ai., 2000; Rabes et ai., 2000). 
Analysis of any correlation bctween NTRKI rearrangcments with clinical and 
pathological features did not produce unequivocal data. This is related not only to the 
limited number of PTCs carrying TRK oncogenes so far identified, but also to the fact that 
in the majority of studies the genotyping of PTCs is restricted to RET rearrangements and 
ERAF mutation analyses. 
18 
Experimental evidence suggests that TRK oncogenes exert a direct role and represent 
an early event in the process of thyroid carcinogenesis. Transgenic mice carrying the TRK-
Tl oncogene under the control of the thyroglobulin promoter (Tg-TRK-Tl mice) develop 
thyroid hyperplasia and PTC (Russell et aI., 2000). Crossing of Tg-TRK-Tl mice with 
p27kipl-deficient mice increased the penetrance of TC and shorte~ed the latency period of 
tumour incidence, indicating that TRK-T 1 gene requires cooperation with oncosuppressor 
genes to transform thyroid epithelium (Fedele et aI., 2009). 
Table 1.1 Fusion oncogenes in thyroid tumours 
ONCOGENE DONOR GENE CHROMOSOME 
LOCATION 
RETIPTCI CCDC6 (coiled-coil domani containing 6)1H41DIOSI70 IOq21 
. RETIPTC2 PRKARIA (protein kinase; cCAMP-dependent, regulatory, type I, 17q23 
alpha) 
RETIPTC3 NCOA4 (Nuclear coactivator 4)IRFGIELEIIARA70 IOql1.2 
RETIPTC4 NCOA4 (Nuclear coactivator 4)1RFGIELEIIARA70 IOql1.2 
RETIPTC5 GOLGAS (golgin subfamily a, 5)IRFG5IRET-ll 14q 
RETIPTC6 TRIM24 (triparlile motif-containing 24)ITIFIITIFIA 7q32-34 
RETIPTC7 TRlM33 (tripartite motif-containing 33)1RFG7ITIFIG Ipl3 
RETIPTCB KTNI (Kinectin I)ICGI 14q22.1 
RETIPTC9 RFG9 ISq21-22 
ELKS-RET ELKS! RAB61P21KIAAJ081 12p13.3 
PCMI-RET PCMI (pericentriolar material I) 8p21-22 
RFP-RET TRlM27 (tripartite motij-containing 27)1RFP 6p21 
HOOK3·RET HOOK3 (Homo sapiens hook homolog 3)IJlK3 Spl1.21 
TRK TPM3 (Tropomyosin3) Iq22-q23 
TRK·TI; TRK-T2 TPR (Translocated promoter region) Iq25 
TRK-T3 TFG (Trk1used gene) 3qll-ql2 
AKAP9-BRAF AKAP9 (A-kinase anchor protein 9) 7q21-q22 
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1.3.4 RAS mutations 
The human HRAS, KRAS and NRAS genes encode highly related G-proteins that 
reside in the inner surface of the cell membrane and transmit signals arising from cell-
membrane receptor tyrosine kinases and G-protein-coupled receptors along the MAPK, 
phosphatidylinositol3-kinase/protein kinase B (PI3K1AKT) and other signalling pathways. 
Activating point mutations typically affect the codons 12, 13 and 61 of the RAS 
genes. In thyroid cancer, NRAS codon 61 and HRAS codon 61 mutations are most 
common. RAS mutations are found in a variety of thyroid tumours, including 10-20% of 
PTC, 40-50% of FTC and 10-40% of poorly differentiated and ATCs (Esapa et aI., 1999; 
Ezzat et aI., 1996; Motoi et aI., 2000; Namba et aI., 1990; Suarez et aI., 1990). Among 
PTCs, tumours with RAS mutations forming neoplastic follicles, and not papillary 
structures, are diagnosed as the follicular variant of PTC. RAS mutations are also found in 
20-40% of benign follicular adenomas, suggesting that the latter may serve as a precursor 
for RAS-positive FTC and the follicular variant of PTC (Adeniran et aI., 2006; Zhu et aI., 
2003). Furthermore, RAS mutations may predispose well-differentiated cancers to de-
differentiation and anaplastic transformation (Garcia-Rostan et aI., 2003). RAS activation 
by itself is not sufficient to induce malignant growth but may predispose cells to acquire 
further genetic or epigenetic alterations that lead to a fully transformed phenotype. This is 
consistent with the observation that RAS mutations may affect chromosomal stability in 
vitro (Saavedra et al., 2000). 
A significant correlation between RAS mutations, metastases and poor prognosis has 
been found in patients (Garcia-Rostan et aI., 2003). As RAS mutations are a marker for 
aggressive TC behaviour and poor outcome, surgical resection of RAS-positive adenomas 
might be proposed to prevent progression to carcinoma (Nikiforova and Nikiforov, 2008). 
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1.3.5 Paired box gene 81 peroxisome proliJerator-activated receptor (PAX8IPPARyJ 
rearrangement 
The PAX81PPARy rearrangement results from the translocation (t(2;3)(q13;p2S) 
between the P AX8 gene, which encodes a paired domain transcriptional factor, and the 
PPARygene, expressed at low level in normal thyroid with unknown functions (Nikiforova 
and Nikiforov, 2008). The resulting fusion protein encodes a nearly full length PPARy, the 
expression of which is under the transcriptional regulation of the P AX8 promoter (Kroll et 
al., 2000). The functional consequences of this rearrangement are not yet fully understood. 
PAX81PPARy is a prototypic alteration found in FTC, where it occurs with a 
frequency of 30-35%. This rearrangement has also been found in some FA (2-13%) and in 
a small proportion (1-S%) of the follicular variant ofPTC (Nikiforova et al., 2003b) 
A novel CREB3L21PPARy fusion generated by t(3;7)(q34;p2S) rearrangement has 
been detected in <3% of FTC (Lui et al., 2008). It has been reported that both of the 
PAX8IPPARy and CREB3L2/PPARy fusion proteins have oncogenic properties in normal 
human thyroid cells, but their mechanisms of action are still unclear (Lui et aI., 200S). 
With respect to the mechanisms activated by PAX8IPPARy, both gain and loss of 
function activities have been suggested. Specifically, deregulation of the normal functions 
of P AX8 and PPARy and the unique transcriptional activities of the fusion oncoprotein 
have been reported (Nikiforova and Nikiforov, 2008). It has been proposed that 
PAX8lPPARy-stimulated growth could depend at least in part on loss of PPARy functions 
caused by the inhibition of wild-type protein (Nikiforova and Nikiforov, 2008). This is 
consistent with the concept that PP ARy down-regulation or inhibition may be a key event 
in thyroid carcinogenesis (Placzkowski et aI., 2008), as also suggested by the evidence that 
P P ARy is downregulated in translocation-negative papillary or follicular thyroid tumours. 
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The PAX81PPARyrearrangement and RASpoint mutations rarely overlap in the same 
tumour suggesting that they represent distinct pathogenetic pathways in the development 
of FTC. In keeping with this, analyses of gene expression profiles of PAX81PPARypositive 
FTCs have confirmed that these carcinomas have a distinct transcriptional signature 
(Nikiforova and Nikiforov, 2008). Although based on its presence in both benign and 
malignant lesions, the diagnostic and preoperative value of P PAR y rearrangement is 
subject to debate, it is plausible that benign nodules carrying the translocation may be 
considered at risk for progression. 
1.3.6 PI3K1AKTpathway mutations 
The PI3K1AKT pathway exerts an important role in many cellular events, including 
growth, proliferation and apoptosis. This pathway is particularly activated in many 
tumours, including thyroid tumours (Ringel et aI., 2001; Vasko et aI., 2004). In fact, FTC 
are characterized by high levels of AKT activation in comparison with normal tissue and 
PTC (Ringel et aI., 2001; Vasko et aI., 2004). The mechanisms underlying this activation 
could include mutations or amplification of the PIK3CA gene, encoding the catalytic 
subunit of PI3K (Wang et aI., 2007), decreased expression or inactivation of its negative 
regulator phosphatase and tensin homologue (PTEN) (Paes and Ringel, 2008) and 
activation by constitutively active RAS oncogenes (Vasko et aI., 2004). PIK3CA mutation, 
however, is not a common mechanism in the activation of this pathway in TC, but the 
amplification of this gene is more frequent. In PTC, the presence of rare mutations and 
more frequent amplification are detected in 15-53% of tumours (Abubaker et aI., 2008; 
1I0u et aI., 2007a). Although PIK3CA amplification is also observed in FTC and even in 
FA (Hou et aI., 2007a; Wu et aI., 2005) it is most frequently observed in anaplastic TC. 
The occurrence of PIK3CA amplification and RAS mutation, even in follicular adenomas, 
has suggested that the PI3K1AKT pathway plays a role at an early stage of thyroid 
tumourigenesis. Of note, the mutual exclusivity of these genetic alterations has not been 
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observed in ATC, implying a role of the PI3KJAKT pathway in progression of FTC to 
ATC (Hou et aI., 2007a). 
PTEN is a dual-specific phosphatase, a negative regulator of the PI3KJAKT pathway 
by dephosphorylating phosphatylinositol-3,4,5-triphosphate (PIP3), another protein that 
can also influence the MAPK pathway. PTEN acts as a tumour suppressor gene, its 
germline loss of function mutation predisposes to multiple tumours including FTC (Yeh et 
aI., 1999). Single cases of a loss of function somatic mutation of PTEN have been 
described in FTC (7%), in ATC (12-50%) and rarely in PTC (2%) (Frisk et aI., 2002; 
Garcia-Rostan et aI., 2005; Hou et aI., 2007a; Smallridge et aI., 2009). A novel 
rearrangement involving in PTEN and the H4 gene has been described in PTC (Puxeddu et 
aI.,2005). 
1.3.7 Tumour protein 53 (IP53) mutation 
TP53 encodes the multifunctional nuclear protein p53 that is important for cell cycle 
arrest at DNA damage, senescence or apoptosis and it is one of the most commonly known 
tumour suppressor genes. Contrary to what is seen in many other cancers, TP 53 loss of 
function mutations occur late in thyroid tumourigenesis and are practically absent in 
differentiated TC (0-9%), while the prevalence reaches 17-38% in poorly differentiated 
and 55-88% in anaplastic cancers (Fagin and Mitsiades, 2008; Smallridge et aI., 2009). 
Such mutations are associated with cell proliferation and loss of differentiation, as 
restoration of p53 function in A TC cell lines causes a reduction in the proliferation rate of 
the tumour cells, their re-expression of thyroid specific genes and responsiveness to TSH 
stimulation (Fagin et aI., 1996; Moretti et aI., 1997). 
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1.3.8 Other alterations in TC 
Loss of heterozygosity (LOH) 
TCs accumulate a number of alterations at the genomic level. Chromosome 
instability has been identified in follicular adenomas and carcinomas, which are frequently 
aneuploid with a high prevalence of LOH. This is in contrast to the diploid or near-diploid 
. 
content of most papillary carcinomas, which generally show less frequent LOH (Castro et 
aI., 2005; Sobrinho-Simoes et aI., 2005). 
The most frequently deleted chromosomal regions in FC and FA are on chromosome 
2p, 3p, 9q, 10q, 11 p, 15q and 17 p (Zedenius et aI., 1995) (Ward et aI., 1998) (Kitamura et 
aI., 2001). The average rate of allelic loss of target regions is significantly higher in FC(30-
50%) than in FA (6-15%) (Hunt et aI., 2003; Ward et aI., 1998). HCC usually reveal a 
comparable or even higher rate of LOH than conventional follicular tumours (Segev et aI., 
1998). Some studies have found a correlation between the frequency of LOH, tumour 
aggressiveness and outcome in patients with follicular carcinomas (Hunt et aI., 2006). 
Mitochondrial defects 
Oncocytic tumours are characterized by the cytoplasmic accumulation of numerous 
mitochondria in Hurtle (oxyphil or oncocytic) cells that frequently show abnormal 
morphology. Mitochondrial abnormalities probably represent either a primary change 
associated with tumour initiation or a secondary change (Tallini et aI., 1992). 
Mutations of the gene NADfl dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 13 (NDUFA13) (also known as GRIM-19) have been identified in oncocytic 
thyroid tumours (Maximo et aI., 2005). This gene encodes a protein that regulates cell 
death and promotes apoptosis and also affects mitochondrial metabolism by serving as an 
essential component of complex I of the respiratory chain (Angell et aI., 2000). Somatic 
mis-sense mutations in NDUFA 13 were found in 10-20% of oncocytic follicular 
carcinomas and the oncocytic variant of papillary carcinoma (Maximo et aI., 2005). 
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However, the role of NDUFA 13 mutations in carcinogenesis remains obscure although a 
lack of complex I has been proposed to prevent tumour cells from undergoing apotosis. 
Beta eaten in (fJ-eatenin) 
The fJ-catenin protein, when bound to E-cadherin (CDHl), mediates cell 
skeleton/adhesion interactions, and when not sequestered and not degraded, plays a role in 
gene transcription regulation of growth-promoting genes. It also belongs to the Wnt 
signalling pathway which is often associated with tumourigenesis. High levels of Wnt5a 
have been reported in the majority of PTCs and only in some cases of FTC 
(Kremenevskaja et aI., 2005). Mutations in the fJ-catenin gene (CTNNB1) are most 
frequent in poorly differentiated and anaplastic cancers (Garcia-Rostan et aI., 2001). 
CDH1, is a calcium-dependent transmembrane glycoprotein, which functions as a 
cell-cell adhesion molecule and forms complexes with catenin proteins in the regulation of 
the Wnt pathway. CDHI expression is reduced in thyroid carcinomas and has been 
associated with poor prognosis in PTC (von et aI., 1997) and FTC (Brecelj et aI., 2005), as 
well as the PTC-to-A TC transition (Wiseman et aI., 2007). Expression of CDH 1 in 
undifferentiated TC is extremely low (Brabant et aI., 1993) probably due to promoter 
hypermethylation (Rocha et aI., 2003; Soares et aI., 1997). 
Hepatocyte growth/actor receptor (MET) oncogene 
The receptor-tyrosine kinase MET is the main signalling receptor for hepatocyte 
growth factor (HGF). HFG is a potent mitogen for epithelial cells and promotes cell 
motility and invasion. About 50% of cases of PTC are characterized by MET 
overexpression (Di Renzo et aI., 1992) which is believed to be a sign of more aggressive 
disease (Mineo et aI., 2004). BRAF-positive tumours were also associated with MET 
overexpression in aneuploid PTC (Rodrigues et aI., 2007a). MET overexpression IS, 
however, rare in other histological types of thyroid tumours (Ruco et aI., 2001). 
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Epidermal growth factor receptor EGFR 
The EGFR family includes EGFR (also known ERBB1 and HER1), ERBB2 (HER2), 
ERBB3 (HER3) and ERBB4 (HER4). Multiple ligands bind.to EGFR. 
Thyroid tumours overexpress EGFRs and their ligands thus implicating EGFR 
signalling in thyroid tumourigenesis (Schiff et al., 2004). EGFR protein levels are 
increased in PTC in comparison to normal tissue and the high expression of EGFR has 
been suggested to be associated with worse outcome of PTC after thyroidectomy (Akslen 
and Varhaug, 1995; Ruan et al., 2008). HER2 could also be considered a predictor of 
metastasis in PTC (Kremser et aI., 2003). A functional TGFAIEGFR autocrine signalling 
loop has been shown to sustain the proliferation of PTC cells, contributing to PI3 KI AKT 
activation. TGF AlEGFR was common in PTC cells harbouring BRAF and RET/PTC 
mutations. Since other signal pathways have been demonstrated to function in tandem with 
EGFR pathway, the therapeutic targeting of EGFR only could be inadequate 
(Degl'Innocenti et aI., 2010). 
Mitogen-inducible gene 6 (MIG-6) 
MIG-6 is an immediate early gene, the expression of which is induced by cellular 
stress, hormones or growth factors in many cells (Ferby et al., 2006). It exerts a negative 
role on EGFR signalling through a negative feedback loop, a process lost in cancer. In 
PTC, MIG-6 inversely directly correlates with EGFR expression and its higher mRNA 
level was associated with better overall survival in PTC patients. MIG-6 expression was 
found to be independently predictive of disease-free survival in BRAF-positive patients 
(Ruan et aI., 2008). 
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Vascular endothelial growth/actor (VEGF) 
VEGF overexpression is a characteristic feature of malignant tumours, including 
thyroid tumours (Wiseman et al., 2008). The quantitative evaluation of VEGF expression 
in PTC showed an association with the concomitant expression of other angiogenic factors 
in metastatic PTC (Klein et al., 2001). VEGF expression was closely correlated with 
tumour size, extrathyroidal invasion, lymph node metastasis and BRAFV600E mutation (10 
et al., 2006) 
Cell cycle regulation 
The growth activity of well-differentiated TC is low compared with poorly 
differentiated and undifferentiated TC with MIBI indexes of 1-3%, 6-7% and 14-52% 
respectively (Katoh et al., 1995; Kjellman et al., 2003). The differences in proliferation are 
governed by altered cell-cycle regulators. Although the expression of cyclin D 1 and cyclin 
E 1 remain undetectable in normal thyroid follicular cells, cyclins D 1 and E 1 are observed 
in approximately 30% and 76% ofPTC, respectively (Basolo et al., 2000; Brzezinski et al., 
2004). Cyclin Dl overexpression correlates with metastatic spread in PTC and it is 
observed in undifferentiated carcinoma (Khoo et al., 2002; Wang et al., 2000). Although 
the copy number of the cyclin Dl (CCNDl) gene is amplified in many tumours, neither 
major genetic alterations nor amplification of CCNDI and cyclin El gene (CCNEl) have 
been found in TC (Khoo et al., 2002; Lazzereschi et al., 1998). The overexpression of 
cyclins is, therefore, probably a secondary effect induced by other genetic aberrations in 
thyroid tumours. 
CDK inhibitors are commonly downregulated in TC. In fact, there is a progressive 
loss of p21 CIPI (encoded by CDKN 1 A gene) with advancing tumour stage of PTCs, and 
13% of PTC harbour CDKNIA deletions (Brzezinski et al., 2005). The expression of the 
cyclin-dependent kinase inhibitor p27K1P1 (encoded by the CDKNI B gene) is significantly 
reduced in PTC, metastatic forms and undifferentiated carcinoma (Erickson et al., 2000). 
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Although point mutations of CDKN2A (which encodes p 16INK4A) are rare in TC (Elisei et 
aI., 1998; Yane et aI., 1996), LOH in the region of CDKN2A is associated with FTC (27%) 
and undifferentiated TC (50%) (Tung et aI., 1996). Hypermethylation of its promoter has 
also been detected in 30% of thyroid tumours (Elisei et aI., 1998). 
Lastly, Transcription factor (E2FI) is one of the main targets of Rb protein. It is 
upregulated in 35-89% of well-differentiated carcinoma and 67% of undifferentiated 
carcinomas (Onda et aI., 2004; Volante et aI., 2002). 
Mucin (MUC1) 
MUC 1 is a glycoprotein that is important for cell adhesion and is overexpressed in 
about 25% of PTC (Wreesmann et aI., 2004). It has been demonstrated that MUC 1 is able 
to promote an aggressive phenotype of PTC (Patel et aI., 2005). MUC 1 overexpression is 
frequent in tall cell variant of PTC known for its poor prognosis (Ghossein and LiVolsi, 
2008). 
Cytokines and inflammation 
In the last few years it has become evident that PTC represents an excellent model to 
study the link between inflammation and cancer. This connection is documented by two 
different types of evidence: 1) PTC-associated oncogenes trigger a pro-inflammatory 
programme in thyrocytes; 2) inflammatory cells, such as leukocytes and macrophages, are 
frequently found to infiltrate PTC. 
Several inflammation related genes have been demonstrated to be convergent targets 
induced by all of the main known PTC-related oncogenes. RET/PTC1 has been reported to 
induce an inflammatory programme directly in primary human thyrocytes (Borrello et al., 
2005). BRAF, RAS and RET/PTCs were all shown to up regulate cytokines such as CXCLI 
and CXCL 10 and metalloprotcascs (Melillo et aI., 2005). 
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The chemokine receptors interleukin 8 receptor ~ (CXCR2), CXCR3, CXC4 and 
CXCR7 are expressed on PTC cells (Melillo et aI., 2005) (Sancho et aI., 2006).CXCR7 
was reported to be associated with certain pathologic factors of PTC aggressiveness such 
as extra-thyroidal tumour extension, angio-Iymphatic invasion and the presence of lymph 
node metastases (Wagner et aI., 2008). CXCL14 was also described to be associated with 
metastatic PTC (Oler et aI., 2008). 
Osteopontin (SPPl) is a cytokine regulating cell trafficking within the immune 
system, binding a splice variant of CD44, that is not only overexpressed in PTC but 
contributes to mitogenesis (Figge et aI., 1994), the survival and motility of PTC thyrocytes 
and their invasion potential (Guarino et aI., 2005). In PTC, the gene expression level of 
. SP PI was associated with metastasis and not with the BRAF status of the tumour (Oler et 
aI., 2008). 
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1.4 Mechanisms of thyroid cancer aetiology 
Despite the high frequency of chromosomal rearrangements occurring in PTC, the 
molecular basis underlying the predisposition of thyrocytes to undergo chromosome 
rearrangements is not completely understood. A strong association exists between papillary 
thyroid cancer-specific chromosomal rearrangements and the exposure to ionizing 
radiation. As previously reported, RET/PTC rearrangements are found in up to 80% of 
papillary carcinomas in individuals exposed to either accidental radiation or therapeutic 
radiation (Bounacer et aI., 1997; Rabes et aI., 2000). 
Although the exact molecular mechanisms involved in the formation of 
chromosomal rearrangements following radiation exposure are not well understood, 
several reports have proposed that the spatial proximity of translocation-prone gene loci 
may favour gene rearrangements (Nikiforova et aI., 2000; Roccato et aI., 2005). Spatial 
proximity may predispose the neighbouring genes to simultaneous damage by radiation 
and facilitate the mis-rejoining of free DNA ends located immediately adjacent to each 
other. In support of this, proximity between rearranging gene pairs such as RET and H4, 
and NTRK1 and TP R, has been reported in interphase thyroid nuclei (Pierotti and Greco, 
2006). Another possibility is that following DNA damage thyrocytes would be more prone 
to DNA repair than apoptosis, and this would increase the likelihood of gene 
rearrangements (Pierotti and Greco, 2006). 
In addition to ionizing radiation, the induction of the RET/PTC rearrangement may 
also be associated with chromosome fragility. The 1 Oq 11.2 and 10q21 regions on 
chromosome 10 where the RET and CCDC6 (RET/PTC1) genes reside have been known to 
contain the fragile sites FRAG10G and FRA10C (Buttel et aI., 2004; Richards, 2001). 
Chromosome fragility may be caused also by hypoxia, ethanol, endogenous and exogenous 
factors, and might therefore represent another mechanism of formation of the RET/PTC 
fusion gene in thyroid cells (Butte I et aI., 2004; Richards, 2001). 
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In contrast to chromosomal rearrangements, point mutations are prevalent in thyroid 
cancers that lack any association with radiation exposure thus suggesting other aetiologic 
factors are involved. Many studies report a high prevalence of BRAF point mutations in 
PTe from several regions where there is a very high iodine intake by the population and 
exposure to certain specific chemical compounds such as boron, iron, vanadium and 
manganese (Lind et aI., 1998; Pellegriti et aI., 2009). 
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Figure 1.2 Model of multistep carcinogenesis of thyroid neoplasia. a) Risk factors promote genomic 
instability resulting in early genetic alterations involving the MAPK signalling pathway. This, in turn, 
induces genomic instability resulting in the induction of other late genetic alterations.; b) three distinct 
pathways are proposed for neoplastic proliferation of thyroid follicular cells: 1) hyper-functioning follicular 
thyroid adenoma; 2) follicular thyroid carcinoma and papillary thyroid carcinoma. In the figure frequent early 
and late alterations are reported. Poorly differentiated and undifferentiated thyroid carcinoma are considered 
to derive from pre-existing FrC and PTC through additional genetic events; however, even though not 
shown in the figure, they can arise de novo from follicular cells (from (Kondo et aI., 2006». 
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1.5 Therapy in thyroid cancer 
1.5.1 Multikinase inhibitors as target therapy 
Most thyroid cancers are effectively treated by surgical thyroidectomy and selective 
use of lymph-node dissection. In the case of differentiated thyroid cancers (PTC and FTC), 
thyroid-stimulating hormone (TSH) suppression and ablation of residual tissue using 
radioactive iodine 131 (RAI) are used. For the majority of patients the prognosis is 
excellent, with an overall survival rate of 85% at 10 years. Nevertheless, despite low 
mortality rates, local recurrence occurs in up to 20% of patients and distant metastasis in 
approximately 10% at 10 years (Eustatia-Rutten et aI., 2006). Metastatic PTC and FTC 
poorly concentrate radioactive iodine as the disease becomes less differentiated (Dohan et 
aI., 2003). In ATC surgery is not often technically feasible due to the local extension and 
invasion of the contiguous anatomic structures. 
At present, RAI resistant thyroid carcinomas and A TC represent the most important 
challenges for therapy. 
The molecular discovery described in the previous paragraphs has unveiled that the 
two most important pathways involved in TC pathogenesis progression are: the 
deregulation of TC genes such as BRAF, RAS, RET and angiogenesis. Since both signal 
through the MAPK and PI3K1Akt pathways a major therapeutic strategy is to block these 
intracellular signalling cascades. An important approach is through the use of Tyrosine 
kinase inhibitors (TKls) which compete with ATP for the binding to the catalytic pocket of 
a TK. Several compounds belonging to this class have been developed and approved for 
treatment of different tumour types. Some of them are being used in advanced thyroid 
cancer and are listed in Table 1.2 (reviewed in (Gild et aI., 2011). 
At present, only those patients with advanced TC unsuitable for surgery, showing 
evidence of progression disease and exhibiting RAI-refractoriness are candidates for TKI 
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therapy. Over the last year, the employment of multikinase inhibitor has achieved 
promising results in the management of advanced thyroid cancer. 
Table 1.2 Tyrosin kinase inhibitors in current trials and their targets 
Drug Targeted tyrosine kinase 
Axitinib VEGFR1-3, PDGFR, c-Kit 
Cabozantinib HGFR, VEGFR2, RET 
(Xl184) 
Lernatinib VEGFR1-3,FGFR1-4,RET. 
(E70BO) c-Kit, PDGFR 
Motesanib VEGFR1-3, PDGFR, c-Kit, RET 
Pazopanib VEGFR, PDGFR, c-Kit 
Sorafenib VEGFR1-3, PDGFR, RET, 
RAF, c-Kit 
Sunitinib PDGFR, VEGFR 1-3 , c-Kit, RET, 
CSFiR, FLT3 
Vandetanib VEGFR2-3, RET, EGFR . 
(ZD6474) 
(adapted from Gild M Let aI., 2011) 
Other therapeutic approaches consist of the use of compounds targeting molecules 
other than TKs. For example, demethylating and re-differentiating agents act by interfering 
with the epigenetic mechanisms involved in thyroid cancer pathogenesis, while other 
compounds exert their action through the inhibition of proteosome and angiogenesis. 
The molecular targets for thyroid cancer therapy are reported in Figure 1.3 
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Figure 1.3 Molecular pathways involved in thyroid tumourigenesis and molecular targets for new 
drugs (from (Brilli and Pacini, 2011) 
1.5.2. Conclusions on therapeutic options 
The rationale for the employment of target therapy is to block off known aberrancies 
involved in TC pathogenesis, but until now none of the genetic defects have been 
identified as clearly linked to the activity of the experimental compounds. Possible 
explanations include the possibility of multiple redundancies in the oncogenic pathways so 
that more than one pathway could be activated in signal transduction in the tumour cells, in 
addition to the targeted molecules. 
Success with single-agent therapies for TC has been modest. It is worth noting that 
translational studies looked for targets on the primary thyroid tumours which might have 
Occurred several years before the appearance of metastases, which could include the 
acquisition or loss of genetic defects. 
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Improved anti-tumour efficacy might be achieved through the use of inhibitors with 
greater specificity for mutant kinases (e.g. vemurafenib for patients with BRAFV600E 
mutation) thus targeting a specific oncogenic mechanism. Alternatively through the use of 
inhibitors that target different kinase pathways known to be active within thyroid cancer 
thus avoiding pathway switching. 
Several clinical issues regarding TKI therapy remain open. These include patient 
selection, the lack of predictive biomarkers of response and toxicity profile, the length of 
time and optimal sequence of TKI administration, the problems of drug resistance, the 
endpoints of clinical trials, overall survival (OS) versus progression-free survival (PFS). 
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2. Expression profiles in thvroid cancer 
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2.1 Expression profiles in thyroid cancer 
The majority of thyroid tumours are characterized by specific lesions such as 
rearrangements or mutations, alternative pathways relevant for thyroid carcinogenesis are 
not, as yet, completely understood. Larger scale studies analyzing gene expression profiles 
provide an important approach to the identification of other molecular mechanisms 
underlying thyroid carcinogenesis. An increasing number of studies have used micro array 
technology in order to understand the molecular aetiology of the tumour and to identify 
genetic markers that could improve differential diagnosis. Moreover, gene expression has 
demonstrated the potentiality of unveiling genes involved in the pathogenesis of thyroid 
tumours and possible new therapeutic targets. In fact, recent reports highlight the power of 
gene expression analysis as a tool for the identification of putative oncosuppressor and 
tumour promoter genes. 
2.1.1 PTC signature 
The first microarray-based study was performed by Huang et al. in 2001 (Huang et 
aI., 200Ia). Expression profiles of eight PTC samples compared with paired normal tissue 
exhibited distinct clustered profiles. Differential expression occurred for numerous genes, 
already known to be involved in thyroid carcinogenesis, as well as for new identified 
genes. These genes grouped in functional categories such as cellular adhesion and 
extracellular matrix, cytoskeleton, growth factors and receptors, and signal transduction. 
Among genes underexpressed in PTC, several genes relating to specialized thyroid 
functions such as thyroid peroxidase (TPO), DIOI, DI02 and SLC5A5 (also named NIS, 
encoding sodium iodide symporter) were found. These findings are consistent with the fact 
that most malignant thyroid tumours are hypo functioning in trapping iodine and producing 
thyroid hormone. Other underexpressed genes were GAS1, CDCL] and BCL2 and other 
involved in fatty-acid binding such as FABP4, CRABP 1 and APOD. Among the 
overexpressed genes, fibronectin 1 (FNl), AfET, dipeptidylpeptidase IV (DPP4), alpha 1· 
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antitrypsin (SERPINA1), keratin 19 (KRT19) , galectin-3 (L GA LS3), previously associated 
with PTC, were found. Such analysis leads to identification of genes overexpressed and not 
previously associated, such as Cbp/p300-interacting transactivator 1 (CITEDI), ADORAl, 
SCEL, aDZ and DUSP6. Other genes overexpressed in PTe encoded cell adhesion-
associated proteins such as Tissue inhibitor of metalloproteinase 1 (TIMP 1), midkine or 
neurite growth-promoting factor 2 (MDK) and MUC 1, thus suggesting that the 
overexpression of adhesion-related genes is a characteristic feature of PTC (Huang et aI., 
2001a; Jarzab et aI., 2005). 
Jarzab et al. (Jarzab et aI., 2005) confirmed the previous gene expression profile of 
PTC and proposed an optimal "20 best genes" to differentiate between PTC and normal 
tissue. This classifier gene set includes some genes with a very distinct change in 
expression signal (previously known to be up-regulated in PTC). The authors confirmed 
that the most frequent gene ontology class modulated in PTC referred to adhesion genes. 
Genes involved in signal transduction like CITED I or calcyclin (S 1 00A6), the cell cycle 
regulators stratifin (SFN) and CCNDI, the estrogen-responsive gene EBAG9, or CD44 
antigen constitute other examples of genes that were already indentified in previous PTC 
studies. Signal transduction and apoptosis/cell cycle genes were moderately abundant 
(about 10%) in the gene set. Moreover, the authors also found upregulation of MET, which 
is a consistent feature found in nearly all of the PTC genomic studies (Huang et aI., 2001a). 
Vasko et al. (Vasko et aI., 2007) performed a comparative gene expression profiling 
of the intratumoural invasive region of PTCs with the central region of the tumour. Genes 
found to be overexpressed were related to transcription, cell signalling (integrinlTFGbeta 
pathway), regulation of nuclear localization, small G protein and guanine nucleotide 
exchange factors. Genes underexpressed were related to cell-cell adhesion and 
communication processes. Authors concluded that genes differentially expressed in the 
invasive regions of PTCs are involved in the epithelial to mesenchymal transition process, 
a common feature of aggressive PTCs. 
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Several studies were devoted to assessmg whether the various PTC-associated 
genetic lesions could generate different and specific gene expression patterns. In this 
respect, the first study was performed by Frattini et al. (Frattini et al., 2004). In this study, 
unsupervised hierarchical clustering showed that the PTC samples did not group according 
to their genetic lesion, but behaved as an homogenous group in terms of gene expression 
profiles, although triggered by different genetic lesions. Whereas the supervised analysis 
did not show any differences between PTC with unknown lesions and "RTK-rearranged" 
and "BRAF-mutated" PTCs, comparison between "RTK rearranged" and "BRAF mutated" 
PTCs identified 69 genes differentially expressed, all related to signal transduction 
pathway, tumour invasion, and angiogenesis. This finding suggested that although RTK 
and BRAF act along the same signal transduction pathways, they regulate different gene 
sets. 
In 2005, Giordano et al. (Giordano et aI., 2005) showed that the gene expression 
profile of the BRAF-associated PTC differs profoundly from the RET/PTC or RAS-
associated PTC. In particular, over 3800 genes were found to be differentially expressed in 
PTC with BRAF mutation compared to those with RET alterations. The results were 
indicative that the tumour mutational status correlated with the gene expression profile. In 
contrast to Frattini et al., these authors hypothesized that these mutations signalled through 
alternative pathways. 
Gene expression profiling preformed by Melillo et al . (Melillo et aI., 2005) revealed 
that the ectopic expression of the three oncogenes RET/PTC, RAS and BRAF activate a 
common transcriptional program in thyroid cells. This included the upregulation of the 
CXCL 1 and CXCL 10 chemokines, which are involved in cell proliferation and invasion 
promotion. 
Borrello et al. (Borrello et aI., 2005) demonstrated that the RET/PTC 1 oncogene 
activates a pro inflammatory program, and, in particular induces the expression of a large 
set of genes encoding chemokines (CCL2, CCL20, CXCL8, CXCL12), chemokine 
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receptors (CXCR4), cytokines (fLlB, CSF-l, GM-CSF, G-CSF), matrix degrading enzymes 
(UPA, MMP9) and adhesion molecules (L-selectin). All these molecules are involved in 
proliferation, survival, migration, invasion, metastasis, leukocyte recruitment, homing to 
lymph nodes. 
2.1.2 Post Chernobyl-PTC signature 
It is well known that there has been a considerable increase in the occurrence of 
PTCs after the Chernobyl power plant explosion, particularly in those patients who were 
children or adolescents at the time of exposure (Baverstock et aI., 1992). Four 
transcriptomic studies comparing radiation-induced and sporadic thyroid cancer have been 
reported. 
The first analysis of gene expressIOn profiling compared sporadic and post-
Chernobyl PTC, and autonomous adenomas were used as controls. Unsupervised 
clustering of this data did not distinguish between the post-Chernobyl and sporadic PTC, 
but separated both cancers from adenomas (Detours et aI., 2005). A limit of this work was 
the low number of investigated genes (2400), thus the authors extended the study covering 
more genes and by studying more patients. In conclusion, also the latter analysis confirmed 
that post-Chernobyl and sporadic PTC had similar overall gene expression profiles, 
indicating that they both represent the same disease. However, subtle differences between 
these two groups in the expression of 118 genes, involved in response to I h02, radiation 
and homologous recombination were observed. This suggests that different susceptibility 
profiles distinguish sporadic and radiation-induced PTC (Detours ct aI., 2007). 
A third study by Port et al. (Port et aI., 2007) found seven genes (SFRP 1, AIAIP 1, 
ESAll, KRTAP2-1, COL13Al, BAALC and PAGEl) completely discriminating post-
Chernobyl from sporadic PTC. Moreover, six proteins (NTRKl, MJvIP 1, AIAIP9, MAfP 13, 
calhepsins Wand X) were found significantly overexpressed in post-Chernobyl PTCs. In 
the same samples, authors observed a marked down-regulation of the genes coding for 
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immunoglobulins suggesting the existence of a weakened immune defense (Port et al., 
2007). 
A recent study (Stein et al., 2010) investigated copy number and gene expression 
alteration in 10 post-Chernobyl PTCs and compared their results with sporadic PTC. They 
identified 141 gene expression changes that were specific to paediatric radiation-induced 
PTC, and these could be considered potential biomarkers of radiation exposure to the 
thyroid. 
In conclusion, the existence of conflicting results from all these studies, might be 
attributed to differences in gene expression, complicated by the presence of factors such as 
age, ethnicity, differences in iodine uptake and heterogeneity of stage- and pathological 
variant-related factors. 
2.1.3 FTC signature 
The biology of FTC and its gene expreSSIon profile IS much less known m 
comparison with PTC. 
The majority of gene expression studies have concentrated on the search for gene 
signatures differentiating FTC from FA. Specific markers identified include LGALS3; 
haemoglobin E I(HBEl), CK19 and TPo. The accurate classification of benign FA and 
malignant FTC was also achieved by using the combination of the, CCND2, PCSK2 and 
PLAB, genes enabling a resulting sensitivity of 100% and 94% specificity (Weber et al., 
2005). This combination was also able to distinguish the follicular variant of PTC. 
Aldred et al. (Aldred et al., 2004) reported that PTC and FTC show distinctly 
different microarray expression profiles and can be distinguished by a minimum of the 
following 5 genes, CITEDl, CAVl, CAV2, IGFBP6 and CLDNI0. 
Borup et al. (Borup et aI., 2010) performing global expression profiling of FTC 
found expression changes involved in DNA replication and mitosis, loss of growth arrest 
and proapototic factors. 
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Few studies were addressed to assessing whether the various FTC-associated genetic 
lesions could generate different and specific gene expression patterns. 
FA and FTC are equally affected by RAS point mutations, for this reason, RAS 
mutations are considered an early event in follicular neoplasia; Few studies analysed the 
RAS-related signature of FTC. The impact of RAS mutation on the gene expression of 
thyroid cells derives from studies of FRTL-5 rat thyroid epithelial cells, infected with the 
Kirsten murine sarcoma virus carrying the v-Ki-Ras oncogene, and from a panel of thyroid 
cell lines (Visconti et al., 2007). From this study, Annexin A2, RALA (v-ral simian 
leukemia viral oncogene homolog A) were found upregulated, whereas dual-specificity 
phosphatase 1 (DUSP 1) and small cell lung carcinoma cluster 4 antigen (CD24) were 
downregulated. 
The gene signature of the P AX81P P ARy rearrangement, the other genetic lesion 
associated with FTC, has also been studied. Lacroix et al. (Lacroix et al., 2005) revealed a 
pattern of 93 genes that discriminated FTCs, carrying or not this translocation (examples 
include angiopoietin-like 4, and aquaporin 7), but no differences in the expression of 
thyroid specific genes were noted. 
Giordano et al. (Giordano et al., 2006) reported that the presence of this balanced 
translocation is associated with a specific gene expression signature composed of known 
PP AR target genes, involved in fatty acid and carbohydrate metabolism. 
2.1.4 PDTC and ATC signatures 
As already reported, PDTC and ATC could arise de-novo from thyrocyte or from de-
differentiation of DTC. It is agreed that PDTC represents an intermediated form between 
differentiated and undifferentiated tumours. 
Fluge at al. (Fluge et al., 2006) analysed the gene expression profiles of PTC and 
PDTC, including tumours with extensive local invasion or distant metastases. CITED1, 
fibronectin, growth/differentiation factor 15, potassium inwardly rectifying channel 
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(KCNJ2), glutaminil peptide cyclotransferase, WNT7 A and dipeptidyl peptidase IV were 
found overexpressed in carcinomas of both the aggressive and classical PTC group. The 
growth factor homologue Nel-like 2, dual specificity phosphatase 5, the serine protease 
kallikrein 1 0, the tight junctions genes claudin 1 and 16 were up regulated only in PTC, 
which may be consistent with altered cell polarity frequently found in the differentiated 
PTC. The aggressive, poorly differentiated PTC group was characterized by the up-
regulation of genes involved in cell proliferation, e.g. CDC2, CDC7 and topoisomerase IIu, 
ubiquitin conjugating enzyme E2C, and by the up regulation of genes encoding 
extracellular matrix proteins such as seprase, extracellular matrix protein 1 and several 
collagens. 
Montero-Conde et al. (Montero-Conde et aI., 2008) compared the gene expression 
profiles of ATC and PDTC versus well-differentiated tumour samples. Transcriptome 
comparison of the differentiated and well differentiated tumours identified a large number 
of overexpressed genes, belonging to MAPK signalling and TGF-p pathway, focal 
adhesion and cell motility, cell cycle and chemokines. They also found a prognosis 
signature that recognized A TC and PDTC, but also recurrent and metastatic well DTC. 
Salvatore et al. (Salvatore et aI., 2007) presented a gene expression signature of ATC 
characterized by the upregulation of genes involved in cell cycle progression and 
chromosome segregation. They stressed the importance of the Polo-like kinase 1 (PLKl) 
protein for A TC cell proliferation and cell survival in contrast to normal thyroid cells. 
Ito et al. (Ito et aI., 2009) reported high expression of the S 1 00 calcium-binding 
protein S 1 00A8 and S 1 00A9 in ATC but a lack of these proteins in well differentiated 
thyroid tumors. A TC are also characterized by the loss of the pleomorphic adenoma gene-
like J (PLAGLJ) (Rodrigues et aI., 2007b) and by the downregulation of epithelial cell 
adhesion molecule (EpCAM), which, on the contrary. are expressed in well DTC and 
PDTC (Ensinger et aI., 2006). 
44 
2.2 miRNA profiling in thyroid cancer 
MiRNAs are small non-coding RNAs of approximately 21-25 nucleotides that 
negatively regulate gene expression at both the transcriptional and post-translational levels. 
Several studies have shown the deregulation of miRNAs expression in human TC and 
functional studies support a critical role of miRNAs in thyroid carcinoma development. 
A study analysing the miRNA genome-wide expression profile in human PTC has 
reported an aberrant miRNAs expression profile that clearly separates PTC from normal 
tissue (He et aI., 2005; Pallante et aI., 2006). In particular, a set of seven miRNAs (miR-
221, -222, -146, -21, -155, -181a and 181b) was identified. 
He et al. (He et aI., 2005) observed the overexpression of a small set of miRNAs 
(miR221,222,147b) in PTC compared to normal thyroid tissue that acted efficiently as 
class predictors. Interestingly, miR-221 expression was not only up-regulated in PTC 
tumours, but also showed a clear-cut variation in the unaffected thyroid tissue of the same 
patients, suggesting that the unaffected normal thyroid tissue adjacent to tumours may 
harbour genetic changes before the appearance of morphological malignancy. 
Overexpression ofmiR221 and miR222 was also identified by Pallante et al. in fine needle 
aspiration biopsies (FNAs) of PTC. Further functional studies have determined that 
miR221 and miR222 negatively regulate p27kipl, an inhibitor of cell cycle progression 
and p27kip 1 (Visone et aI., 2007b), and c-KIT (He et aI., 2005). Other studies have shown 
that miR-221can also target CDKNIC/p57, a gene that has a critical role in the cell cycle 
control (Fomari et aI., 2008). This evidence suggests that the upregulation of miR221/222 
significantly modifies the cell cycle of thyroid cells, and, when associated with a genetic 
lesion affecting the MAPK pathway, could lead to the malignant phenotype. 
MiR146 represents one of the most upregulated miRNAs in PTCs. Jazdzewski et al 
(Jazdzewski et aI., 2008) showed that a common polymorphism inpre-miR-146a, affecting 
the amount of mature miRNAs, also contributes to the genetic predisposition to PTC, and 
plays a role in tumorigenesis through somatic mutation. Preliminary evidence suggests that 
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these effects are mediated through target genes whose expression is affected by the SNP 
status, such as NF-kB dependent genes. Moreover, miR146b was proposed as a potential 
marker for diagnosis since it is overexpressed in PTC but not in FTC, FA and hyperplasia 
(HP). (Chen et al., 2008) 
Even though most of the studies conducted on miR expression in thyroid cancer have 
focused on PTC, recently several papers have also reported miR deregulations in FTC. 
Nikiforova et al. (Nikiforova et al., 2008) found a different signature associated with FA 
and FTC both in conventional variants and in oncocytic tumours. The most upregulated 
miRNAs in FTC were miR-187, -224, -155, -222 and -221, whereas the most highly 
upregulated in conventional FA were miR-339, -224, -205, -210, -190, -328 and -342. It 
has also been shown that oncocytic tumours display a peculiar set of upregulated miRNAs 
that are distinct from other follicular tumours. In particular the authors showed that a set of 
7 miRNAs can be used to distinguish hyperplastic nodules from thyroid tumours in thyroid 
FNA samples (Nikiforova et aI., 2008). Weber et al. (Weber et aI., 2006) compared the 
miRNA expression of FTC and FA cases and. identified overexpression in FTC of a small 
set of miR involved in cell proliferation and apoptosis. 
With respect to ATC, a significant downregulation of miR-30d, -125b, -26a and -
30a-5p has been described (Visone et aI., 2007a). Recent results report a role of miR-30a in 
regulating Bedin 1, a key autophagy-promoting gene (Zhu et aI., 2009). Another study 
revealed that miR-21, -146b, -221 and -222 were overexpressed in ATC. miR-26a, -138, -
219 and -34 were found to be downregulated (Mitomo et al., 2008). These results suggest 
that the loss of miR-138 expression may partially contribute to the gain of hTERT protein 
expression in A TC cells (Mitomo et al., 2008). 
2.3 Gene silencing by promoter methylation in thyroid callcer 
As shown in other human cancers, methylation-mediated gene silencing is an 
important mechanism in thyroid tumourigenesis (Xing, 2007b). Aberrant methylation of a 
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large number of tumour suppressor and thyroid-specific genes in TCs has been detected by 
several groups. Methylation of tumour suppressor genes, including those for tissue 
inhibitor of metalloproteinase-3 (TIMP3), death-associated protein kinase (DAPK) , 
SLC5A8, and retinoid acid receptor-beta-2 (RARP2), was found· to be linked with tumour 
aggressiveness and BRAF mutation in PTC (Hu et al., 2006). 
An association of aberrant methylation of DNA repair genes, particularly the 
hMLHlgene, with BRAF mutation and aggressiveness of PTC was recently demonstrated, 
suggesting a role for hMLHl silencing in BRAF mutation-promoted thyroid tumourigenesis 
(Guan et aI., 2008). 
Another gene silenced through this epigenetic mechanism is PTEN, a negative 
regulator of the PI3K1AKT pathway, which was found to be progressively increased from 
benign thyroid FA to FTC and to aggressive ATC (Hou et aI., 2008). 
The expression of thyroid-specific molecules, such as TSHR, NIS, TPO, Tg, and 
pendrin, is often lost in TC resulting in the impairment or loss of the ability of TC cells to 
concentrate radioiodine. Aberrant methylation of these thyroid specific genes provides an 
explanation for their commonly seen silencing in TC. In particular, the TSHR gene was 
silenced through the BRAF mutation promoted MAPK pathway signalling, as this event 
was partially reversible by MAPK inhibitors (Xing, 2007c). This suggests that the 
functional disruption of this important gene through epigenetic methylation can be directly 
linked to the aberrant activation of a major signalling pathway in Te. 
The following tables summarize the most important gene expression studies in the 
thyroid cancer field. In particular, signatures related to the different histotypes and 
differentially expressed genes as potential prognostic and diagnostic biomarkers are 
reported. 
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Table 2.1 Gene expression profiles in PTe compared with normal thyroid tissues 
Geae~Les1l12a~igaatlla:s 
Huang et al., 20011 
Finley et al ., 2004 2 
Wreesmann et aI., 2004' 
Jarzab et al., 2005' 
Vasko et aI., 2007' 
GENES UP-REGULATBl GENES DOWN-REGULAnO 
codinl for cell cycle, adhesion and codins fo r tumour suppressors, 
extracellular matrl)( proteins (Le. thyroid function-related 
FN1. MIT, DPP4. SERPINA1 , KR719, proteins. fatty-acid bindlnl 
LGALS3,ClTED1, ADDRA1, SCE~ proteins: (l.e .TPO, DI01 , 0102. 
DOl. OUSP6, TlMP1.LAMB3, MDK, NIS,GAS1, CDCll, BCU, FABP4, 
MUCl) CRABP1, APOD ) 
Ad,.nom.dullln, TROP-2. MIT, 
NRP2 
DPP4. GlB3, S714. SERPINA1.LRP4. 
MIT, £VA l , SPUVE. LGALS3. HBB. 
MKRN2, MRC2, IGSF1, KIAADB3D, 
RKRG. P4HA2, CDH3,Ill3RA1, 
MTMR4 
lenes rellted to EMT-process, TGF-
beta. NFkB and tntearln pathway. 
small G proteIn feaulators and 
CDC42 ,vlm.ntin, RUNX2 
T,.fo il factor 
GeaUl1PLeSSkHt.pLDfi/.esJIu~l.a1kNUIl.I11u1Cl1i.onaLslgtus 
FraUlnl et aI., 20046 
Giordano et aI., 2005' 
Borrello et al., 20051 
Melillo et aI., 2005' 
Detours et al. ,2007, 200810 
Port et aI., 200711 
Stein let al., 20101) 
He at al., 200513 
Nlklforova et al ., 200814 
Pallante et al., 201015 
Yip et aI., 201110 
QNA .melbyJatlDn..slgaatllce.s 
Hu et al., 200617 
Smith at aI., 200711 
Guan et al., 200811 
69 eenes differentially expressed, 
all related to sisnal transduction 
pathway, tumour Invasion, and 
anllalsnesls 
,anes related to Immune response 
(I. •. TM7SF4, CLECSF2, STATl,LY75) 
,enls Involved In inflammation, 
tumour Invls ion (chemokl nes, 
matrl, dOlradinlen2ymes and 
adhesion moleculls chemoklnes 
(I. • . CCU, CCUD, CXCL8, 
CXCll2,CXCR4,IllB, CSF-l , GM-
CSF, G-CSF,UPA, MMP9.L-s.l.ctln) 
.en.llnvolved In cell proliferation 
and InvlSlon promotion (I. •. 
CXCll. CXCll D) 
646 aenel (some ones rellted to 
oMldoreduttases, G~prot.l ns a nd 
Irowth fl ctorl) 
TESC, PDZRN4, TRAa(r/!Da, 
GABBR2, CA12 
mIR-211, m1R-222, mIR-146. mlR-
21, and m1R-181a 
mIR-IB1,-221,-222.-224, -146b, -
155, -197 
mIR-221, -222. -146, -21. -155, -
I Bla.-18Jb 
677 l ene. (.ome onll codi nl for 
Immunoll obul ln) 
P,Io.P552, PDLM3, BEXI, ANK2, 
SORBS2, PPARGCIA 
mIR-l ,·19J.-486,-45 J 
m1R-H6b, mlR-221, mIR-222, mlR- mlR-l , miR-Hb. mlR-llDb, miR-
155, m1R-31 138 
PUTATIVE MARKERs 
0 : dlilllnostlc; P: prolnostlc 
MET. LGALS3,FN1 . 
CITEDl(D) 
MUCl (P) 
SFRP1, MMP1 , ESM1 , 
KRTAP2-1. COL13A1, 
BMLC, PAGEl (0) 
CAMK2Nl, Ml, DHR53. 
PDEM (D) 
mIR-221 . mIR-222, mlR-
146, m1R-21, and mlR·181a 
(0) 
mIR-IS 7, -211, -221,-224, -
146b, -ISS, -197 (OJ 
m1R-22J, -222. -lBlb (0) 
mlR-H6b (~rlotlnl MET) 
in 8RAf ~positlv. tumours 
(P) 
REMARKS 
comparative analysis of Indolent 
conventional cPTe ind tall~ell 
variint PT (Iuresslve 
morpholog ical variant) 
comparative analysis between 
the invasive and central fr ont of 
PTC 
comparison between BRAF -
posltlve.nd RTX'-rearranled PTe 
si milariti es in the Itne 
.)Cpr.uion profiles of pre with 
various mutations 
BRAF -lSsocl.ted ys RET/PTC 
ass Oell ted PTC : 3800 lines 
differentially expressed 
th'aen. epress Ion profiles of 
MAF -lSsocilted PTC differs from 
RET/PTe or RAS -lSsocllted PTe 
ectopic ",pression of RET/PTC 
onco,ln.ln human prlr-nary 
thyrocyt.s 
ec topic expression of RAS, BRAF, 
RET/PTe onco,enes In thyroid 
cells 
118lentlS dlfflrentiall.,. 
exprened, Involved In the 
dlfferentlll res pan .. to H202, 
.,mma-radiation and 
homolo,ous recombination 
comparison between auresslve-
and non allreulve PTe 
Genes frequently 
hypermethylated 
flMP1, OAP,," StCSAB, RARe}, 
TSHR, [CIID, NIS-~ ATM. DoIPII 
DNA rtpalr . _nu (J. t . 
hMlHlaen.) 
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I (Huang et aI., 200 I a); 2 (Finley et aI. , 2004a); 3 (Wreesmann et aI. , 2004); 4 (Jarzab et aI. , 2005); 5 (Vasko et aI., 2007); 6 (Frattini et 
aI. , 2004); 7 (Giordano et aI. , 2005); 8 (Borrello et aI. , 2005); 9 (Melillo et aI., 2005); 10 (Detours et aI. , 2007; Detours et aI. , 2008); II 
(Port el aI. , 2007); 12 (Stein et aI. , 20 I 0); 13 (He et aI., 2005); 14 (Nik iforova et aI., 2008); 15 (Pallante et aI., 20 I 0); 16 (Yip et aI. , 
2011); 17 (Hu et aI. , 2006); 18 (Sm ith et aI. , 2007); 19 (Guan et aI. , 2008) 
Table 2.2 Gene expression profiles in PTC compared with FTC tumours 
GENES UP· REGULATED 
Aldred et aI., 200420 ClTfDl. CLDNlG, IGFBP6 
l U (AlOreCl et aI., l UU4 ) 
GENES DOWN-REGULATED PlITAnvE MARKERs 
0 : dlacno'tic; P: procno,tic 
ClTED1. CAV1, CAV2. 
IGFBP6 CLDNIG ( OJ 
'. REMARKS 
Table 2.3 Gene expression profiles in FTC compared with normal thyroid tissues 
• , " -',- .". .', GENES UP-REG ULATED 
Barden et aI., 200321 
Cerutti et aI., 200422 
Weber et aI., 200523 
Foukakls et aI., 200724 
Visconti et al., 200is 
Lacroix et al ., 200526 
Giordano et aI., 200627 
ADM, GPCl, TGFA, MET, IGFBP3 
TER!, TFF3, PPARG, CITfD1, EGR2 
Annexln A2, RALA 
angiopoletln-like 4, aquaporln 7 
genes involved In fatty acid 
metabolism. amino aci d and 
ca rbohydra te metaboli,m.mi R-
101, mIR-30A-3P, mIR-200f\, mlR-
199A 
GENES DOWN-REGULATED 
0101, CREM, FBLN5, MTl 
OUSP1, C024 
PlITAnvE MARKERs 
0 : dlacnostic; P: prolnostic 
DDIT3, ARG2, ITMI . 
[lorf24 ( D) 
CCND2, P[SK2, PLA B ( 0 ) 
TER!, TFF3 ( P) 
REMARKS 
Ros-related ,Ignature 
PAX8/PPARgamma -related 
signa ture 
PAX8/PPARgamma -related 
signature 
21 (Darden et aI. , 2003); 22 (Ceru tti el aI. , 2004); 23(Webcr et aI. , 2005); 24 (Foukakis el aI. , 2007); 25 (Visconti el aI. , 2007): 26 
(Lllc roix et aI. , 2005); 27 (Giordano ct ai. , 2006), 
Table 2.4 Gene expression profiles in ATe compared with normal thyro id tissues 
,; , 
" .. 
Salvatore et al ., 200728 
Montero-Conde et ai., 
200a29 
GENES UP·REGULATED 
genes Involved In the regulati on of 
cel l cycl e progress I on and 
chromosome segregation 
genes belongi ng to MAPKl nase and 
TGFbeta signalling pathway. focal 
adhesion and cell motili ty, 
activa tion of actin polymeriza ti on 
a nd coli cvcl e 
GENES DOWN·REGULATED 
28 (Salvlltore ct ai., 2007); 29 (Montero-Conde ct aI. , 2008), 
PUTA'l'lVt! MARKERs 
0: dl ,nostic; P: pro,no,t lc 
23 genes (I e. ANLN. BIRC5, 
RRM2, PDK2, PPAP2B) (PI 
! REMARKS 
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Table 2.5 Overview of the most relevant gene expression studies of malignant thyroid tumours 
I" ~ ;~., .;.- " t!" :r CDntrlbulJon '" 1M .tudy to thlldfnt/flcatlon of: 
" 
Mazzanti et aI. , 200430 10 and 6 gene model'as di agnos tic tool for thyroid tumours 
Finley et a I., 200431 gene expression profiles capable of differentia ting aggressive thyrOid carcinomas from non-aggre<isive ones 
Zou et a i., 200432 metastasis-associated genes (MET. ~lfin; Int~ann. motility related protein 1, cadhen'n P, NfDDS, SJOOA4) 
Kebebew et ai., 2005,33 cel l cvcle regulatory and angiogenesis-modulating genes (I.e. ANGPT2, TlMP1. (CMI. TMPRSS4) as diagnost ic and prognostic markers 
Griffith et a i. , 200634 MET, Tff3, SERPlNAl, nMPl, fNl and TPO, TGfA, QPCT, CRABPl , FCGBP, [PS8, PROSl as diagnostic and prognostic markers 
Prasad et ai., 20083S overe'pressed genes IHMGA2, LRRK2, PLAGl, DPP4, CDH3, CEACAM6, PRSS3, SPOCKl, PDf SA) 
Nlkolova et al ., 2008" RG54 gene as dla8nostlc tumour marker and putative therapeutic target 
Ducena et al., 201131 multiplex biomarker and diagnostic model based on 6 genes (LGLS3, BIRCS, TFF3, CCNDl , MET, ClTED l ) 
Vrlens MR et ai., 2011" 4 ml Rs (mIR- JOO, miR12Sb, miR-138, ond m iR-768-3b) as marker s for diagnOS ing thyroid cancer 
30 (Mazzanti et aI. , 2004); 31 (Finley et aI. , 2004b); 32 (Zou et aI. , 2004); 33 (Kebebew et aI. , 2005a; Kebebew et aI. , 2005b); 34 
(Griffith ct aI. , 2006); 36 (Nikolova et aI. , 2008); 37 (Ducena et aI. , 20 11 ); 38 (Vriens et aI., 2012). 
2.4 Conclusions ofgene expression studies 
Microarray technology has become a powerful tool to analyze the gene expression of 
tens of thousands of genes simultaneously, In general, microarray investigati ons in TC arc 
focused on two main aims: first, understanding of the molecular aetiology of thyroid 
neoplas ia and second, identification of genetic markers that could improve pre-operat ive 
differential diagnosis. These studies have been performed in order to bypass the current 
limitations in the histological and molecular class ification of thyro id tumours, 
An additional level of complexity in gene express ion profiling is related to the fac t 
that thyroid tumours consist of neoplas ti c cell s intermingled irregularly with nonnal (e,g, 
epithelial cell s, connective ti ssue and endothelium) and reactive cell s (e,g, stromal and 
immune) cell s. AlI these components might represent poss ible bias for gene expression 
profiles, Despite thi s, many studies identified promising class ifiers that are able to 
differentiate between benign and malignant tumours in microarray analysis. 
Although there are several problems that still remain to be resolved (e,g. 
investi gations on larger numbers of tumours and the development of technology to enable 
accurate analyses from FNA samples), gene expression profiling represents a potentially 
inva luable means to develop panels of informative robust biomarkers to fac ilitate 
diagnosis, prognosis and disease management of TC. 
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Aim of the thesis 
Global gene expression analyses have contributed to the dissection of thyroid tumour 
pathogenesis and to the identification of tumour suppressor genes and new candidate 
therapeutic targets. Despite the numerous gene expression studies, there are few data 
addressing the role of differentially expressed genes in the pathogenesis of thyroid 
tumours. 
Using the cDNA microarray platform, our laboratory has previously determined the 
gene expression profile of four different histotypes (PTC, FTC, follicular adenomas, 
normal thyroid tissues) and levels were compared with each other by means of a class 
comparison analysis. This study allowed us to identify 393 genes regulated in the PTC 
versus normal thyroid. Among the genes differentially expressed in PTC detected by our 
analysis, we selected Tissue Inhibitor of Metal/oproteases-3 (TIMP-3), SlOOlcalgizzarin 
and CITED1(CBPIp300·Interacting Transactivators with glutamic acid (E) and aspartic 
acid (D) rich C-terminal domain 1) genes for which a role in the pathogenesis of PTC was 
also suggested by recently published gene and protein expression data. 
The aim of this thesis was the dissection of the role of these selected genes whose 
expression was found di fferentially regulated in PTC with respect to normal thyroid. The 
strategy involved meta-analysis of public gene expression data, as well as functional 
studies, based on PTC-derived cell lines, aimed at the dissection of the effect of their 
expression modulation on tumour cell phenotype. 
A large part of the work was devoted to studying TIMP3 and S 1 OOA 11. These 
sections have been well developed, whereas CITED 1 studies were presented at an early 
stage. The thesis also includes a brief report of a study on Insulin-like growth factor-
binding protein 7 (IGFPB7), another gene found downregulated in PTC, in which the 
candidate collaborated. 
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3. Materials and methods 
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3.1 Microarray data sets and statistical analysis . 
The expression of TIMP3 and SlOOAll was examined on microarray data sets 
containing normal thyroid tissue and PTC. One data set, generated in our laboratory, 
contains the expression profile data of 59 thyroid samples collected at the Department of 
Pathology of our Institute. All the patients gave their written informed consent. Sample 
collection includes: 9 normal thyroid tissues and 32 PTC. The PTC case collection consists 
of 25 classical variant and 7 tall cell (TC) variants; 12 samples carry the BRAFV600E 
mutation, 7 samples carry RET/PTC rearrangements, 2 samples carry TRK rearrangements; 
for the remaining 11 samples none of the above genetic lesions was detected. The eDNA 
microarray used in this study contains 4451 unique clones selected from the Human 
sequence verified I.M.A.G.E. clone collection (Research Genetics/Invitrogen, Carlsbad, 
CA, USA) along with plant geries, printing controls (waterIDMSO) and spike genes 
(Amersham Bioscience, Amersham, UK) added as internal controls. Each eDNA fragment 
was PCR-amplified and spotted in triplicate on type 7 star slides (Amersham Bioscience, 
Amersham, UK). The procedures of RNA isolation, probe labelling, sample hybridization 
and scanning were performed as described by Dc Cecco et al. (Dc Cecco et aI., 2004). 
Supervised analysis (class comparison and hierarchical clustering) was performed using 
DRB ArrayTool v.3.3_Betal (http://linus.nci.nih.govIBRB-ArrayTools.html). 
The expression levels of T1MP3, SJOOAll and CITEDl genes in all the tissue 
samples hybridized on the array were measured as log ratio between the expression level of 
the specimens and that of the reference (a total of 10 human cell lines of different origins). 
Genes showing a positive log ratio value (Le. more expressed in the thyroid sample than in 
the reference) are called up-regulated; those with a negative log ratio value are called 
down-regulated. 
The other data sets are publicly available and are all derived from experiments using 
fIG-UI33 series microarrays (Affymetrix, Santa Clara, CA, USA). These data derive from: 
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a) 51 PTC samples including 26 classical types, 10 TC and 4 normal thyroid tissues. 
Of the tumour samples, 26 carried the BRAFV600E mutation, 9 RET/PTC 
rearrangements, 5 RAS mutation, 10 were negative for these alterations and 1 was 
not investigated (HG-U133A) (Giordano et al., 2005)); 
b) Paired PTC and unaffected thyroid tissue samples from 9 patients (HG U133 Plus 
2.0) (He et al., 2005); 
c) Paired PTC and contralateral thyroid tissue samples from 16 patients (HG Ul33 
Plus 2.0) (Jarzab et aI., 2005); 
d) Paired PTC and contralateral thyroid tissue samples from 7 patients (HG Ul33 
Plus 2.0) (Reyes et aI, 2006); 
e) Paired PTC and contralateral thyroid tissue samples from 8 patients (HG-U95Av2) 
(Huang et al., 2001b); 
f) Paired central and invasive region of PTC and normal tissue from 4 patients (HG 
V133 Plus 2.0) (Vasko et al., 2007). 
RMA normalized data were extracted from the NCBI Gene Expression Omnibus database 
(GSE3467 for the He dataset and GSE6004 for the Vasko dataset) or from the author's 
website (Giordano and Jarzab dataset). The mean RMA log2 intensity values of the four 
probesets specific for TIMP3 (201147 _s_at; 201148_s_at; 201149 _s_at and 201l50_s_at 
in HGVI33-A and HG-V133Plus2 platforms) was considered. For S100AII the following 
probesets 200660_at in HG-V133Plus2 platforms and 38138_at in Affymctrix HG-
V95Av2 platform were considered. 
Statistical analysis and graphs were generated using GraphPad Prism version S.O. 
Comparison between two groups was performed, for unmatched samples, by the non 
parametric Mann-Whitney and for matched samples by Wilcoxon signed pairs test. When 
three or more groups were considered, ANOV A followed by post tests was performed. 
p<0.05 was considered significant. 
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3,1 Molecular biology 
3.2.1 RNA extraction and RT-PCR 
RNA extraction was perfonned using TRIZOL reagent (Invitrogen, Carlsbad, CA, 
USA). One J,Lg of RNA was retro-transcribed using SuperscriptlII (Invitrogen, Carlsbad, 
CA, USA). Details ofRT-PCR conditions are reported in table 3.1. 
PCR products were separated on 2% agarose gels, stained with ethidium bromide and 
visualized under UV transillumination. 
Table: 3.1 Details ofRT-PCR conditions for TIMP3, SJOOAll, CITEDl and GAPDH genes 
Templale Primers Fragment Ienght PCR condition 
TIMP3 5' ·CTGACAGGTCGCGTCT ATGA·3' 240 bp 95' T + ( 95'1' + 56' 30" + 72' 301 x 38 + 72' 5' 
5' ·GGCGT AGTGTTTGGACTGGT·3' 
S100A11 5··GTCCCTGATIGCTGTCTICC·3' 130 bp 95' 7'+ (95' 1'+ 56' 30"+ 72' 30") x 33+ 72' 5' 
5'·ACCAGGGTCCTICTGGTICT -3' 
CffED1 5'·TCACTIGCTGGCTAGTATGCAG·3' 190 bp 95' 7'+ (95' 1'+ 56' 40"+ 72' 40") x 33+ 72' 5' 
5'· TGGGTCCGAATCGATGATAGCAG·3' 
GAPDH 5'·ACCATCTICCCAGGAGCGAGAT -3' 
5'·GGCAGAGATGATGACCCTTI -3' 
142 bp 94' 2' + (94' 1'+ 54' 1'+ 72'1' ) x 35 + 72' 2' 
3.2.3 Real-Time RT-PCR 
For each sample, 20 ng of retrotranscribed RNA were amplified in PCR reactions 
carried out in triplicate on an ABI PRISM 7900 using TaqMan gene expression assays 
(Applied Biosystem, Foster City, CA). Hs00271612_AI was used for SIOOAII 
expression; human HPRT (HPRT-Hs99999909_AI) was used as housekeeping gene for 
the nonnalization among samples. Data analysis was perfonned using the SDS (Sequence 
Detection System) 2.2,2 software. 
3.2.4 Construction of expression vectors 
TIMP3 vector: 
The TIMP3 cDNA was isolated by RT-PCR from a human placenta cDNA library 
using the following primers: S'-CCGGA TTCGGCGGCAGCGGCAATGA-3' and 5'· 
CGCGGATCCGGGGTCTGTGGCATTGATGATGCTT·3', containing the EcoRI and the 
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BamHI restriction sites (bold), respectively. The 650 nucleotides PCR product was 
digested with EcoRI and BamHI endonucleases and inserted into the pcDNA3.lImycHis(-
) A vector (Invitrogen, Carlsbad, USA) carrying compatible ends. The resulting construct 
carries the TIMP 3 cDNA in the sense orientation with respect to the CMV promoter 
present in the vector and encodes the TIMP3-myc fusion protein. This construct was used 
for NIM 1 cells transfection. 
SJOOAll vectors: 
pcDNA3-S100Allmyc: SIOOAII cDNA was isolated by RT-PCR from a human 
placenta cDNA library using the following primers: 5'-
CCGGAATTCCAAGCTCCAACATGGCAAAAA TCTCC-3' and 5'-
CGCGGATCCGGTCCGCTTCTGGGAAGGGACAGC-3' containing the EcoRI and the 
BamHI restriction sites (bold), respectively. The 325 nucIeotidcs PCR product was 
digested with EcoRI and BamHI endonucleases and inserted into the pcDNA3.l/mycHis(-
)A vector carrying compatible ends. The resulting construct carries the SIOOAII cDNA in 
the sense orientation with respect to the CMV promoter present in the vector and encodes 
the SlOOAll-myc fusion protein. This construct was used for Kl cells transfection. 
pIRESneo-SlOOAllmyc: SJOOAll cDNA was amplified from pcDNA3-S100Allmyc 
using primers 5' -GGAATCGATATCCAAGCTCCAACATGGCAAAAATCTCC-3' and 
5'-GGAATCGATATCTAGAAGGCACAGTCGAGG-3' containing the EcoRV 
restriction sitses (bold). The 500 bp PCR product (containing SJOOAll cDNA in frame 
with myc/hys epitope derived from pcDNA3.myc) was inserted into plRESneo vector 
(Clontech Laboratories, Mountain View, CA, USA) (digested with EcoRV) that allows 
high level expression of the gene of interest and the neomycin resistance gene from the 
same bicistronic mRNA transcript. Sense orientation with respect to the CMV promoter 
present in the vector was verified by Bamll J digestion. This construct was used for 
transfcction experiments in NIH3T3 cells (Focus Forming Assay). 
56 
CITED 1 -vectors: 
pcDNA3-CITEDlmyc: CITED1 cDNA was isolated by RT-PCR from a human 
placenta cDNA library usmg the following primers: 5'-
CCGGAATTCTGCCAAGGCTCTGAAA TG-3' and 5'-
CGCGGATCCGCAGCTAGATGGAAAGTCCGCAGT-3' containing the EeoR! and the 
BamHI restriction sites (bold), respectively. The 600 bp nuc1eotides PCR product was 
digested with EeoRI and BamHI endonuc1eases and inserted into the pcDNA3.1/mycHis(-
)A vector carrying compatible ends. The resulting construct carries the CITED 1 cDNA in 
the sense orientation with respect to the CMV promoter present in the vector and encodes 
the CITED l-myc fusion protein. 
pIRESneo-CITEDlmyc: C1TED1 cDNA was amplified from pcDNA3-CITEDlmyc 
using primers 5'-GGAATCGATATCTGCCAAGGCTCTGAAATGCCA-3' and 5'· 
GGAATCGAT ATCTAGAAGGCACAGTCGAGG-3' containing the EeoRV restriction 
site (bold). The 750 bp PCR product (containing CITED1 cDNA in frame with myc/hys 
epitope derived from pcDNA3.myc) was inserted into pIRES neo vector (digested with 
EeoRY) that allows high level expression of the gene of intcrest and the Neomycin 
resistance gene from the same bicistronic mRNA transcript. Scnse orientation with respect 
to the CMV promoter present in the vector was verified by BamHl digestion. 
Both ofthcse constructs were used for HEK293T cells transfection. 
TRK-T3 vector 
TRK-T3 cDNA was released from pCRT3 plasmid (Greco et aI., 1995) by digestion 
with BamH1 and Not! restriction enzymes and inserted into pIREShygro carrying 
compatible ends. This construct was used for transfection experiments in NllBT3 cells 
(Focus Forming Assay). 
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3.3 Cell biology 
3.3.1 eel/lines 
TPCI, NIMI, BCPAP and KI cell lines, derived from PTC; WROS2-1 cell line, derived 
from FTC; FROSl-2, FBI, BHTlOI, 8505C cell lines, derived from ATC and the Human 
Embryonic Kidney (HEK) 293T cells were cultured at 37°C in a 5% C02 humidified 
atmosphere. With the exception ofKl cell line, grown in DMEM:HAM'S F12:MCDB 105 
(2: 1: 1) containing 2mM glutamine and 10% fetal calf serum (FCS), and Nthy-ori 3-1, 
grown in RPM I medium (Lonza, Basel, Switzerland), the other cell lines were maintained 
in DMEM medium containing 10% FCS, 2mM glutamine and 100U/ml 
penicillin/streptomycin. Primary thyrocyte cultures were established and maintained in 
nutrient mixture Ham's F12 medium (custom made by Invitrogen, Paisley, UK) containing 
5% calf serum and bovine hypothalamus and pituitary extracts, as previously described 
(Curcio et aI., 1994). Information regarding mutational status and in vivo tumourigenicity 
of thyroid cell lines is provided in table 3.2. 
Mouse NIH3T3 fibroblasts were cultured in DMEM with 10% of calf serum (Colorado 
Company, CO) in a 10% CO2 humidified atmosphere. 
Conditioned media were obtained by incubating subconfluent cultures in serum free 
medium for 24h. 
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Table 3.2 Mutational status of thyroid ceUlines 
eel/line Hystologicai type mutational status· 
RET HRAS BRAF P13K TP53 
NThy-ori 3-1 nonnal human thyrocytes" 
TPCl PTC RET/PTCI His27His WT 
Kl PTC WT His27His V600EIWT Glu542Lys Arg213Arg 
NIMI PTC V600ElWT"· 
BCPAP PTC WT V600E Asp259Tyr 
WR082-1 FfC V600EIWT Pro23Leu 
8505C ATC WT His27His V600E Arg248Gln 
BHTlOI ATC 
FBI ATC 
FR081-2 ATC WT V600EIWT 
(. from Pilli et al. 2009,·· SV40 Large T antigene, "·our unpublished results) 
In vivo tumourigenicity of thyroid cell line 
cell line 
TPCI 
Kl 
NIMI 
BCPAP 
WR082-1 
8505C 
BHTlOI 
FBI 
Tumourigenk·;ty Reference 
no 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
our unpublished results 
Ferrario et aI, Laboratory Investigation, 2008, 88(5):474-81 
Vizioli et aI, Oncogene, 2010, 29(26):3835-44 
Fabien et al Cancer, 1994, 73(8):2206-12) 
Estouret al Virchows Arch B Cell Pathol IncJ Mol Pathol1989 57(3): 167-74 
Nucera et al Thyroid, 2009, 19 (10): 1077·84 
Palyi et al Virchows Arch B Cell Pathol Incl Mol Pathol, 1993,63(4):263-9 
Fiore et aI, J. Clin. Endocrinol. Metab., 1997,82: 4094-4100 
3.3.2 Cell treatments 
• The recombinant TIMP3 protein (R&D Systems, Minneapolis, MN, USA) 
(50 nM) was applied to NIMI cells; 
• S'~Aza-2'~deoxycytidine (Sigma Aldrich, St. Louis, MO, USA) ( 5 JAM) was 
applied to NIMI cells for four days, 
• PMA (Sigma Aldrich, St. Louis, MO, USA) (100 ng/ml) was applied to 
NIM 1 cells 5 hours; 
• TRAIL (Alexis, San Diego CA, USA) (SOng/ml) was applied to NIMI cells 
for 5 hours; 
• Ca2+ (1.5 mM and 10 mM) was applied to KI cells for 1, 6, 16 and 24 hours; 
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• Recombinant EGF protein (PeproTech, London, UK) (20 ng/ml) was applied 
to Kl cells for 20 minutes, 8 and 24 hours; 
• Recombinant TGF-~ (Peprotech, London, UK) (10nglml) was applied to Kl 
cells for 1 and 8 hours. 
3.3.3 Cell transfection 
• For TIMP3 studies, transient and stable transfections ofNIMI cells were performed 
using Lipofectamine LTX (Invitrogen, Carlsbad, CA). Cells (4xl05) were seeded in 
60mm dishes and transfected with 2 Ilg of plasmid DNA and 5 III of L TX the 
following day. After 48 hours transfected cells were either harvested and processed, 
or subjected to G418 (Lifetechnologies, Invitrogen, Carlsbad, CA, USA) selection 
(400 Ilglml). G418-resistant colonies were isolated and propagated in G418-
containing medium two weeks later. 
• For SIOOAll studies, transient transfection in Kl cells was performed using 
FuGene6 (Roche, Mannheim, Gremany) following manufacturer's instructions. 
Cells (1.5 x lOS) were seeded in 60mm dishes and transfected with 2 Ilg of plasmid 
DNA and 5 III of FuGene6 the following day. After 72 hours transfected cells were 
harvested and processed, 
• For CITEDI studies, transient transfection in HEK293T cells was performed with 
Lipofcctamine2000 (Invitrogen, Carlsbad, CA) according to manufacturer's 
instruction. Cells (3x lOs) were seeded in 60mm dishes and transfcctcd with 2 Jlg of 
plasmid DNA and 5 Jll of Lipofectamine2000 (Invitrogen, Carlsbad, CA) the 
following day. After 48 hours transfccted cells were harvested and processed. 
3.3.4 TIMP3 and SJOOAll silencing 
Transient knock-down of TIMP3 and SlOOAll in KI cells was performed by 
transfection with ON-TARGET plus SMART pool for human TIMP3 or NON-TARGET 
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siRNA control (ThermoScientific, Dharmacon Inc, Chicago, IL.) using Lipofectamine 
RNAiMax (Invitrogen, Carlsbad, CA) following manifacturer's instruction. 
Stable S 1 OOA 11 silencing in Kl cells was performed by transfection of S 100-specific 
shRNA expression pRS vector (OriGene, Rockville, MD, USA). Scrambled shRNA 
expression pRS vector was used as control. The transfection was carried out using 
FuGene6 (Roche, Mannheim, Gremany) following manufacturer's instructions. After 72 
hours, transfected cells were either harvested and processed, or subjected to puromicyn 
(Lifetechnologies, Invitrogen, Carlsbad, CA, USA) selection ( 1 JIg/ml). Puromycin-
, 
resistant colonies were isolated and propagated in Puromycin-containing medium two 
weeks later. 
3.3.5 Focus forming assay 
The NIH3T3 cells (2.5 x 104) were plated in 100mm Petri dishes. The day after cells 
were transfected by the CaP04 method using 1 JIg of expression plasmid DNA together 
with 30 JIg of mouse carrier DNA. NIH3T3 cells were transfected with: SJOOAll cDNA, 
cloned into pIRES vector containing the G418-resistant gene and producing a myc-tagged 
protein; TRK-T3 cDNA, cloned into pIRES vector containing hygromycin-resistant gene. 
The expression plasmids were transfected alone or in combination. Transfectcd cells were 
selectcd in DMEM supplemented with 10% serum in the presence of antibiotics 0418 
(500JIg/ml), Hygromycin (50 JIg/ml) (Roche Diagnostics, Indianapolis. IN, USA) to 
determine the transfection efficiency, and in medium containing 5% serum to determine 
the transforming activity. After 20 days, G418R, HygroR, G418R IHygroR foci or colonies 
were either fixed and Giemsa stained or isolated and propagated for further studies. 
3.3.6 Cell cycle analysis 
Flow cytometry analysis was carried out using FACS Calibur (Becton Dickinson, 
San Jose, CA, USA). Both adherent and floating cells were harvested, washed twice with 
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PBS and fixed in cold ethanol (70%) for 24 hours. After two washes with PBS, cells were 
incubated in PBS containing 1 Jlg/ml RNase and 50 Jlg/ml propidium iodide at room 
temperature for 30 min in the dark. Data were analysed by using Cell Quest software 
(Becton Dickinson, San Jose, CA, USA). 
3.3.7 Growth curves 
Growth curves were determined' by alamarBlueAssay (Biosource, Nivelles, 
Belgium). Cells were plated in 96-multiwell (400 cells per well). After adhesion of cells, 
the alamarBlue reagent was added to the medium at 10% v/v. The fluorescence at A= 590 
and 535nm was detected every 24hrs for different days, using a microplate reader 
(TecanUltra Tecan Trading AG, Switzerland). Data were normalized for 
values detected at day 1. 
3.3.8 Colony forming assay 
Cells were plated at different densities (200 cells in 60 mm2 culture dish for TIMP3 
experiment, 2000 cells in 60 mm2 culture dish for S 1 OOA 11 experiment) and cultured for· 
different days. Where required, conditioned media were used. Colonies were fixed with 
methanol and stained with Giemsa ( Sigma-Aldrich, St.Louis, MO USA). 
3.3.9 Cell adhesion assay 
After 24 hours incubation with appropriated conditioned medium, cells (3x104 
cells/well) were seeded in sextuple in a 96-well plate pre-treated with 30 Jlg/ml Type IV 
Collagen (BD Biosciences, Bedford, MA, USA). After 1 hr of incubation, non-attached 
cells were removed by gently washing twice with 100 JlI PBS. Attached cells were fixed 
with 10% buffered formalin solution for 20 minutes at room temperature, followed by 
staining in 0.2% (w/v) crystal violet for 10 minutes. Stained cells were lysed in 1 % SDS 
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and the intensity of stain was quantified by a spectrometer at the absorbance of 595 nm 
(TecanUltra Tecan Trading AG, Switzerland). 
3.3.10 Wound healing assay 
Cells were seeded in 60 mm dishes. At confluence, a scratch was applied with a tip. 
Plates were washed with PBS, reefed with complete medium, and returned to the 
incubator. Pictures were taken at 0, 8 and 24 hours at lOX magnification by using a digital 
camera system coupled with a microscope (LEICA, DMIRB). 
3.3.11 Migration and Invasion Assay 
In TIMP3 migration assay, cells were seeded in the upper chamber (1.2 xlOs cells 
per well) of 24-well Transwell plates equipped with polycarbonate filters (Costar; Coming 
Incorporated, NY, USA), in serum-free medium. Conditioned media were added to the 
lower chamber as chemoattractant. After 5 hours incubation at 37°C, filters were cleaned 
on the upper side with a cotton swab, fixed with 99% ethanol and stained with a 0.4% 
sulforhodamine B/I % acetic acid solution. Migrated cells were counted under an inverted 
microscope in six randomly chosen fields. The same procedure was used for invasion 
assay, except that cells were seeded at 2.4 xlOs cells per well in Transwell chambers 
coated with 12.5 J1g of Matrigel Iwell (BD Biosciences, Bedford, MA, USA), and samples 
processed after 24 hours incubation. All samples were performed in duplicate. 
For NIH3T3 transformed foci, the invasion assay was performed using the QCM™ 
Cell Invasion Assay (Millipore, Billerica, MA USA) according to manufacturer's 
instructions. Briefly, 2x I OS cells were allowed to invade through a coated transwell toward 
10% FBS for 48 hours. Invaded" cells on the bottom of the insert membrane were 
dissociated from the membrane, subsequently lysed and detected by CyQuant GR® dye. 
The fluorescence at i..= 590 and 53Snm was detected using a microplate reader (TecanUltra 
Tecan Trading AG, Switzerland). 
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3. 3.12 Soft agar assay 
Cells were suspended in 1.5 ml of DMEM medium containing 0.33% agar and 10% 
FCS, added into a layer of medium containing 0.5% agar and 10% FCS in 60mm dishes, 
and incubated for 3 weeks. For NIH3T3 cells 5% FCS was used. After staining with p-
iodonitrotetrazolium chloride (Sigma Aldrich, St Louis, Mo, USA) the plates were 
analysed for colony number and size. Pictures were taken at 4X or lOX magnification by 
using a digital camera system coupled with a microscope (LEICA, DMIRB). 
3.4 Biochemical assays and studies 
3.4.1 Western blot analysis 
Proteins were extracted in RIPA modified buffer (20mM Tris-HCI, pH 7.4, 150mM 
NaCI, 5mM EDTA, 1% NonidetP-40) supplemented with Complete Mini EDTA-free 
protease Inhibitor Cocktail (Roche, Manheim, Germany), ImM Na3V04 and ImM PMSF. 
Cell fractionation was performed using the ProteoExtract Subcellular Proteome Extraction 
(S-PEK) Kit (Calbiochem, San Diego, CA) according to manufacturer's instructions. 
Protein and conditioned medium samples were boiled in NuP AGE LDS sample buffer 
(Invitrogen, Carlsbad, CA, USA) and separated on 4-12% or 10% NuPAGE Novex Gel 
(Invitrogen, Carlsbad, CA) in MES or MOPS running buffer, respectively. Proteins were 
transferred into nitrocellulose filters and immunoblotted with the appropriated antibodies 
listed in Table 3.3. The immunoreactive bands were visualized using horseradish 
peroxidase-conjugated secondary antibodies followed by enhanced chemiluminescence 
(GE, Bio-Rad Hercules, CA, USA). The membranes were scanned using the Chemidoc 
XRS and densitometric analysis was performed by using Quantitative One software (Bio-
Rad Hercules, CA, USA). 
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3.4.2 Dot blot analysis 
For dot blot, conditioned media were harvested, concentrated by centrifugation at 
4000 rpm using AgilentSpin Concentrators (Agilent Technologies Inc, Wilmington, DE, 
USA), and applied to a nitrocellulose membrane (Hybond™-C Super, GE Healthcare) 
under vacuum in an immunodot apparatus (Millipore, Bellerica, MA USA). The membrane 
was blocked for 1 hour with 5% BSA in TBS-0.05% Tween and incubated overnight at 
4°C with the appropriated antibodies listed in Table 3.3 . 
Table 3.3: List of antibodies used for western and dot blot analysis 
Akt 
ALCAM 
beta-actin 
beta-tubulin 
Cleaved P ARP 
C-myc (9E 1 0) 
Cell Signaling Technology (Beverly MA, USA) 
Novocastra (Newcastle, UK) 
Sigma-Aldrich (St Louis, Mo, USA); 
Sigma-Aldrich (St Louis, Mo, USA); 
Cell Signaling Technology (Beverly MA, USA) 
Roche (Indianapolis, IN, USA); 
Cytokeratin 8/18 Novocastra (Newcastle, UK) 
E-cadherin (H-I08: sc 7870) Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
EGFR Cell Signaling Technology (Beverly MA, USA) 
ERK 112 
NBSI 
Nucleolin 
p21 (C-19)-G 
pAKT 
phospho-EGFR 
phospho-ERK1I2 
phospho-SMAD2 
S 100A 11 (FL-I05) 
SMAD2/3 
Syndecan-4 5G9 
TIMP3 
TRK (C-14) 
Vimentin 
Vinculin 
Sigma-Aldrich (St Louis, Mo, USA); 
Novus Biologicals (Littleton, CO, USA) 
MBL Medical & Biological Laboratories Co. (Naka-ku Nagoya, 
Japan) 
Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
Cell Signaling Technology (Beverly MA, USA) 
NanoTools (Teningen, Germany) 
Sigma-Aldrich (St Louis, Mo, USA); 
Cell Signaling Technology (Beverly MA, USA) 
Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
Cell Signaling Technology (Beverly MA, USA) 
Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
Abcam (Cambridge, UK); 
Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
Novocastra (Newcastle, UK) 
Sigma-Aldrich (St Louis, Mo, USA); 
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3.4.3 TNF-a detection 
TNF-a concentration In conditioned media, produced as described above, was 
evaluated by a fluorescent bead immunoassay (FlowCytomix'" Kit, Bender MedSystems, 
Vienna, Austria), according to manufacturer's instructions. The limit of detection of the 
assay for the TNF-a analyte is 3.2 pg/ml. 
3.5 In vivo studies 
Animal studies were reviewed and approved by the Ethics Committee for Animal 
Experimentation of the Fondazione IRCCS Istituto Nazionale dei Tumori and are in 
accordance with the guidelines of the UK Coordinating Committee for Cancer Research 
(U.K.Coordinating Committee on Cancer Research, 1988). Female CD-l nu/nu mice (8- to 
9-weeks old) (Charles River, Calco, Italy) were injected subcutaneously into the left flank. 
Tumour growth was assessed by evaluating tumour latency, ie days to reach 0.1 g, and by 
monitoring tumour weight (TW) twice a week. TW was estimated by the formula 
TW(g)=d2xD/2 where d and D are the shortest and the longest diameters of the tumor, 
respectively, measured in cm. 
3.5.1 Immunohistological studies 
Representative portions of excised tumour xenografts were fixed in 10% neutral 
buffered formalin, routinely processed and embedded in paraffin blocks. Four Jlm-thick 
sections were stained with hematoxylin and eosin (HE) and evaluated under a light 
microscope to assess the pattern of tumour growth. To establish the extent of tumour 
angiogenesis, serial sections were immunostained with a primary rat monoclonal antibody 
against CD31 antigen (clone SZ31, DIA 310M, Dianova) and positive endothelial outlines 
identified within the tumour stroma andlor capsule were counted in four randomly selected 
200x microscopic fields. To establish the number of histiocytes associated with the tumour 
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growth, additional serial sections were immunostained with a primary rat monoclonal 
antibody against F4/80 antigen (clone CI: A3-I, MCA497G, AbD Serotec) and positive 
cells were counted in five 400x microscopic fields randomly selected along the tumour 
edge. Both the immunostains were performed using a standard immunoperoxidase protocol 
(Vectastain Elite ABC kit, PK-6100, Vector Lab) followed by diaminobenzidine 
chromogen reaction (Peroxidase substrate kit, DAB, SK-4100, Vector Lab). 
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4: TIMP3 studies 
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4.1. Introduction 
4.1.1. TIMP3 
The Tissue Inhibitor of Metalloproteinase-3 (TIMP3) gene encodes a member of 
TIM:P family molecules that inhibit the proteolytic activity of matrix metalloproteinases 
(MMPs). TIM:P3 is a secreted protein and, unlike other TIM:P family members, which after 
secretion become freely diffusible within the cell microenvironment, binds tightly to the 
ECM. In addition, TIM:P-3 exhibits direct inhibitory activity against several ADAMs 
including TNF-a convertase (TACE, ADAM-17) (Fata et aI., 2001), and this inhibition is 
crucial for controlling TNF-mediated inflammation (Mohammed et aI., 2004). TIM:P-3 also 
inhibits cell shedding of several molecules (L-selectin, syndecans-I and -4, IL-6 receptor, 
c-MET) and cleavage of IGF binding proteins-3 and 5 (Fata et aI., 2001). TIM:P3 also 
regulates ADAM-mediated activation of the EGF receptor ligands, TGF-a, EGF, 
amphiregulin and heregulin (Gschwind et aI., 2003) and it is able to block MMP-mediated 
cleavage oflaminin-5 (Schenk et aI., 2003). 
TIM:P3 differs from the other MMPs as point mutations in its gene have been linked 
to Sorsby's fundus dystrophy (SFD), an autosomal dominant inherited retinal degenerative 
disease that leads to blindness (Yeow et aI., 2002). 
TIMP3 silencing through promoter hypermethylation has been associated with poor 
prognosis in a range of human cancers, and this evidence points to a role of TIMP3 as a 
tumour suppressor. TIMP3 is frequently hypermethylated in kidney, brain, colon cancer 
(Bachman et al., 1999), non small cell lung carcinoma (Zochbauer-Muller et al., 2001), 
pancreatic carcinoma (Ueki et aI., 2000) and hepatocellular carcinoma (Yuan et al., 2006). 
In esophageal and gastric carcinoma TIMP 3 was also found frequently methylated, and the 
loss or reduction of resulting TIMP3 expression was associated to shorter survival (Gu et 
aI., 2008). Furthermore a recent study by Barski et al. (Barski et aI., 20 I 0) reported that 
TIMP 3 downregulation by promoter methylation is associated with a more aggressive, high 
grade meningioma phenotype. 
69 
Conversely, recent studies showed that over expression of TACE and TIMP3 mRNA 
in head and neck cancer (HNSCC) is associated with tumour development and progression, 
suggesting that TIMP3 overexpression is a compensatory mechanism to counterbalance the 
pathologic increase in TACE sheddase activity (Kornfeld et a1., 2011). 
Loss of TIMP3 expression, through loss of heterozygosity on chromosome 22q, is 
also frequently observed in various cancers, such as secondary glioblastoma (Nakamura et 
a1., 2005) and clear renal cell carcinomas (Masson et a1., 2010). 
Evidence is emerging that the downregulation of TIMP3 expression in tumours can 
be achieved also through deregulation of microRNAs. In fact, TIMP 3 is a target of several 
microRNAs upregulated in human tumours: 1) miR21, involved in glioma invasion 
(Gabriely et a1., 2008) and in ductal adenocarcinoma (Nagao et a1., 2012); 2) miR181b, 
induced by TGFbeta and involved in hepatocarcinogenesis (Wang et a1., 2010); 3) 
HsamiR-191 can target TIMP3 mRNA and suppress TIMP3 protein expression In 
hepatocellular carcinoma (He et aI., 2011); 4) miR221 and 222, controlled by MET. 
targeting also PTEN and involved in NSCLC and BCC (Gabriely et aI., 2008; Garofalo et 
a1., 2009; Wang et aI., 2010). A reciprocal relationship between TIMP3 and miR-
22112221181b expression was also observed in primary human breast carcinomas. These 
miRNAs facilitate growth factor signalling in tamoxifen resistant breast cancer by 
downregulating TIMP3 (Lu et aI., 2011). 
The tumour suppressor role of TIMP3 is also documented by a large body of data 
showing its capability to inhibit growth, invasion and metastasis of several cancers 
(Anand-Aptc et aI., 1996; Qi et aI., 2003). Treatment of human melanoma, lung. prostate 
and breast cancer cells and xenografts with recombinant TIM:P3 protein reduced cell 
proliferation, induced caspase-mediated apoptosis, sensitized cells to paclitaxel, reduced 
tumour growth and metastasis (Mahller et a1.. 2008). In melanoma cells TIMP3 is involved 
in the stabilization of death receptors TNF-RI. FAS and TRAIL-RI on the surface of cells, 
sensitizing them to apoptosis induced by their ligands (Ahonen et aI., 2003). TIM:P3 
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promotes apoptosis In non adherent small cell lung carCInoma cells lacking functional 
death receptor pathway (Kallio et al. , 20 11). 
Anti-tumoural effects of TIMP3 are also ascribed to its anti-angiogenic properti es 
which are based on its abi lity to block the binding ofVEGF to its receptor (Qi et aI. , 2003). 
Restoration of TIMP3 expression by different approaches also resulted in the reduction of 
neovascularization in tumour xenografts of melanoma, neuroblastoma and malignant 
peripheral nerve sheath tumours (MPNST) (Ahonen et al., 2003; MahlIer et aI., 2008). 
A summary ofTIMP3 activities is shown in Figure 4.1. 
Active MMPs 
VEGF 
Dill 
HSPG 
ADAM 
Angiogonc6is Signal5 Probferation Signals 
Death Domain 
Receptof1l (Fa,. 
TNFR·1 . TRAIlR·1) 
FADD 
Apoplosla Signals 
Figure 4.1 Mechanisms involved in TlMP3 effects on apoptosis, angiogenesis, cell proliferation and 
migrlltion. TIMP3 promotes apoptos is by blocking the MMP-mediated shedding of death receptors; it 
inhibits angiogenes is blocking of VEGF to its receptor; it inhibits migration blocking the MMP-mediated 
cleavage of laminin-5, and proliferation by inhibiting ADAM-mediated release of EGF receptor ligands 
(from Edwards, 2004) 
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4.1.2. TIMP3 and thyroid cancer 
Thyroid tumours show hypermethylation of the TIMP3 gene (Hoque et al., 2005). In 
addition, TIMP3 was identified within a group of tumour suppressor genes (also including 
SLC5A8, DAPK, RAR/32) which were hypermethylated in a consistent fraction (53%) of 
PTCs in association with tumour aggressiveness and the presence of a BRAF mutation (Hu 
et al., 2006). In particular, methylation of TIMP3 was significantly associated with several 
aggressive features of PTC, including extrathyroidal invasion, lymph node metastasis, 
multifocality and advanced tumour stages. Methylation of TIMP 3 was also associated with 
BRAF mutation and occurred more frequently in the more aggressive classical and tall-cell 
PTC subtypes than in the less aggressive follicular-variant PTC, with the latter known to 
infrequently harbour the BRAF mutation. (Hu et al., 2006). Moreover, the TIMP3 gene was 
found to be downregulated in primary thyrocytes infected with RET/PTC} retroviral vector 
with respect to uninfected cells (Borrello et al., 2005). 
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4.2 Aims of the chapter 
At variance with other tumours, there are no studies regarding the functional role of 
TIMP3 in thyroid tumour biology. To investigate the role of TIMP3 in the pathogenesis of 
PTC, we used an integrated approach including analysis of several gene expression data 
sets and functional studies. 
The aims of this chapter are: to analyze TIMP3 expression in PTC samples using 
publicly available microarray data sets; to investigate the effect of TIMP3 restoration in 
NIM 1 cells, a PTC-derived cell line, on: 
• Cell growth and apoptosis; 
• Adhesion, migration and invasion; 
• Anchorage-independent growth; 
• In vivo tumourigenicity. 
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4.3. Results 
4.3.1. Expression analysis ofTIMP3 in PTC samples and thyroid tumour eel/lines 
Hypermethylation of the TIMP3 promoter has been detected in a high proportion 
(53%) of PTCs and associated with aggressiveness and BRAF mutation (Hu et aI., 2006). 
Based on the evidence that TIMP3 can also be regulated at post-transcriptional level by 
microRNAs, it was believed that gene expression analysis could represent the most 
accurate method for the assessment of TIMP 3 downregulation in PTC. Several microarray 
datasets of tumour and normal thyroid tissues were therefore analysed. cDNA microarray 
analysis previously produced in our laboratory (Ferrario et aI., 2008) showed that TIMP 3 
gene expression was downregulated in both the classical histotype as well as in the tall cell 
(TC) variant (p<O.Ol) compared with normal thyroid (Figure 4.2a). Frequent 
downregulation of TIMP3 compared with normal samples was also observed when a 
number of independent data sets of microarray gene expression data of PTC samples, 
publicly available and all obtained using Affyrnetrix HG-U133 series platforms were 
considered. As shown in Figure 4.2b, in the Giordano data set a significantly reduced 
expression of TIMP3 (p<0.05) was observed in the TC series (10 out of 26) though not in 
the classical histotype ofPTC when compared with normal thyroid (Giordano et aI., 2005). 
In both the He and Jarzab data sets (He et al., 2005; Jarzab et at, 2005), a statistically 
significant reduced (p<O.Ol) TIMP3 expression was displayed by PTe when compared 
with unaffected thyroid tissues from the same patients (Figure 4.2c and d). Although not 
statistically significant, in the Vasko data set (Vasko et al., 2007), both microscopically 
dissected central and invasive region of PTC of three out of four patients displayed a 
reduced expression of TIMP3 transcript in comparison with the corresponding normal 
region (Figure 4.2e). 
Overall this meta analysis suggests that TIMP 3 downregulation was a general event 
in PTC carcinogenesis. 
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Figure 4.2 Meta-analysis of T1MP3 gene expression levels in PTC in five different data sets. Data are 
reported as scatter plots oflog2 values and median is recorded. a) Our data set: TlMP3 downregulation was 
significant in both classical (C) and tall cell (TC) variants ofPTC ("p<O.Ol by Kruskal-Wallis followed by 
Dunns multiple comparisons post-test); TIMP3 relative expression values were measured as log2 ratio 
between expression level of the specimen and that of the reference. b) Giordano data set: in comparison to 
normal samples, TIMP3 downregulation was significant in TC variants of PTC ("'p<O.05 by Kruskal-Wallis 
followed by Dunns mUltiple comparisons post-test.). c and d) Jarzab and He data sets included normal and 
PTC samples taken from the same patient: in each data set PTC samples displayed decreased expression of 
TIMP3 when compared to the normal thyroid in paired tissue samples ("p<O.Ol or "'p<O.05 by Wilcoxon 
paired test). E) Vasko data set: central and invasive region of PTC and corresponding normal region have 
different symbols for each patient; three out of four patients displayed reduced expression of TIMP3 
transcripts in their tumoural area. 
The expression of TIMP3 by RT-PCR in a panel of thyroid tumour cell lines 
including PTC-derived (TPCl, NIMI, BCPAP and Kl), FTC-derived (WR082-1) and 
ATC-derived (FR081-2, FBI, BHTIOI and 8505C) cell lines and the human HEK293T 
cell line (known to express TIMP3 protein) was performed. With the exception of the 
TPCl (which carries the RET/PTe) oncogene) and BHTlOl (no genetic lesion is known), 
all the other thyroid tumour derived cell lines harbour the BRAFV600E mutation 
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(Schweppe et aI., 2008). (Details of the mutational status of these cells lines are reported in 
Table 3.2 of materials and methods section). The experiment reported in Figure 4.3a 
showed that although TIMP3 expression was undetectable in the TPC I and NlM 1 cell 
lines, treatment with the demethylating agent 5-Aza-2' -deoxy-cytidine (5-Aza-dC) restored 
the TlMP3 mRNA expression (Figure 4.3b). This suggests that aberrant promoter 
hypermethylation silences the TlMP3 gene in TPC 1 and NfM 1 cells 
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Figure 4.3 TlMP3 mRNA expressio n by RT-PCR a) Analysis ofa panel of thyroid tumour derived cell 
lines; GAPDE gene express ion was used as loading control. b) Effect of 5-/\za-2 ' -deoxy-cytidine (5-/\za-
dC) treatment on TIMP3 express ion in NIM 1 and TPC 1 ce ll lines. 
4.3.2. Effect 0/TlMP3 restoration on cell growth 
We produced an in vitro model based on the restoration of TlMP3 expression in 
NfM I , a PT -derived cell line harbouring the BRAFV600E mutation, derived from a 
metastasis and tumourigenic in nude micc (Zeki et aI., 1993). The TIMP3-myc expression 
plasmid carrying the TIMP3 cDNA fused in frame with the myc epitope was constructed. 
This produced a 27 kDa TIMP3-mye protein reacting with both anti-myc (Figure 4.4.a) 
and anti-TIMP3 antibodies, as assessed by western blot analysis of transiently transfected 
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NlMl cells. The TIMP3-myc expressIOn construct was used to generate stable NIMI 
clones expressing the exogenous TIMP3-myc protein, following transfeetion and selection 
in geneticin. Western blot analysis identified II out of 27 independent clones expressing 
variable levels of TlMP3-myc protein. Three NIMI-TIMP3 clones, named NTMI-TII, 
NIM 1-T 14 and NlM 1-T23 were further characterized. The exogenous TIMP3-myc protein 
was dctectable both in thc cell extracts and in the conditioned media, as shown in Figure 
4.4b. 
a b NIM1-T 
NIM1 11 14 23 NIM1 
EV T-myc 
TIMP3-myc -l TIMP3-myc 
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Figure 4.4 Restoratjon of T1MP3 expression in NIM 1 cell line. Detection of TTMP3-myc protein by 
western blot using anti -myc antibody in: a) NIM I ce ll line transiently transfected with empty (EV) or 
TTMP3-myc (T-myc) vector, and b) in whole ccll Iysates (WCL) (top) and condit ioned medium (CM) 
(bottom) of stab ly TIMP3 transfected clones. p-tubulin was used as loading control for whole cell Iysates; 
conditioned media were normalized for cell number 
TIMP3 inhibits, among others, TACE/ ADAM 17, a convertase involved in the 
production of soluble TNF-a (Fata et aI. , 200 I) . Thus, the cleavage of TNF-a represents a 
read-out of TIMP3 activity. The TNF-a present in conditioned media oC NIM I-TIM P3 
clones was determined by flow cytometric analysis. NIMI clones transCected with empty 
vector (NIM I-EY) were used as controls. As shown in figure 4.5, the amount of soluble 
TNF-a in the NIM I-TIMP3 clones was dras tica lly reduced with respect to NIM \-EY 
clones, thus demonstrating the activity of TIMP3-myc protein. Further evidence was 
provided by the reduction of syndecan-4 and ALCAM in the NIM I-TIMP3 clones 
conditioned media. The shedding of both of these proteins is mediated by TACE/ ADAM 17 
(Fata et aI., 2001 ; Rosso et aI. , 2007), and wi ll be shown later. 
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2 14 23 
NIM1-EV NIM1-T 
Figure 4.5 Detection of TNF-a protein in the conditioned media of NIM l-EV and NIM I-T clones. Ce lls 
were treated with PMA (I OOng/ml, 2h) and the amount of released TNF-a in the conditioned media was 
analysed by flow cytometry. Values are expressed as mean ± SD of duplicate samples. The asterisk indicates 
differences significant by the Student's t-test (p< 0.05). 
A large body of published data shows that TJMP3 is able to inhibit cell growth and to 
promote apoptosis in several tumour types such as melanoma and non adherent small cell 
lung carcinoma (Anand-Apte et aI., 1996; Kallio et aI., 20 II). The effect of TIMP3 on 
NIMI growth rate was investigated using a variety of approaches. In cells exposed to 
conditioned medium containing (CM+) or Jacking (CM-) TIMP3 protein (derived from 
NIMI-T23 or untransfected NIMI cells, respectively), no differences in growth rate were 
observed (Figure 4.6). 
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Figure 4.6. Cell proliferation analysis of NIM 1 treated with conditioned media. Proliferation of NIM I 
cell s in the presence of T1MP3 -containing (CM+) or control (CM-) medium determined by the alamarBlue 
Assay. The experiment was conducted in the presence of FCS; at the indicated time points the Relative 
Fluorescence Unit (RFU) was determined and data were normalized for va lues at day 1. 
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In keeping with these results, flow cytometric analyses showed the NIMI-TIMP3 clones 
and the control NIMI-EV clones display comparable cell cycle dynamics (Figure 4.7a). 
TIMP3 is able to sensitize melanoma cells to undergo apoptosis induced by death 
receptors ligands (Ahonen et al., 2003). We investigated whether TIMP3, alone or in 
combination with the pro-apoptotic agent TRAIL effective in NIM 1 cells, was capable to 
induce apoptosis in our system. NIMI cells were treated for 24h and 48h with CM+ or 
CM- and the levels of cleaved PARP were detected by Western blot analysis. The results 
are shown in Figure 4.7b. In CM- treated cells we observed basal levels of cleaved PARP, 
not affected by treatment with CM+ medium. As positive control, the induction of PARP 
cleavage by treatment of TRAIL is shown (Figure 4.7b, top left panel). When TRAIL was 
administered to cells pre-treated with the CM+, no difference in PARP cleavage with 
respect to the control was observed (Figure 4.7b, top right panel). Similar results were 
observed by analyzing the NIM 1-TIMP3 clones, which showed levels of cleaved P ARP 
similar to those of NIMI-EV clones and untransfected NIMI cells (Figure 4.7b, bottom 
panel). 
These data indicate that TIMP3 is neither able to promote apoptosis in NIM 1 cells, as 
also suggested by FACS analysis (Figure 4.7a), nor to sensitize them to TRAIL-induced 
apoptosis. 
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Figure 4.7 Effect of TIMP3 re-expression on NIMI cell cycle and apoptosis. a) lop: flow cylometric 
analysis of NIMl clones transfected with empty vector (NIMI-EV1) or TIMP3-myc construct (NIMI-T23); 
percentage of cell cycle distribution is shown; bottom: the data represent the percentage avarage of cells in 
different stages of the cell cycle of three independent experiments; b) Western blot detection of cleaved 
PARP protein. Top: NIMl cells treated with CM+ or CM- medium (left panel), or treated with TRAIL (50 
nglml for 5h) following 24 h pre-incubation with CM+ or CM- (right panel); vinculin was u ed as loading 
control. Bottom: NIMI-T and NIMI-EV clones; p-tubulin was used as loading control. 
80 
4.3.3. Effect ofTIMP3 restoration on cell adhesion 
When NIMI cells were plated at low density in CM+ or CM-, no differences in 
colony numbers or dimensions were observed at days 10 and 17 (data not shown), a result 
in keeping with the lack of effect of TIMP3 on growth rate described above. Interestingly, 
a difference was observed at day 24 where the NIMI colonies grown in CM+ were more 
compact and dense than those in CM-, which underwent cell detachment (Figure 4.8a), 
suggesting an effect ofTIMP3 on cell adhesion. To further dissect this issue we perfonned 
an adhesion assay in which NIMI cells were pretreated with CM+ or CM- for 24 hand 
seeded in a 96 plate coated with type IV collagen (a component of ECM, known to interact 
with cell-surface heparin sulfate proteoglycans (Khoshnoodi et al., 2008), whose shedding 
is inhibited by TIMP3 (Fitzgerald et al., 2000) in the presence of the same media. The 
number of cells attached to the substrate 1 h after seeding was measured. As shown in 
Figure 4.8b, treatment with CM+ increases the adhesion ofNIMl cells by 1.4 fold. Similar 
results were obtained in the presence of recombinant TIMP3 protein, which caused a 1.8 
fold increase in NIMI cell adhesion (Figure 4.8c), thus ruling out the possibility of 
ascribing the above reported results to the presence in the CM+ of secreted factors other 
than TIMP3. The adhesion assay was also applied to the NIMI-TIMP3 clones and all 
showed a 2 to 3 fold increase in adhesion with respect to the NIMI-EV control clones 
(Figure 4.8d). Collectively these data indicate the involvement of TIMP3 in the regulation 
ofNIMl cell adhesion. 
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Figure 4.8 Effect of TTMP3 expression on NIM 1 cell adhesion. a) Colonies formed by NIM I cells in the 
presence of TIMP3-contain ing (CM+) or control medium (CM-). Two hundred cell s were plated into 100 
mm2 Petri di shes; colonies were fixed and stained after 24 days; representative pictures of colonies at a 
higher magnification are shown. b) Adhesion ofNIM I cell s to ECM in the presence of CM+ and CM-.Cells 
that adhered to the plate after I hour incubation were fixed and stained wi th crystal violet. The adhesion 
capability was calculated by measuring the absorbance at 595 nm and the resu lts of one representative 
experiment is shown. c) Adhesion ofNIMl cells to ECM in the presence or absence of recombinant TTMP3 
protein. The graph shows mean values from two diffcrent experiments. d) Adhesion ofNIM I-T and NIMI-
EV clones. The graph shows a representa ti ve experiment; the datu represents mean values ± SD. The asterisk 
indicates significant differences by the Student 's t-test (p< 0.05). 
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4.3.4. Effect ofTIM?3 on cell migration and invasion 
A wound healing assay was perfonned to investigate the migratory capability of 
NIMI-TIMP3 clones. As shown in Figure 4.9a the NIMI-TIMP3 clones showed reduced 
wound healing capability with respect to the NIM l-EV clones. At 24 hours the scratch of 
the control clones was completely healed, whereas the repair of the NIM 1-TIMP3 clones 
was only 39 to 79%. Comparable results were obtained in the presence of recombinant 
TIMP3 protein which reduced the migration capability of NIMI cells by approximately 
50% at 8 and 24 hours after scratch ing (Figure 4.9b). 
To further support these results, the effect of TIM?3 silencing on the migration capability 
of Kl cells (derived from a PTC, carrying the BRAFV600E mutation and expressing high 
amount of TIM?3 mRNA) was investigated. The results are shown in Figure 4.9c. Kl cells 
transiently transfected wi th TIMP3 siRNA showed abrogation of TIMP3 expression 
(Figure 4.9c, left). Concomitantly, a 2.3 fold increase of migration capability, with respect 
to control, was observed, as assessed by wound healing assay (Figure 4.9c, right). 
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Figure 4.9 Effect of TlM]>3 expression on wound healing. A scratch was app lied to ce ll monolayer, and 
migration of the ce lls toward the "wound" was recorded by taking pictures at the indicated time points. a) 
NIM l-T and NIM l-EV clones; in each panel the percentage of wound healing, determined by dividing the 
migrated distance by the scratched distance, is indicated . b) NIM 1 cells exposed (DMEM rTIMP3) or not 
(DMEM) to recombinant TIMP3 protein. Data arc expressed as percentage of wound healing (WH %) 
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calculated by dividing the migrated distance by the scratched distance. c) Kl cells transfected with either 
control or TIMP3 specific siRNAs. Left: TIMP3 mRN~ expression was checked by RT-PCR as described in 
Materials and Methods section. Right: Wound healing assay was performed in triplicates 48 hours after 
siRNA transfection. Data represent mean values ± SD; the asterisk indicates differences significant by the 
Student's t-test (p< 0.05). 
Boyden chamber assays were then performed to investigate both the migratory and 
invasive capability of NIMI-TIMP3 and NIMI-EV clones using their own CM as 
chemoattractant. In the migration assay all the NIM 1-TIMP3 clones showed a drastic 
reduction (78-87%) in migration with respect to the control NIMI-EV clones (Figure 
4.10a, top). When the assay was performed in the presence of Mat rigel, very similar results 
were obtained. The NIM 1-TIMP3 clones showing an invasion capability reduced by 86-
95% with respect to NIMI-EV clones (Figure 4.10a, bottom). 
To rule out the possibility that the above data could be ascribed to clone variability, 
we performed Boyden chamber assays in which NIM I cells transiently transfected with 
TIMP3-myc construct or empty vector were exposed to their own or the other CM as 
chemoattractant. In this case the CM+ and CM- were derived from TIMP3-myc or empty 
vector transiently transfected cells, respectively. The results are reported in Figure 4.1 Ob. 
NIMI-TIMP3 transfected cells exposed to CM+ showed a reduction of migration (33%) in 
comparison with those exposed to CM-. Similarly, the migration of EV-transfected NIMI 
cells was reduced by 49% in the presence of CM+ compared to CM-. The invasion assay 
showed similar results. The invasive capability of NIM 1-TIMP3 transfected cells in the 
presence of CM + was reduced by 47% compared to that occurring in the presence of the 
CM-. Similarly, NIMI-EV cells showed a 51% reduction of invasion in the presence of 
CM+ with respect to that found in the presence ofCM-. As reported above for the adhesion 
and wound healing assays, results consistent with those in the presence of CM+ were 
obtained by performing the invasion assay in the presence of recombinant TIMP3 protein. 
A consistent reduction (41%) of invasiveness ofNIMI-EV cells was detected. 
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Figure 4. t 0 Effect of TIMP3 expression on migration, invasion and anchorage-independent growth. a) 
Migration and invasion ofNIMI -T and NIMI -EV clones by Boyden chamber assays. Cells were seeded in 
the upper part of the Boyden chamber whi le their own conditioned media were used as chemoattractant in the 
bottom chamber. Migration and invasion rates arc normalized over the control. RMR: rehl ti ve migrating rate; 
RIR: relative invad ing rate. Data represent the mean va lues ± SO of four independent experiments. The 
asterisk indicates significant differences using the Student's t-test (p< 0.05). b) Migration and invasion of 
NIM I ce lls transiently transfected with T1MP3-myc (T-myc) or empty vector (EV) and exposed to one of the 
followin g, their own or other conditioned medium (CM+ and CM-) as chemoattractant, or to recombinant 
TIMP3 protein (rTIMP3). The experiment was performed as in a. 
4.3.5. Effect 0/ TIM?3 on anchorage-independent growth 
Tumour cell s di splay the capabi lity to grow in the absence of adhesion. A soft agar 
assay was performed to inves ti gate whether adhes ion in the NTM I cells is affected by 
TIMP3. The NTM 1-TIMP3 clones and, as control , the NTMI -EV I clone and untran fected 
NTM 1 cells were used. After three weeks of incubation in so ft agar the NTM I-TIMP3 
clones form ed colonies with efficiency reduced (68-9 1 %) wi th respect to control cell s 
( igure 4. 11 , top). Moreover, the soft agar clones fomled by NTMI -TTMP3 cells were 
smaller than those of the control cell s (Figure 4. 11 bottom). 
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Figure 4.11 Anchorage-independent growth in TIMP3 transfected and control cells . Top: Colony-
forming efficiency was detennined by the ratio between number of co lonies and number of plated ce lls. The 
asterisk indicates differences significant by the Student's t-test (p< 0.05) . Bottom: Representative pictures of 
colonies formed after 22 days of growth in soft agar. 
4.3.6. Analysis a/proteins mediating TIMP3 effects 
The status of several proteins, involved in the regulation of cell adhesion, migration 
and invasion by TIMP3 was investigated. Syndecan-4 and ALCAM are two proteins 
involved in cell adhesion and regulated by shedding mediated by ADAM 17/TACE, a 
TIMP3-sensitive metalloprotease (Fata et aI. , 200 I ; Rosso et aI. , 2007). The soluble form 
of syndecan-4 was less abundant in the CM of the NlM 1-TJMP3 clones with respect to the 
control cell s, as demonstrated by immune dot blot (Figure 4.12a, top) . Similarl y, the level 
of the 96 kDa soluble form of ALCAM, detected by westem blot, was reduced in the 
NlM 1-TJMP3 clones with respect to the control cells (Figure 4.12a, bottom). 
E-cadherin, an adhesion molecule whose defi ciency in cancer cells promotes 
invasion (Margineanu et aI., 2008), was undetectabl e in the naive NIM I cells, a result in 
keeping with the metastatic origin of these cell s, and its expression was not res tored in 
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TIMP3-expressing clones. The expression of E-cadherin in human primary thyrocytes is 
shown as a control (Figure 4. 12b). 
Vimentin is involved in invasion and its expressIOn IS upregulated in several 
tumours, including PTC (Vasko et aI., 2007). As shown in Figure 4.12c (top) the vimentin 
level in the NTM 1-TIMP3 clones was reduced with respect to that present in the NrM I-EV 
cells. 
The Cytokeratins 8118 are regulators of integrin-dependent adhesion and migration 
(Bordeleau et aI. , 20 10) and their levels were increased in the NIM 1-TTMP3 clones with 
respect to control (Figure 4.12c, bottom). 
On the whole these results indicate that TIMP3 regulates adhesion, invasion and 
migration ofNIMI cells by modulating the amount ofsyndecan-4, ALCAM, and vimentin 
and cytokeratins 8/ 18. 
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Figure 4.12 Modulation of adhesion molecules by TIMP3 expression . a) Analysis of shedd ing of 
Syndecan 4 by dot blot (upper panel) and ALCAM by Western blot (lower panel) in conditioned media of 
NTM I-EV and NIM 1-T clones. Samples were normalized for cell number. b) Detection of E-cadherin and c) 
of viment in and cytokcT3tins 8/ 18 cxpression in NIM-T and NIM-EV clones by Westcrn blot ana lysis. p-
actin was lIsed as loading control for cell cxtracts. N-Thy indicates human primary thyrocy1cs. 
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4.3. 7. Effect ofTIMP3 restoration in mOUSe tumour xenografts 
To investigate the in vivo consequences of TIMP3 re-expression in NIMI cells, the 
NIMI- TIMP3 clones (TIl, TI4 and T23) and NIMI cells were injected into nude mice. 
Tumour growth was observed in 3/3 mice injected with the NIM 1 cells. In mice 
xenografted with NIMI-TII cells 3/3 takes were observed although regression occurred in 
113 animal. In mice injected with the NIMI-TI4 and NIMI-T23 clones tumour growth was 
observed in 2/3 mice. Collectively, the tumours produced by NIMI-TIMP3 clones grew 
more slowly than the NIM 1 derived tumours (Table 4.1). 
Table 4.1 In vivo tumour growth ofNIMI cells and NIMI-TIMP3 clonesB 
Cell line Tumor- Rcgres.v;on Days Da)'s 
bearing m;~ at 0.1 g at/g 
NtMI 3/3 0/3 <8 12 (12-18) 
NIMI-TII 3/3 1/3 11 «8 to 14) 20,38 
NTMI-TI4 2/3 0/'2 10.49 26,62 
NIMI-T23 2/3 0/2 11.62 >32. >66 
BParental NIM 1 cells and NIM 1-TIMP3 clones (2x 1 06) were inoculated 
subcutaneously into the left flank of athymic nude mice as described in Materials and 
Methods section. Tumour growth was assessed by evaluating tumour latency, ie days to 
reach 0.1 g, and by monitoring tumour weight (TW) twice a week. TW was estimated by 
the formula TW(g)=d2xD/2 where d and D are the shortest and the longest diameters of the 
tumour, respectively, measured in cm. 
As soon as the tumours were visible through the skin of the nude mice TIMP3-
expressing tumours appeared to be paler than the NIM I-induced tumours. This difference 
was confirmed at excision of the tumours. In addition, TIMP3-expressing tumours were 
less hemorrhagic compared to the NIMI-induced tumours (data not shown). Cell cultures 
were established from the explanted tumours. Western blot analysis confirmed the 
expression of TIMP3 protein in tumour-derived cells (Figure 4.13a). In addition, functional 
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analysis of the xenograft-derived cells revealed that TIMP3-expressing cells maintain the 
reduction of wound healing, migration and invasion relative to NIM I cells (Figure 4.13b, 
c, and d). 
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Figure 4.13 Analysis of cell cultures established from tumours induced in nude mice by NIM I and 
NIMI -T clones. a) Detection ofTIMP3-myc protci n by Western blot ana lysis. b) Wound healing assay. A 
scra tch was applied to cells grown in mono layer and the distances between the edges measured immediately. 
and then after 8 and 24 hours. Data arc expressed as the percentage of wound healing (WH %) calculated b I 
dividing the migrated distance by the scratched distance. Migration (c) and invasion (d) capabi lities of 
xenograft-derived cell cu ltures measured by Boyden chamber assays. ell s were seeded in the upper part of 
the Boyden chamber whi le in the bottom part their own condi tioned media were used as chemoattractant. as 
described in Material and methods. Data arc expressed as number of migrated (c) or invading (d) cells per 
field . A representative experiment is shown; simi lar results were obtained in three independent experiments. 
Data represent mean va lues ± SO. The asteri sk indicates differences significant by the tudent' s t-tes t (p< 
0.05). 
Histopathologically, both NTM I and NIM \-TIMP3 subcutaneous tumour xenografls 
appeared as we ll -demarcated expansi le multinodular growths. Tumour ti ssue was 
composed of large polygonal anaplastic epithelial cells arranged in small dense cellular 
lobu les and papillary projections often delimiting central cystic spaces. The e tumour units 
were supported by variable amounts of fibrovascular stroma and surrounded by a loose 
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capsular reaction with sparse infiltration of inflammatory cells. Locally extensive necro-
hemorrhagic areas were consistently observed at the periphery of NIM I-induced tumours. 
Similar lesions were not observed in association with the NIMI-TIMP3-induced tumours 
(Figure 4.14 top panels, hematoxylin and eosin). Taken together, these findings may 
explain why grossly detectable hemorrhages were recorded in tumour xenografts deriving 
from the NIM I cells but not from those induced by the NIM 1-TIMP3 cells. 
To assess the extent of vascularisation in tumour xenografts, the microvessel density 
was determined by IHC using an anti-mouse CD31 antibody (Figure 4.14, middle panels). 
The mean microvessel count in TIMP3-expressing tumours was reduced with respect to 
that present in the NIM I-induced tumours. The difference was statistically significant for 
the NIM 1-T23 tumours. 
In several human tumours, including thyroid cancer and related animal models, it has 
been observed that tumour angiogenesis correlates with the extent of macrophage 
infiltration (Detoraki et al., 2009; Dhar et al., 1995; Russell et al., 2003). To investigate the 
presence of infiltrating macrophages in our in vivo tumour model their presence in the 
tumours was evaluated by IHC with an F4/S0 antibody. As shown in Figure 4.14 (bottom 
panIcs, F4/S0), the number of macrophages was significantly reduced in tumours 
expressing TIMP3 with respect to those induced by naive NIMI cells. 
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Figure 4.14 Microscopic and immunohistochemical analysis of NIMI-TIMP3 and NIMI induced 
tumours. HE -left panel: NIMI-induced tumor xenograft where the periphery of the tumour is effaced by a 
locally extensive hemorrhagic area (*) and few neoplastic papillary projections (T) are still present; right 
panel: in the NIMl-TIMP3-induced tumour xenograft, the periphery of the tumour is composed of solid 
lobules surrounded by a fibrovascular capsular reaction without any evidence of hemorrhagic lesions. CD3l 
- representative pictures of CD3l irnmunostaining in NIMI (left panel), NIMl-T14 (central panel) and 
NIMl-T23 (right panel) tumour xenografts. T shows the position of the tumor lobules while (*) denotes the 
tumour capsule-stroma (*), F4/80 - representative pictures of F4/80 immunostaining in NIMl- (left panel), 
NIMI-T14 (central panel) and NIMl-T23 (right panel) induced tumour xenografts. Tumour capsule-stroma 
(*), tumour lobules (T). 
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4.4. Discussion 
Using an integrated approach which included the analysis of gene expression data 
and functional studies, TIMP3 has been demonstrated to exert a negative regulatory role in 
thyroid carcinogenesis. Analysis of gene expression data produced in our laboratory 
demonstrated the consistent downregulation of TIMP 3 in PTC with respect to normal 
thyroid, and also highlighted an association with the tall cell variant. Downregulation of 
the TIMP 3 gene in PTCs with respect to normal thyroid was also observed by in silico 
analysis of three different public available gene expression data sets. Collectively the gene 
expression data support the notion that TIMP3 may exert an oncosuppressor role in PTC, a 
function also suggested by previous studies. For example, the TIMP3 gene was found to be 
downregulated in primary thyrocytes infected with RETIPTCl retroviral vector with 
respect to uninfected cells (Borrello et aI., 2005). Moreover, TIMP3 was identified as being 
within a group of tumour suppressor genes (also including SLC5A8, DAPK, RARfi2) which 
were hypermethylated in a consistent fraction (53%) of PTCs and was associated with 
tumour aggressiveness and BRAF mutation (Hu et aI., 2006). In the present study promoter 
hypermethylation was also identified as the mechanism silencing TIMP 3 gene expression 
in the two PTC-derived tumour cell lines TPCl and NIMI with levels of TIMP3 mRNA 
increasing upon treatment with the demethylating 5-Aza-C agent. 
Different effects of TIMP3 restoration on tumour cell growth have been reported. 
Although no effects on the in vitro proliferation of murine neuroblastoma and melanoma 
cells have been observed (Spurbeck et aI., 2002), TIMP3 expression in human melanoma, 
neuroblastoma and MPNST was reported to induce apoptosis (Ahonen et aI., 2003; 
Mahller et aI., 2008). The contribution of TIMP3 to thyroid carcinogenesis was therefore 
studied by restoring TIMP3 expression in the TIMP3-negative NIMl, a PTC-derived cell 
line. This was achieved by exposure of the NIM 1 cells to TIMP3-containing conditioned 
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medium and by transient or stable transfection with TIMP3-myc eDNA. No effects on 
growth control, the induction of apoptosis or the activation levels of major signal 
transduction pathways known to function in NIM 1 cells were observed. The lack of effect 
of TIMP3 on the growth rate of NIM I cells might be related to their thyroid origin and/or 
to the advanced tumour stage they represent, being derived from a PTC metastasis. In this 
context it is worth noting that multiple elements contribute to the growth regulation of 
NIMI cells. In addition to the BRAFV600E mutation, NIMI cells carry a homozygous 
deletion of the tumour suppressor p 16INK4 (Calabro et aI., 1996), produce mUltiple 
cytokines including GM-CSF, IL-6, IL-ll, and their growth is regulated by IL-l through 
an autocrine mechanism (Tohyama et aI., 1992; Zeki et aI., 1993). Moreover, we have 
recently demonstrated that the growth of NIM 1 cells is regulated by an autocrine 
TGFalEGFR loop (Degl'Innocenti et aI., 2010) and by the IGFBP7 pathway (Vizioli et al., 
2010). 
Although not involved in growth control in thyroid tumour models studied here, 
TIMP3 expression modified some features of the phenotype of treated NIM I cells. Cells 
exposed to soluble TIMP3 protein or transfected with the TIMP3-myc construct showed 
increased adhesion and a reduced migratory and invasive capability. Analysis of some ccll 
adhesion mediators in the TIMP3-expressing clones showed reduction of syndecan-4 and 
vimentin protein levels, decreased ALCAM shedding, but an increase of the epithelial 
marker cytokeratin. All these features, which are consistent with the inhibitory effect of 
TIMP3 on MMPs and on ADAM 17 IT ACE, indicate a reduced degradation of the ECM, 
and suggest that the transformed phenotype of NIM 1 cells can be modulated by TIMP3 
restoration. 
The most striking effect of TIMP3 restoration in NIM I cells was observed in mouse 
tumour xenografts. When compared to TIMP3-negative NIM I-induced tumours, TIMP3-
positive NIMI expressing tumours showed consistently reduced growth and appeared paler 
and less hemorrhagic. In this context, histopathological examination confirmed the 
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presence of hemorrhagic areas in the NIMI TIMP3-negative induced tumours, but not in 
the NIM-I TIMP3-expressing tumours. In keeping with this, angiogenesis (assessed 
through the evaluation of microvessel density) was reduced in the NIM 1 TIMP3-
expressing tumours and this was associated with reduction of tumour infiltrating 
macrophages. The antiangiogenic effect of TIMP3 observed in the tumour xenografts 
suggests a link between the frequent increase of angiogenesis and TIMP3 downregulation 
detected in PTC (Akslen and LiVolsi, 2000; Hu et aI., 2006). It has been described that the 
antiangiogenic effect ofTIMP3 is related to its inhibition ofVEGFA binding to VEGFR-2, 
thus attenuating downstream signalling (Qi et aI., 2003), and that VEGFR inhibition is 
responsible for the anti-tumoural role of TIMP3 in several models (Ahonen et aI., 2003; 
Mahller et aI., 2008). Based on the evidence that NIMI cells produce VEGFA (Melillo et 
aI., 2010), the same mechanism could be responsible for the effects observed in our tumour 
xenograft model. 
The reduction of infiltrating macrophages in the NIMI TIMP3-expressing tumours is 
worth noting, since the extent of macrophage infiltration is associated with progression in 
thyroid epithelial tumours (Ryder et aI., 2008). It has also been shown that the inhibition of 
VEGF A binding to VEGFR-2 reduces macrophage infiltration in orthotopic xenografts of 
pancreatic and breast tumours (Dineen et aI., 2008; Roland et al., 2009). Thus, it is 
tempting to speculate that in the mouse xenograft tumour model the inhibitory effect of 
TIMP3 for VEGFA binding to VEGFR-2 may be responsible for reduction of both 
angiogenesis and macrophage infiltration, thus leading to restriction of in vivo tumour 
growth. Further studies are needed to dissect the mechanisms through which TIMP3 
regulates angiogenesis and macrophage infiltration in PTC. 
In summary, restoration of TIMP3 in the PTC-derived NIMI cell line had no effect 
on growth rate; however, it reduced migration, invasion and anchorage independent growth 
and in vivo tumourigenicity, supporting a tumour suppressor role in thyroid carcinogenesis. 
(Figure 4.15) 
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Figure 4.15 In vitro and in vivo effects of TIMP3 restoration in thyroid tumour cells. Restoration of 
TIMP3 in the PTe-derived NIMI cell line had no effect on growth rate; however, it reduced migration, 
invasion and anchorage independent growth and in vivo tumourigenicity, supporting a tumour suppressor role 
in thyroid carcinogenesis. 
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5. S100All studies 
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5.1 Introduction 
5.1.1 S100A11 
S 1 OOA 11, also known as S 1 OOC and calgizzarin, is an EF hand-type Ca2+ -binding 
protein belonging to the S 1 00 protein family. S 1 00 proteins are named after their solubility in 
100% saturated ammonium sulphate solution (Moore, 1965), and are small proteins with a 
molecular weight ranging from 9 to 14 kDa. Although the molecular structures of S 1 00 
proteins are similar, their expression profiles and cellular functions differ greatly depending 
on cell types and functional conditions. A large proportion of S 1 00 proteins belong to the 
S100A family. In humans, 16 family members (SlOOAl to S100A16) are currently known 
and they are clustered in a region of chromosome 1 q21. 
S 1 OOA 11 has been proposed to have biological functions in the processes of endo- and 
exocytosis (Seemann et aI., 1997), regulation of enzyme activity (Zhao et aI., 2000), cell 
growth (Sakaguchi et aI., 2000), apoptosis (Makino et aI., 2004) and inflammation (Cecil et 
aI., 2005). In addition, S 1 OOA 11 has been identified as a ligand of the receptor for advanced 
glycation end products (RAGE), and could regulate the chondrocyte differentiation to 
hyperthrophy in osteoarthritis pathogenesis (Cecil et aI., 2005). 
One of the most widely accepted theories about the role ofSl00All, has been proposed 
by Sakaguchi et aI. (Sakaguchi and Huh, 2011), who presented S 1 OOA 11 as a key mediator of 
calcium-induced growth inhibition in cultured normal human keratinocytes (NHK). An 
increase in extra-cellular calcium may cause phosphorylation of S 1 OOA 11, with subsequent 
binding to nucIeolin and translocation to the nucleus. S 1 OOA 11 may then liberate Sp 113 from 
nucIeolin, leading to increased transcription of p21 CIP llW AF and p 16INK4a which are 
negative regulators of cell growth (Figure 5.1). The same authors also showed that SIOOAll 
mediated a TGF-p-triggered signalling for growth suppression in a manner similar to that 
from high calcium (Sakaguchi et aI., 2004). Notably, the S I OO-mediated pathway was 
deteriorated in human squamous carcinoma cell lines that are resistant to TGF-p (Sonegawa 
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et al., 2007), indicating that it IS at least partly involved In conferring human epithelial 
cancers resistance to TGF- p. 
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Figure 5.] Mechanism of SlOOAll-mediated growth inhibition in NHK cells. High ea2+ and TGF-~ 
stimulation promotes SIOOAII phosphorylation, its binding to nucleolin and consequently translocation into the 
nucleus. SIOOAll then liberates Spl/3 from nucleolin, leading to increa ed transcription of p2ICIPl/WAF and 
pl6INK4a (from (Sakaguchi and Huh, 2011) 
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Another growth-suppressive function of SlOOAll has been found in NHK, whose 
growth depends on arachidonic acids (Sakaguchi et aI., 2007). Annexin 1 (ANXAl) 
complexed with SlOOAll efficiently binds to and inhibits cPLA2, a rate limiting enzyme of 
the arachidonic cascade. Upon exposure of NHK to EGF, ANXAI is cleaved at 12W, and the 
truncated ANXAlloses binding capacity to SlOOAll, resulting in maintaining cPLA2 in an 
active state (Figure 5.2). In squamous cancer cells, this pathway was shown to be 
constitutively activated (Sakaguchi et aI., 2007). 
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Figure 5.2 Alternative mechanism of SlOOAJ I-mediated growth inhibition in NHK cells. EGF-activated 
EGFR leads to the cleavage of ANXAl. This hampers the formation of the complex with SIOOAll, resulting in 
loss of inhibition of cPLA2 activity, which is important for NHK growth (from (Sakaguchi and Huh, 2011) 
More recently, the same authors have shown that in addition to being an essential 
mediator of growth suppression, SlOOAll could also enhance growth of human keratinocytes 
through the induction of EGF, or other ligands of the EGF receptor, functioning as a dual 
mediator for growth regulation of epithelial cells (Sakaguchi et aI., 2008). Extracellular 
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SlOOAll binds to its receptor, RAGE, and this signal causes intracellular Akt 
phosphorylation. Activated Akt can phosphorylate CREB, which liberates CREB from the 
seventh AP-l site of EGF promoter, and then, AP-l binds to the spare site and triggers the 
transcription of EGF, and causes cell growth (Figure 5.3). Production and secretion of 
SlOOAll are markedly enhanced in human squamous cancer cells. These findings indicate 
that SlOOAll plays a dual role in growth regulation, being suppressive in cells and being 
promotive from outside of cells (Sakaguchi et aI., 2008). 
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Figure 5.3 Mechani m of IOOAll-mediated growth promotion in NHK cells. The EGF/EGFR pathway 
activation induces the expre sion and secretion of SlDDAll. The secreted SlDDAll protein binds to RAGE and 
promote the activation of Akt signalling pathway, resulting in the induction of EGF famjJy proteins expression 
(from (Sakaguchi and Huh, 2011) 
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SIOOAll, as other members of its family, is supposed to regulate cytoskeleton 
dynamics and have a significant influence on cell morphology by interacting with the 
components of cytoskeleton. It has been shown that S 1 OOA 11 can bind, in a Ca2+ -dependent 
manner, to the N-terminal domain of ANXAI. This interaction is indispensable for membrane 
localization of SlOOAll (Sakaguchi et aI., 2007). Besides ANXAl, SlOOAll could interact 
with annexin II (Rintala-Dempsey et aI., 2006) and annexin IV (Chang et aI., 2007). It is 
proved that S 100All can associate with actin (Sakaguchi et aI., 2000; Zhao et aI., 2000), p-
tubulin (Broome and Eckert, 2004) and intermediate filaments (Bianchi et aI., 2003). 
S 1 OOA 11 also controls actin organization and causes the formation of the cells protrusions 
(Sakaguchi et aI., 2000). S 1 OOA 11 is shown to be essential for pseudopod protrusions and 
tumour cell migration and invasion. Knockdown of S 1 OOA 11 in metastatic cells resulted in 
reduced actin cytoskeleton dynamics and induction of mesenchymal-epithelial transition 
(MET) (Shankar et aI., 2010). 
Among the biological roles of S 1 OOA 11, a recent study demonstrates that it mediates 
hypoxia-induced mitogenic factor (HIMF)-induced smooth muscle cell migration, vescicular 
exocytosis and nuclear activation (Fan et al., 2011). In rat lung hypoxia resulted in 
transcriptional activation of the S100All promoter through hypoxia-inducible factor-l (HIF-
1) (Amano et al., 2003). 
More recently, the involvement of S 1 OOA 11 in DNA repair mechanisms has been 
demonstrated. Murzik et a1. (Murzik et aI., 2008) found a specific interaction of S I OOA 11 and 
Rad54B, a DNA-dependent ATPase, involved in recombinational repair of DNA damage. 
S100All/Rad54B foci are spatially associated with sites of DNA double-strand breaks 
(DSBs). Furthermore, downregulation of S 1 OOA 11 by siRNA abolished Rad54B targeting to 
DSBs and drastically reduced p21 WAFlICIPl protein levels, that are normally increased in 
cells undergoing DNA repair. Gorsler et al. (Gorsler et al. l 2010) found that DNA damage 
induces a nucleolin-mediated translocation of S 1 OOA 11 from the cytoplasm to the nucleus, 
resulting in the increase of p21 WAF lICIP 1 protein level. This translocation is impeded by 
101 
inhibition of the phosphorylation activity of PKCa. These observations suggest that 
regulation of the subcellular distribution ofSIOOAl1 plays an important role in DNA damage 
response and p21-mediated cell cycle control. 
There have been various speculations about the specific function of S I OOA 11 in cancer 
and tumour promoting, as well as tumour suppressor roles proposed. A tumour promoting 
role has been suggested by a large number of studies of different tumour types. 
In neoplasms such as colon cancer (Tanaka et al., 1995; Wang et al., 2008) , uveal 
malignant melanoma (Van Ginkel et al., 1998), and anaplastic large cell lymphoma (Rust 
et al., 2005). SIOOAll was highly expressed. SIOOAll expression was also found 
significantly increased in leiomyoma compared with myometrium and suppression of 
S100All by siRNA led to apoptosis in human uterine smooth muscle tumour cells 
(Kanamori et al., 2004). S100All could also sustain the cell growth of squamous 
carcinoma cell lines (Sakaguchi et al., 2008) and may be involved in prostate cancer 
development and progression (Rehman et aI., 2004). By gene expression analysis Mori et 
al. (Mori et al., 2004) found SIOOAli gene overexpressed in gastric adenocarcinoma 
specimens with respect to non-cancerous mucosa, and this was associated with the 
presence of lymph node metastasis. This suggested that SIOOAll gene expression status 
could be . useful to predict gastric cancers with lymph node metastases. By 
immunohistochemical analysis, a significant high level of S 1 OOA 11 in primary non small 
cell lung carcinoma (NSCLC) tissues was associated with higher tumour-node metastasis 
stage and positive lymph node status, suggesting SlOOAll involvement in promoting 
invasion and metastasis (Tian et al., 2007). lIao et al. found that both mRNA and protein 
levels of S 1 OOA II were overexpressed in adenocarcinomas (ADC) and squamous cell 
carcinomas (SCC) compared with paired non-cancerous lung tissues, while S 1 OOA 11 was 
detected downregulated in small cell lung cancers (SCLC). They found S 1 OOA 11 protein 
level increased in the sera of NSCLC patients. When SIOOAli was knocked down in lung 
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adenocarcinoma cells the cell proliferation was significantly inhibited in vitro and in vivo 
(Hao et aI., 2012). 
However, on the other hand, S100All could act as a tumour suppressor in some 
cancers. 
Kondo et aI. (Kondo et aI., 2002) found a decrease in the S 1 OOA 11 immunostaining levels in 
some tumours, such as lung, breast, kidney, prostate, uterus and testis. SIOOAII is also 
downregulated in esophageal squamous cell carcinoma (Ji et aI., 2004). In pancreatic 
tumours, it has been proposed that overexpression of S 1 OOA 11 may be an early tumourigenic 
event and then expression of S 1 OOA 11 may be decreased during subsequent progression to a 
more malignant phenotype (Ohuchida et aI., 2006). Low expression of S100All was 
associated with poor survival of bladder cancer patients, and its expression was suppressed 
during early development of bladder cancer (Memon et aI., 2005). In breast cancer, there is 
controversy regarding the expression pattern, subcellular localization and functions of 
SI00Al1. Kondo et aI. (Kondo et aI., 2002) found that the expression of SIOOAll was 
decreased in breast tumour cells and found a prevalent cytoplasmic staining in normal tissues. 
Cross et al. (Cross et aI., 2005) found that S100AI1 displayed increased expression in breast 
carcinoma and the subcellular localization changed from a strictly nuclear-localization in 
normal tissue to a more cytoplasmic-localization in tumour tissues suggesting that, in breast 
carcinomas, the loss of nuclear translocation may lead to the inability to control or suppress 
cell growth. 
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5.1.2. SIDDAll and thyroid cancer 
Different studies of gene expression profiling reported SIDDAll as a gene differentially 
expressed in thyroid carcinogenesis. Jarzab et al. (Jarzab et aI., 2005) found SIDDAll in a list 
of genes whose expression is increased in PTC in comparison with normal samples. In the 
analysis performed by 8tolf et al.(8tolf et aI., 2005), SIDDAll was found overexpressed in 
papillary carcinomas as compared to normal thyroid, adenomas and goiter. More recently, 
81 OOA 11 was found overexpressed in PTC with respect to benign thyroid tissue, however not 
included among genes able to discriminate between the follicular and classical variant of PTC 
(Finn et aI., 2007). 
Concomitantly with gene expression studies, 81 OOA 11 was also analysed by 
immunohistochemistry. By comparative 2-dimensional gel electrophoresis of microdissected 
cells from tumours and normal tissue, Torres-Cabala et al. (Torres-Cabala et aI., 2004) 
identified 81 OOA 11, among several proteins belonging to different categories, highly 
expressed in papillary thyroid carcinoma By immunohistochemical analysis, 810011 protein 
was found expressed in the nuclei of normal tissue, hyperplastic nodules and follicular 
adenomas and carcinomas, whereas PTC showed a strong, but cytoplasmatic, pattern of 
staining. These findings suggested that immunohistochemical staining of 81 OOA 11 could be 
helpful in the pathological assessment of thyroid lesions, especially in cases in which 
follicular variants of PTC and FTC are considered in the differential diagnosis. In a 
subsequent study, the same authors proposed 81 OOA 11, in association with galectin-l and 
galectin-3, helpful in discriminating between benign and malignant thyroid lesions (Torres-
Cabala et aI., 2006). 
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5.2 Aims of tlte cltapter 
The aim of this chapter is to study the involvement of SIOOAII in thyroid carcinogenesis. 
We tried to gain insight into the relevance of SIOOAll in PTC biology, performing 
analysis of gene expression data sets and functional studies in different cellular models. In 
particular, in the PTC-derived KI cell line we investigated: 
• the sub-cellular localization of S 1 OOA 11 ; 
• a possible interaction ofSIOOAII with the EGF/EGFR pathway; 
• the effect of RNA interference-mediated knockdown of S 1 OOA 11 expression, by 
performing in vitro and in vivo studies. 
In parallel, we assessed the effect of 8100A11 gene modulation on the transforming 
potential of the PTC-associated TRK-T3 oncogene in NIH3T3 cells, which represent a 
useful model for studying in vitro oncogene activity. 
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5.3 Results 
5.3.1. Expression analysis of Sl OOAll in PTC samples and PTC-derived cell lines 
SlOOAll expression has been proposed as a discriminating factor between benign and 
malignant thyroid disease (Torres-Cabala et ai., 2006). Expression level of SIOOAII gene 
was first investigated by analyzing cDNA microarray data previously produced in our 
laboratory. Data were obtained using RNA from a collection of 9 normal thyroid tissues 
(N) and 31 PTCs. Analysis of the expression levels of SIOOAII in all the samples showed 
that SIOOAII was significantly overexpressed in a large percentage of PTC cases (19 out 
of 32, 59.4 %) (p<0.01) (Figure 5.4). 
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a:: 
5100A11 _ N 
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Figure 5.4 eDNA array expres ion of SJOOAll gene. Graphic representation of the expression level in 
normal thyroid samples (N, green) and papillary thyroid carcinomas (PTC, blue). The expression level 
(relative expression, RE) of the SI OOA 1 1 gene in all the tissue samples hybridized on the array was measured 
as log ratio between the expression level of the specimens and that of the reference. Gene showing a positive 
log ratio value (ie more expressed in the thyroid sample than in the reference) is called upregulated; that with 
a negative log ratio value is called down regulated. 
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S] OOA]] expression In PTC was also analysed by performing metanalysis of several 
publicly available data sets. As shown in Figure S.S, in Jarzab (Jarzab et aI., 200S)(a), 
Huang (Huang et aI., 2001a) (b) and Reyes (Reyes, 2006) (c) data sets, a significant 
increased expression of S]OOAII (p<O.OS) was observed in PTC samples in comparison 
with controlateral normal tissues. In the Vasko data set (Vasko et aI. , 2007)(d), such 
increase of expression was statistically significant only comparing the invasive regions of 
PTCs with the corresponding normal region. Collectively, data obtained in our laboratory 
and meta-analysis strongly indicate that S] OOA II is frequently overexpressed in PTe. 
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Figure 5.5 Meta-analysis of SJOOAII gene expression levels in PTe in four different data sets. Data are 
reported as scatter plots of log2 values and med ian is recorded. In Jarzab (a) Huang (b) and Reyes (c) data 
sets S I OOA II expression was increased in PTC when compared with the normal thyroid in paired tissues 
samples ( ** p<O.O I or * p<O.05 by Wilcoxon paired test). In the Vasko data set (d) a statistically significant 
increase of S I OOA II express ion was found in the invasive regions of PTC in comparison with the 
corresponding normal region (** p<O.O I by Wilcoxon paired test) . 
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We analysed the expression of S100A11 mRNA in a panel of PTC-derived cell lines by 
reverse transcriptase-PCR (RT-PCR). The following cell lines were used: TPC1, NIM1, 
BCPAP and Kl. Except for TPC1 which carries RET/PTC1 oncogene, the other cell lines 
harbour the BRAFV600E mutation (details of the mutational status of these cell lines are 
reported in table 3.2 of material and methods section). As control, we used the Nthy-ori 3-1 
cells (N-Thy), normal human thyrocytes immortalized by the SV40 large T antigene, and 
normal thyrocytes (N), derived from normal thyroid tissue. 
The experiment reported in Figure 5.6a showed that SlOOAll mRNA was abundantly 
expressed in all PTC-derived cell lines, whereas it was barely detectable in the controls. 
The data were also confirmed by quantitative real time analysis (5.6b). 
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Figure 5.6 Detection of SlOOAll expression in a panel of PTe-derived cell lines a) S100All mRNA 
expression by RT-PCR analysis; GAPDH gene was used as loading control;b) SI00All mRNA expression 
by real time RT-PCR (N-Thy: NThy-Ori 3-1 cell line, N: normal thyrocytes); RO, relative quantity of 
S100All mRNA normalised for HPRT housekeeping gene expression) 
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5.3.2 Analysis of cellular localization of Sl OOAll 
Based on the results of SJ OOA 11 mRNA expression reported above, as a model for 
our studies we selected KI cell line, derived from a PTC, carrying the BRAFV600E 
mutation, and tumourigenic in nude mice as demonstrated in previous studies (Ferrario et 
a1.,2008). 
S 100All has been demonstrated to play different roles depending on its cellular 
localization. With respect to the thyroid, S 1 OOA 11 was found mostly nuclear in normal 
tissue, whereas cytoplasmic in PTC (Torres-Cabala et aI., 2004). To assess S100All 
localization in PTC-derived cell lines, we performed cellular fractioning of K 1 cells and 
investigated the presence of S 1 OOA 11 in nuclear and cytoplasmic fraction by western blot 
analysis with the anti-S 1 OOAll antibody. The quality of cytoplasmic and nuclear fractions 
was assessed using p-tubulin and NBS 1 antibodies, respectively. As shown in Figure 5.7 a, 
we found that S 1 OOA 11 localized in the cytoplasm and was absent in nuclear fraction of 
Kl cells. The cytoplasmic localization was also observed in other thyroid derived cell lines 
(data not shown). According to the model proposed by Sagakuci et al in human primary 
keratinocytes, an increase of extracellular Ca2+ or TGF-p stimulation promotes nuclear 
translocation of S 1 OOA 11 and consequently cell growth arrest through the induction of p21 
expression .. We then investigated whether in our cellular model S 1 OOAll was able to 
translocate into the nucleus upon Ca2+ or TGF-p stimulation. We treated Kl cells with 
different concentrations of Ca2+ (10 mM and 1.5 mM) for 6 hours and then performed cell 
fractionation. In untreated cells the SIOOAll protein was mainly present in the 
. cytoplasmic fraction, whereas after Ca2+ stimulus we observed a dose dependent increase 
ofSIOOAlllevel in the nuclear fractions (Figure 5.7 b). The analysis ofKl cells treated 
with Ca2+ 1.5 mM for different times showed an increase of S 1 OOA 11 protein in the 
nuclear fraction after 1 hour of treatment, followed by a slight decrease after 16 and 24 
hours. In parallel, the analysis of cytoplasmic fractions showed an opposite effect: after I h 
we observed a striking decrease of the amount of S 1 00Al1 protein up to a slight increase 
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at 16 and 24 hours (Figure 5.7 c). Concomitantly, we investigated the effect of Ca2+ 
stimulation on the expression of p21 and S 1 OOA 11 proteins. As shown in western blot 
analysis of whole cell extracts, the amount of both proteins remained unchanged after Ca2+ 
treatment (Figure 5.7 d). 
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Figure 5.7 Analysis of SIOOAI I localization after Ca2+stimulation. a) western blot ana lysis of S IOOA 11 
express ion after K I ce lls fraction ation (C: cytoplasmic fraction; N: nuclear fraction ; WE: whole protein 
extract) ; b) K I ce lls were treated for 6 hours at different Ca tt concentration ( 10 and 1.5 mM) and fract ionated 
for the analysis of S I OOA II expression .; c) S I OOA II express ion in K I nuclear fractions (left panel) and 
cytoplasmic fractions (right panel) after treatment with Ca· ' at the indicated time points. The quality of 
cytoplasmic and nuclear fractions was assessed using p-tubulin and NBS I (nucleolin for Figure b) antibodies, 
respectively; d) analysis of S 1 OA II and p21 expression in whole protein extracts of K I cells treated wi th 
Ca++ at the indicated time points. p-tubulin was used as load ing control for cell extracts. 
110 
In order to investigate the effect of TGF -p on S 1 OOA 11 localization, we treated K 1 
cells with TGF-p for I and 8 hours. Cell fractionation showed that in untreated cells and in 
cells treated for I hour, the S I OOA 11 protein was mainly cytoplasmic; after 8 hours of 
treatment, S 1 OOA II was equally found in nuclear and cytoplasmic fractions, indicating a 
nuclear translocation (Figure 5.8 a). NBS I and p-tubulin distributions are shown as control 
for nuclear and cytoplasmic fraction quality, respectively. Moreover, the treatment of K I 
cells with TGF-p at different time points did not alter the total protein levels of S 1 OOA II 
(5.8 b). As control , the increase of SMAD2 phosphorylation, indicating the efficacy of the 
TGF-p treatment, is shown (Figure 5.8 b). 
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Figure 5.8 Analysis of SJOOAll localization after TGF-p stimulation. a) KI cells were treated 
with TGF-~ (I Onglml) for 1 and 8 hours and fractioned for the analysis of S I DDA II express ion ( : 
cytoplasmic fraction ; N: nuclear fraction); the quality of cytoplasmic and nuclear fractions was 
assessed using ~-tubulin and NBS 1 antibodies, respectively; b) analysis of S I DDA II , pSMAD2 and 
SMAD2/3 protein expression after treatment of K 1 ce lls with TGF-~ (I Onglml) at the indicated 
time points. ~-actin was used as load ing control for ce ll extracts. 
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5.3.3 Analysis of interaction betwe~n S100All and EGFIEGFRpatltway 
According to the model proposed by Sagakuci et al in human primary keratinocytes, 
S100All could have a growth promoting role related to its involvement in the EGFIEGFR 
pathway. To investigate whether the cross-talk between SlOOAll and EGFIEGFR takes 
place also in thyroid tumour cells, we first analysed the effect of EGF on S 1 OOA 11 levels 
in KI cells. As shown in Figure 5.9 a, treatment of KI cells with EGF for different time 
points did not alter S 1 OOA II protein levels. To investigate whether S I OOA II affected the 
EGF-triggered signalling, we analysed the EGFR, AKT and ERK 112 phosphorylation in 
KI cells transiently transfected with SlOOAll-myc construct, treated or not with EGF. As 
control, untransfected and empty vector (EV) transfected cells were used (the details of 
SIOOAll-myc expression plasmid are reported in material and methods section). As shown 
in Figure 5.9 b (left panel), in untreated cells basal phosphorylation of EGFR, AKT and 
ERK 112 was not altered by SIOOAll overexpression. Similarly, cells overexpressing 
SIOOAll-myc protein showed comparable levels of EGF-induced EGFR, AKT and ERK 
112 phosphorylation as control cells. These data indicate the lack of the effect of S 1 OOA 11 
on EGF-triggered pathways. In keeping with this result, the activation of these pathways 
was not altered in S 1 OOA ll-silenced cells in comparison with the control (Figure 5.9 b, 
right panel). (Details for S lODA 11 silencing are reported in the next paragraph). The 
control of SIDDAll overexpression and downregulation in KI cells is shown in Figure 5.8 
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Figure 5.9 Analysis of interaction between S100All and EGF/EGFR pathway. a) western blot analysis 
S I OOA II expression aller treatment of K I ce lls with EGF (20 ng/ml) at the indicated time points, p-tubulin 
was used as loading control for ce ll extracts; b) western blot analysis of the EGFR, AKT and ERK 1/2 
phosphorylation of parental K I cells and K I cel ls transiently transfected wi th S I OOA II -myc construct (left 
panel) or S 100-si lenced K I ce lls (siS I 00) (right panel), treated or not with EG F (20ng/ml) for 20 minutes , 
(EV : empty vector, siNT (si Non Targeting), Total EGFR, ERK 1/2 and AKT were used as loading control of 
cell extracts; c) S I OOA II expression in K I cells transiently transfected with S I OOA II -myc construct and in 
S I OOA II -s ilenced K I ce lls. p-actin was used as loading control of cell extracts (the same panel was used in 
Figure5. 10) 
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5.3.4. Effect of SJOOAll silencing · 
5.3.4. I Transient silencing a/SIOOAI I 
In order to investigate the biological effect of SIOOAI I silencing, Kl cells were 
transiently transfected with specific S I OOA II small interfering RNAs (siS 1 00). As control , 
non targeting small interfering RNAs (siNT) were used. Western blot analysis showed that 
S I OOA 1 I protein was efficiently knocked-down after 72 hours from siRNAs transfection 
(Figure 5. 10 a). The analysis at different time points showed that the abrogation of 
S 1 OOA 11 expression was maintained at least until day seven after transfection. 
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Figure 5.10 Transient si lencing of SIOOA II in KI cells. Westem blot analysis of S I OOA 11 expression in 
K I ce lls transiently transfected with small interfering RNAs (siS I 00 and siNT (Non Targeting) as control. 
The analysis was carried out 72 hours (a) and 5 and 7 days after trans fection (b). ~-act in and ~-tubulin were 
used as loading control for ce ll ex tracts (the same panel a was used in Fi gure 5.9) 
To investigate whether the loss of S 1 OOA 11 expression affected cellular 
proliferation, Kl cells were transfected with siRNAs and cell growth analys is was 
performed after 72 hours and followed for a further 3 days. As shown in Figure 5.11 a 
S 1 OOA II -silenced K 1 cells (K 1 siS 100) displayed the same growth rate as control cells 
(Kl siNT). Flow cytometric analysis performed 72 hours after transfection showed that Kl 
siS] 00 cell s had a similar cell cycle di stribution in comparison with control cells (Figure 
5.11 b). 
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Figure 5.11 Effect of transient SlOOAll silencing on growth rate. a) proliferation of K1 cells transiently 
transfected with specific siRNAs (siSlOO and control siNT). The analysis was carried out after 72 hours of 
transfection and conducted for 3 days. The growth rate was determined by the alamarBlue Assay. At the 
indicated time points, the relative fluorescence unit (RFU) was determined and data were normalized for 
values at day 1; b) top: flow cytometric analysis of K1 cells after 72 hours from transfection with siS100 and 
siNT RNAs; percentage of cell cycle distribution is shown; bottom: the data represent the percentage average 
of cells in different stages of the cell cycle of three independent experiments. 
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The effect of S 1 OOA 11 silencing on Gell proliferation was also assayed by colony forming 
assay. K 1 siS 1 00 cells and K 1 siNT cells were plated at low density 96 hours after 
transfection and cultured for 7 days. No difference between the two samples was observed, 
as both produced colonies with similar efficiency and dimension. 
Collectively, these data indicate that the knockdown of S 1 OOA 11 protein does not 
affect K 1 cell growth 
K1 siNT K1 siS100 
Figure 5.12 Analysis of the effect of SI OOA 11 on growth rate by colony forming assay. K I cells were 
transfected with specific siRNAs (siS I 00 and siNT). After 96 hours from transfection, a total of 2000 cells 
were plated into 60mm Petri dishes; colonies were fixed and stained after 7 days. Representative pictures are 
reported. 
5.3.4.2 Stable silencing o/SIOOAI I 
We investigated the long term effect of a stable S I OOA II knockdown using short-
hairpin RNA technology. Kl cells were transfected with four independent expression 
vectors carrying the shRNA cassette specific for SI aOA JJ gene downregulation (sh I, sh2, 
sh3 and sh4) and a vector containing a non effective (scrambled) shRNA cassette (sh scr), 
as control, and analysed 3 days later. The most efficient silencing of S 1 OOA 11 was 
observed in K I-sh 1 and K I-sh2 cells, showing S 1 OOA 11 protein level reduced by 50% and 
82%, respectively, with respect to KI-sh scr cells (Figure 5.13 b). Cells were grown under 
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antibiotic selection and used for further studies. The S 1 OOA 11 knockdown was periodically 
monitored and found maintained at least for 80 days (data not shown). 
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Figu re 5.13 Knockdown of SIOOAI I expression in Kl cells. a) western blot analysis of SIOOAII 
expression in K I cells after 72 hours from transfection with sh I and sh2. A scrambled shRNA (sh scr) was 
used as control. p-actin was used as loading control for cell extracts; b) the graph represents the densitometric 
analys is of the bands. Data are reported as rat io of S I OOA I lip-actin and normalized for the sh scr value. 
Similarly to the analysis carried out for the transient S lOOA II si lencing, we next 
investigated the effect of the stable silencing of S IOOAl1 on cellular proliferation. As 
shown in Figure 5.14a, Kl-shl and Kl-sh2 transfected cells showed the same growth rate 
in comparison with the control (K I-sh scr) and the parental K 1 cells. In parallel , cells were 
analysed for the activation of the major signal transduction pathways by western blot. The 
same level of ERK. and AKT phosphorylation was observed in K I-sh 1 and -sh2 in 
comparison with the controls (Figure 5.14 b). 
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Figure 5.14 Analysis of stable SIOOAII silencing on growth rate. a) proliferation analysis of K1-sh1 and 
K1-sh2 cells. K1-sh scr and parental K1 cells were used as control. The growth rate was determined by the 
alamarBlue Assay. At the indicated time points, the relative fluorescence unit (RFU) was determined and 
data were normalized for values at day 1; b) western blot analysis of AKT and ERKl/2 phosphorylation in 
S100All-silenced cells. Total AKT and ERKl/2 were used as loading control for cell extracts. 
We investigated whether S100All was necessary for anchorage-independent growth 
of K1 cells by performing a soft agar assay with K1-sh1 and -sh2 cells and K1-sh scr cells 
as control. After 3 weeks of incubation, soft agar colonies were counted. As shown in 
Figure 5.15a, K1 -sh1 and -sh2 cells formed colonies with efficiency reduced (56%) with 
respect to control cells. Moreover, clones fonned by S100 silenced cells were smaller than 
those of the control cells. Representative pictures at different magnification are reported in 
Figure 5.15 b. 
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Figure 5.1 5 Anchorage-independent growth of stable S I OOA II -s ilenced KI cells. A total number of 2500 
ce lls were seeded in 60mm Petri dishes, After 3 weeks, the number of soft agar colonies was counted, a) 
Colony-forming efficiency was determined by the ratio between number of colonies and the number of plated 
ce lls, Asterisk indicates differences signi ficant by the Student's I-test (p<O,O I ); b) representative pictures of 
colonies at different magnification are reported 
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5.3.4.3 Effect o/stable SIOOAII silen~ing in mouse tumour xenografts 
To investigate possible in vivo effects of S 1 OOA 11 silencing, we tested the 
tumourigenicity of Kl-shl and -sh2 cells. As control, we used Kl-sh scr cells, displaying 
tumourigenicity similar to the parental Kl cell line (data not shown). Cells were 
subcutaneously injected into nude mice and results are summarized in table 5.1. Tumour 
bearing mice were 9/10 for Kl-sh scr sample, 10/10 and 8/10 for Kl-shl and -sh2 samples, 
respectively. All the samples showed a similar tumour latency. In Figure 5.16 a, tumour 
growth rate of each cell line is reported. Collectively, we did not observe any differences in 
tumourigenicity of SIDDAll-silenced cells in comparison with control cells. Twenty eight 
days after the injection, tumours were excised and analysed for SIDDAll expression. 
Western blot analysis showed that the SIDDAll silencing was maintained in Kl-shl and -
sh2 derived xenografts over this period (Figure 5.16 b). 
Table 5.1 In vivo tumour growth ofKl-shl, -sh2 and -sh scr cells 
eel/line 
K1- sh scr 
K1- sh1 
K1 sh-2 
tumour·bearing miee 
9/10 
10/10 
8/10 
DaysatO.1g 
17(14-20} 
13(11-24} 
13(11-15} 
Days at 1 g 
26(21->28} 
24(20->28} 
25(22-28} 
K I-sh 1, -sh2 and -sh scr cells (2.5 x 106) were inoculated subcutaneous into the left flank of 
athymic nude mice as described in Materials and Methods section. Tumour growth was assessed by 
evaluating tumour latency, ie days to reach 0.1 g, and by monitoring tumor weight (TW) twice a week. TW 
was estimated by the formula TW(g)=d2xD/2 where d and D are the shortest and the longest diameters of the 
tumour, respectively, measured in cm. 
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Figure 5.16 In vivo tumourigenicity assay. a) tumour growth after subcutaneously injection of Kl-shl , -
sh2, -sh scr cells into the left fl ank of athymic nude mice. Tumour growth was monitored twice a week fro m 
day 10 to day 28; Each data point represent the mean ± SD of 10, 8 and 9 primary tumours respectively; b) 
the expression of SlOOAll protein in tumour explants was determined by western blot. ~-actin was used as 
loading control of protein extracts. 
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5.3.5 Effect of S100All on the transforming potential ofTRK-T3 oncogene 
5.3.5.1 SIOOAll enhances "in vitro" TRK-T3 transforming activity 
In the previous paragraphs we described the effect of S100All silencing on 
tumourigenic properties of Kl, a PTC-derived cell line and carrying BRAFV600E 
mutation. Here we described an alternative approach aimed to determine the effect of 
SIOOAll gene modulation on the transforming potential of a PTC-related oncogene, 
namely TRK-T3. We first investigated the biological consequences of concomitant stable 
expression of TRK-T3 and SlOOAll in the NIH3T3 cellular system, which represents a 
useful model for studying in vitro oncogene activity. By performing focus forming assay, 
NIH3T3 cells were transfected with SIOOAll cDNA construct, producing a myc-tagged 
protein, and TRK-T3 cDNA construct, alone or in combination (details of these constructs 
are reported in material and methods section). For all the constructs similar transfection 
efficiency was observed (data not shown). 
As shown in Figure 5.17, TRK-T3 transfection was able to transform, as expected, 
NIH3T3 cells, as previously demonstrated in our laboratory (Roccato et aI., 2003); on the 
contrary, no transforming activity was detected for S100Al1. When SlOOAll was 
transfected in addition to TRK-T3, we observed the enhancement of the transforming 
capability of the latter. 
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Figure 5.17 Transforming activity of S100Ali and TRK-T3 proteins. NIH 3T3 cells were transfected 
with S I OOA II and TRK-T3 plasm ids. Empty vectors were used as control. All the constructs showed similar 
transfection efficiency. Focus formation assay was performed and representative plates derived from this 
experiment are shown. 
5.3.5.2 Biochemical and biological analysis ofT31S100 foci 
From the above focus forming assay, we isolated transformed foci expressing the 
exogenous TRK-T3 protein (T3 foci: 2A and 2F) and TRK-T3 protein in addition to 
S 1 OOA 11 protein (T3/S 1 00 foci . 60 and 6F) (Figure 5. 18 a ). No morphological 
differences among them were observed, since both of them displayed the typical NIH3T3 
transformed phenotype, marked by loss of contact inhibition and spindle-shaped 
morphology (data not shown). Immunodot blot assay of conditioned media with antibody 
against the myc-epitope showed that 6D and 6F cells secreted the S 1 OOA 11 protein (5 .18 
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b). We next characterized these transformed foci for the major signal transduction 
pathways. Western blot analysis showed that all the foci showed the same level of ERKs 
and AKT activation (5.18 c, d). 
a 
S100-myc b 
TRK-T3 S100-myc 
~tubulin 2A 2F 60 6F 
2A 2F 60 6F 
C d 
pERK 1/2 pAKT 
j ERK 1/2 AKT 
2A 2F 60 6F 2A 2F 60 6F 
Figure 5.18 Biochemical analysis of T3/SIOO foci. a) Western blot analysis of SIOOAII and TRK-T3 
expression in 2 (A,F) and 6(D,F) foci. ~-tubulin was used as loading control for cell extracts; b) dot blot 
analysis of S I OOA 11 secretion in conditioned media produced by transformed foci. Samples were normalized 
for cell number; c) and d) detection of ERK1I2 and AKT phospshorylation in transformed foci. Total ERK 
and AKT were used as loading control for cell extracts. 
Tb investigate whether S lOOAll affected cell proliferation, we determined the 
growth rate of the transformed foci. 2A and F foci, expressing TRK-T3 protein, and 6D 
and 6F foci, expressing both TRK-T3 and SlOOAll proteins, displayed the same growth 
rate (Figure 5.19). This result was also confirmed by flow cytometric analysis of 
transformed foci isolated from a previous and similar focus forming assay (data not 
shown). These data are in keeping with the lack of effect of S 1 OOA lIon cell proliferation 
previously observed in Kl cellular model. 
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Figure 5.19 Analysis of cell proliferation of T3/S100 foci. Proliferation of 2 (A,F) and 6 (D,F) cells 
determined by the alamarBlue Assay. At the indicated time points, the relative fluorescence unit (RFU) was 
determined and data were normalized for values at day 1. 
Several studies reported the importance of S100All on cell invasion. In order to 
investigate this issue, we performed invasion assay of 2F and 6F foci. Cells were allowed 
to invade through a matrigel coated transwell toward 10% FBS for 48 hours and 
subsequently measured through a fluorescence-based detection. As shown in Figure 5.20, 
6F cells displayed a 3.5 fold increase of invasion capability with respect to 2F cells, 
suggesting that SlOOAll enhances this property. 
2000 
1800 
1600 
1400 
:::J 1200 
U. 1000 a:: 
eoo 
600 
400 
200 
0 
2F 6F 
Figure 5.20 Invasion analysis of 2F and 6F cells. 2 x las cells were allowed to invade toward 10% FBS for 
48 hours. The invading cells were detected by using a fluorescent dye. Relative fluorescence unjt (RFU) was 
determined by the ratio between the fluorescence of invading cells and total cell number. The asterisk 
indicates differences significant by the Student's t-tcst (*p<O.Ol). 
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Then we investigated whether SIOOAll was also involved in the anchorage independent-
growth, as previously demonstrated in Kl cell study. A soft agar colony forming assay of 
2F and 6F foci was performed. After three weeks of incubation in soft agar, 6F cells 
formed colonies with efficiency 3.5 fold increased with respect to 2F cells (Figure 5.21 a). 
Moreover, 6F colonies showed an increase in size in comparison with the control. 
Representative pictures at different magnification are reported in Figure 5.21 b. 
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Figure 5.21 Anchorage-independent growth of 2F and 6F foci. A total number of 2 x 104 cells were 
seeded in 60mm Petri dishes . After 3 weeks, the number of soft agar colonies were counted. a) Colony 
forming efficiency was determined by the ratio between number of colonies and the number of plated cells. 
Asterisk indicates differences significant by the Student's (-test (p<O.O I); b) representative pictures of 
colonies at different magnification are reported. 
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5.3. 5. 3 Analysis of the tumourigenic capability ofT31S1 00 foci 
To gain more insight into the contribution of S 1 OOA 11 to the enhanced transforming 
potential of TRK-T3, an in vivo tumourigenicity assay was performed. Transformed 
NIH3T3 cells, expressing TRK-T3 (focus 2F) or TRK-T3 in association with SlOOA11 
(focus 6F), were injected into nude mice. The expression of TRK-T3 and Sl00All-myc 
proteins before injection was confirmed by western blot ( Figure 5.22). 
S100-myc 
TRK-T3 
..... B-tubulin 
2F 6F 
Figure 5.22 Analysis of 2F and 6F cells before injection in nude mice. Detection of S I OOA 11 and TRK-
T3 expression by western blot analysis. ~-tubulin was used as loading control for cell extracts. 
F or each cell line, different doses ( 2 x 105, 4 x 104, 1 x 104 cells) were used. As 
reported in table 5.2, the difference in tumourigenicity was more evident with the 
intermediate dose. As shown in figure 5.23 a, tumours produced by 6F cells grew faster 
than those by 2F cells. Representative pictures of tumour explants are reported in Figure 
5.23 b. Cell cultures were established from the explanted tumours. Western blot analysis 
confirmed the expression of SIOOAII and TRK-T3 proteins in tumour-derived cells 
(Figure 5 .23 c). 
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Table 5.2 In vivo tumour growth of T3/S100 foci 
2F 6F 
n.cells Takes days at Takes days at 
0.19 19 0.19 19 
2 x 105 6/6 13(11-14) 21(18-21) 6/6 11(10-13) 18(17-19) 
4 x 104 6/6 16.5(15-19) 23(22-25) 6/6 13.5(12-15) 20(17-23) 
1 x 104 6/6 20(17-23) 27.5(25-30) 5/5 18.5 (17 -20) 25(20-24) 
2F (TRK-T3 expressing NIH3T3 cells) and 6F (SlOOAll/TRK-T3 expressing NIH3T3 cells) were 
inoculated at different doses subcutaneously into the left flank of athymic nude mice as described in 
Materials and Methods section. Tumour growth was assessed by evaluating tumour latency, ie days to reach 
0.1 g, and by monitoring tumour weight (TW) twice a week. TW was estimated by the formula 
TW(g)=d2xD/2 where d and D are the shortest and the longest diameters of the tumour, respectively, 
measured in cm. 
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Figure 5.23 Tumour xenografts analysis. a) volumes of tumours derived from 2F and 6F cells injection 
(intermediate dose) in nude mice. Each data point represent the mean ± SD of six primary tumours. * p<O.Ol; 
b) representative pictures of tumour xenografts from mice 23 days from injection; c) western blot analysis of 
SlOOAll and TRK-T3 expression of cell cultures established from tumours induced by 6F and 2F foci in 
nude mice. p-tubulin was used as loading control for cell extracts. 
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5.4 Discussion 
Despite the many studies focusing on S 1 OOA 11, its role in cancer is still 
controversial. In fact, although a large amount of data supports the role of S 1 OOA 11 in the 
oncogenesis of several types of tumours; many authors propose S 1 OOA 11 as a tumour 
suppressor. 
In different studies of gene expreSSIOn, SlOOAll was found overexpressed in 
papillary thyroid cancer with respect to normal thyroid tissue. Moreover, Torres-Cabala et 
al. reported, by immunohistochemical analysis, a high S 1 OOA 11 expression in PTC. Even 
though these studies confirm a strong association between the S100Ali expression and the 
papillary histotype, the functional role of this protein in thyroid carcinogenesis is unknown. 
For this purpose, we studied the relevance of S100All in PTC biology by different 
approaches. 
Analysis of gene expressIOn data produced in our laboratory demonstrated a 
consistent upregulation of SlOOAll in PTC with respect to normal thyroid. Our results 
were corroborated by analysing four publicly available microarray data sets. The 
mechanism leading to the upregulation of S100All in tumours, and in particular, in 
thyroid cancers, is still unknown. The SlOO genes are clustered on human chromosome 
1 q21. Gain of this region is a recurrent chromosome aberration in many cancers, including 
thyroid (Kjellman et aI., 2001), and could be responsible for the overexpression of S 1 00 
proteins. 
We analysed a panel of PTC-derived cell lines, and found that all of them express 
high levels of SlOOAll mRNA. Among them, we focused on the Kl cell line as an in vitro 
model to investigate the contribution of S 1 OOA 11 upregulation to the thyroid tumour 
phenotype. Since an opposite role of SIOOAll it has been demonstrated, being pro-
tumoural when in the cytoplasm and tumour suppressor in the nucleus, we first checked its 
cellular localization. Interestingly, we found that in Kl cells, as well as in other PTC-
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derived cell lines, SIOOAll was mainly localized into the cytoplasm. This is in keeping 
with the observations of Torres-Cabala et al. who found a cytoplasmatic pattern of 
S 1 OOA II staining in PTC, and a nuclear staining in nonnal thyroid. We then asked 
whether in our model S I OOA 11 was retained into the cytoplasm and nuclear translocation 
was hampered. In agreement with the model proposed by Sakaguchi et al. for human 
nonnal keratinocytes, after treatment of Kl cells with Ca2+, we observed a nuclear 
translocation of SlOOAI1. However, conversely to the keratinocyte model, S100All 
translocation did not lead to an increase of the level of p2I, a negative regulator of cell 
growth. We demonstrated that also TGF-~ stimulation was able to promote the nuclear 
translocation of S 100A 11. These observations indicate that in K 1 cells this capability is 
preserved although not involved in the regulation of cell proliferation. 
The cytoplasmic function of S100All in our cellular model remains to be 
investigated. The importance of S 100All is known in cytoskeleton remodelling, 
pseudopodial fonnation and in epithelial to mesenchymal transition (Shankar et aI., 2010). 
The involvement of S 1 OOA 11 in these processes in thyroid tumour cells deserves further 
investigation. 
It has been demonstrated in human keratinocytes that a crosstalk between SIOOAII 
and the EGFIEGFR pathway exists, resulting in the promotion of cell growth. We did not 
observe an increase of SIOOAll mRNA and protein levels in KI cells treated with EGF. 
Moreover, overexpression or silencing of S 1 OOA 11 had no effect on the activation of the 
EGFR pathway following EGF stimulation. The absence of SIOOAII involvement in the 
enhancement of this pathway could have some explanations. First, it has been 
demonstrated that in K I, as well as in other thyroid cancer cell lines, a functional 
TGF AlEGFR autocrine signalling loop exists, and it sustains cell proliferation 
(Degl'Innocenti et aI., 2010). Second, the KI cell line, in addition to the BRAFV600E 
mutation, also carries the E542K mutation of the PI3KCA gene (Pilli et aI., 2009), leading 
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to a basal constitutive high level of Akt phosphorylation. Overall, the constitutive 
activation ofEGFR and Akt could overcome the moderate effect ofSl00Al1. 
To further study the function ofSl00All in thyroid cancer, we transiently and stably 
knocked-down S100All protein in Kl cells. With both approaches we did not observe any 
effect of S 1 OOA lIon K 1 growth rate, in keeping with the lack of effect of S 1 OOA lIon the 
expression of the negative growth regulator p21. Cells stably silenced for S 1 OOA 11 
showed no difference in the adhesion and migratory capability, but showed a significant 
anchorage-independent growth reduction. Finally, using mouse tumour xenografts, we 
observed that in vivo the Kl cells with silenced SlOOA11 grow at the same rate as the 
parental cell line. Even though we did not observe any differences in the growth of primary 
tumours, we could not exclude that S 1 OOA 11 silencing might affect the formation of 
distant metastasis as observed in other tumour types. Moreover, analysis of gene 
expression data sets of thyroid tumour samples could be taken into account in order to find 
a possible association of S 1 OOA 11 expression with clinical-pathological features, in 
particular the presence of metastases. To investigate the involvement of SIOOAll in the 
metastatic process with our experimental model, preliminary studies evaluating the 
metastatic potential of K 1 cells, and the employment of an appropriate in vivo metastasis 
assay will be required. 
Except for the reduction of anchorage-independent growth, on the whole we did not 
observe any effect of S 1 OOA 11 silencing in K 1 cells by our in vitro and in vivo studies, and 
this could be due to different reasons. One could be related to the efficiency of S I OOA 11 
knockdown, which although great might not be enough to observe a detectable effect. 
Furthermore, the lack of S 1 OOA 11 in our cellular context could be counterbalanced by the 
activation of compensatory mechanisms. Such mechanisms could involve other members 
of the S 1 00 family such as S 1 00A2 and S 100A4, associated with invasion and metastasis 
and overexpressed in thyroid cancer (Ito et al., 2005; Zou et al., 2005); or S I OOB, known to 
form heterodimers with S I OOA 11 and to associate with vimentin intermediate filaments 
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(Bianchi et al., 2003). In this respect, it would be worth investigating whether the 
expression of S 1 00 genes is concomitantly modulated in thyroid tumours and cell line. 
The second part of our studies focused on the investigation of a possible cooperation 
between the SlOOAll gene and PTC-associated oncogenes. By performing co-transfection 
experiments in NIH3T3 cells, we showed that the SlOOAll gene was able to enhance the 
transforming capability of the TRK-T3 oncogene. The characterization of transformed 
NIH3T3 foci expressing TRK-T3 alone or in combination with SIOOAll showed that the 
latter was not involved in the regulation of cell proliferation. Instead, S 1 OOA 11 was able to 
enhance the invasion and anchorage-independent growth triggered by TRK- T3 oncogene. It 
remains to investigate the mechanism through which S 1 OOA 11 modulates these 
capabilities. In vivo tumourigenicity assays revealed that the TRK-T3/SIOOAII expressing 
tumours showed significant increased growth in comparison with those expressing only 
TRK-T3. This striking effect could be attributed to SIOOAll secretion-related function. It 
has been demonstrated that in normal human keratinocytes and squamous cell carcinoma 
S 100All is secreted and promotes cell growth through the onset of a positive feedback 
loop with the EGFIEGFR pathway. Moreover, the enhancement of this pathway is also 
related to the SIOOAII promotion of different cytokines and other different EGFR ligands 
(Sakaguchi et al., 2008). It has also been demonstrated that a crosstalk between S 1 OOA 11 
and inflammation takes place in chondrocytes. Cytokines such as TNF-a and CXCL8 
upregulate S 1 OOA 11 secretion, which in tum promotes osteoarthritis progression through 
an increased collagen production. (Cecil et aI., 2005). Collectively, this information allow 
us to hypothesize that the effect of secreted S 1 OOA lIon tumour growth, inflammation and 
formation of the extracellular matrix, may be responsible for the enhanced tumourigenicity 
of TRK-T3 oncogene. Further studies, including histopathological analysis of tumour 
xenografts, are needed in order to validate these hypotheses. 
In summary, we found different effects of the SIOOAll modulation in two different 
cellular models. In the Kl cell line we observed that SIOOAll was localized both in 
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cytoplasm and in the nucleus. The latter localization did not influence the levels of p21, a 
negative regulator of cell growth. Moreover, the S100All involvement in the EGFIEGFR 
pathway was not detectable. The effect of S lOOAll silencing was evident on the 
anchorage-independent growth, while not affecting the in vitro and in vivo cell growth, 
suggesting that S100All modulation differently affects the various tumour cell properties. 
Using the other model, the NIH3T3 cells, we observed that SlOOAll was able to 
enhance the transforming capability of TRK-T3. Although performed in an experimental 
model, these data highlight the capability of S 1 OOA 11 to cooperate with PTC-associated 
oncogenes. 
In summary, by comparing the results obtained in the two models, several analogies 
emerge, as well as some differences. In both cases, in vitro cell growth was unaffected 
whereas anchorage-independent growth was affected. However, in vivo tumour growth was 
increased only in the NIH3T3 model. These differences can be ascribed to the different 
cellular context. As reported above, in K 1 cells the effect of S 1 OOA 11 could be masked by 
the activation of compensatory mechanisms, at variance with the NIH3T3 model. 
Furthermore, it has been clearly shown by others that S 1 OOA 11 can display different 
functions on cellular types and tumours. 
In conclusion, our work indicates a role of S 1 OOA 11 in thyroid cancer, whose full 
elucidation requires more efforts in order to assess whether its modulation could result in a 
therapeutic strategy. 
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6. CITED 1 studies 
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6.1 Introduction 
6.i.i CiTEDi (CBP/p300-interacting Transactivators with glutamic acid (E) and aspartic 
acid (D)-rich C-terminal domain i). 
CITEDl (also named melanocyte-specific gene 1 (MSGi) since initially believed to 
be melanocyte-specific), is a part of family of transcriptional cofactors that regulates 
diverse CBP/p300 transcriptional responses. CITEDl enhances transcriptional responses 
involving TGF-WSmad4 and it also functions as a selective coactivator for estrogen-
dependent transcription (Yahata et aI., 2000; Yahata et aI., 2001). These effects are 
dependent on interactions between CITEDl and CBP/p300. Moreover, the transcriptional 
activity of CITED 1 is regulated by phosphorylation in a cell cycle-dependent manner (Shi 
et aI., 2006). 
Expression analysis suggests that CITED1 may playa role in the pathogenesis of 
tumours such as malignant melanoma (Sedghizadeh et aI., 2005), Wilms tumour (Lovvorn 
et aI., 2007) and PTC (Prasad et aI., 2004). In particular, in different microarray studies 
CITED1 was found overexpressed in PTC (Jarzab et aI., 2005; Prasad et aI., 2004). 
Moreover, Aldred et al. reported that CITED1 belongs to a list of five genes (CITED1, 
CAVl, CAV2, IGFBP6 and CLDNI0) capable of distinguishing between PTC and FTC 
(Aldred et aI., 2004). It was also proposed as a highly sensitive and specific diagnostic 
marker, useful in differentiating PTC from benign and malignant thyroid tumours (Ducena 
et aI., 2011). CITED 1 , in association with Galectin-3, fibronectin-l, HBME1 and 
cytokeratin-l9 has been proposed for the differential diagnosis of thyroid tumours (Prasad 
et aI., 2005). The mechanism leading to upregulation of CITED1 gene expression in PTC 
compared to normal thyroid is still unclear. Sassa et al. reported a positive association of 
BRAF mutation with CITEDl overexpression, concomitantly to hypomethylation of the 
CpGs in the promoter region ofCITED1 gene (Sassa et aI., 2011). 
6.1.2 Aims ofCITED1 studies 
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A large number of studies reported the importance of CITEDl in thyroid 
carcinogenesis and, in particular, in the ' papillary histotype. To gain more insight into the 
role of CITEDl in this neoplasia, we planned to follow different approaches including the 
analysis of gene expression data sets and functional studies. Our aims are to: 
l) validate our gene expression data; 
2) analyse the effect of CITED1 gene silencing in a selected tumour cell line; 
3) investigate the effect of CITED 1 on transforming activity of PTC-associated oncogenes. 
6.2 Preliminary results 
1) We explored the expression level of the CITED1 gene by analyzing cDNA 
micro array data produced in our laboratory. The sample collection was the same used for 
TIMP3 and S100Al! analysis. As reported in Figure 6.1, the expression levels of CITED1 
are upregulated in a great proportion of PTC in comparison with normal thyroid tissue (N) 
(paired t-test p < 0.01). These findings are in keeping with the data on CITED1 
overexpression in PTC reported by a large number of gene expression and 
immunohistochemical studies. 
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Figure 6.1 eDNA array expression of CITEDI gene. Graphic representation of the expression level in 
normal thyroid samples (N, red) and papillary thyroid carcinomas (PTe, blue). The expression level (relative 
expression, RE) of the C1TEDJ gene in all the tissue samples hybridized on the array was measured as log 
ratio between the expression level of the specimens and that of the reference. 
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2) An expression analysis of the. CITED 1 gene in a panel of thyroid cell lines has 
been performed (Figure 6.2). We investigated the expression of SIOOAll by reverse 
transcriptase-PCR (RT-PCR) in the following cell lines: TPCI , NIMI , BCPAP and Kl. 
Except for TPCI, which carries RET/PTCl oncogene, the other thyroid tumour cell lines 
are characterized by the BRAFV600E mutation. As a control, we used the Nthy-ori 3-1 
cells (N-Thy), normal human thyrocytes immortalized by the SV40 large T antigene, and 
normal thyrocytes (N) derived from normal thyroid tissue. The aim was to select a cell line 
that overexpresses this gene and then to validate a siRNA sequence against CITEDl. 
BCPAP and KI cell lines, could be considered good candidates for our studies. Reagents 
for silencing of this gene have been selected and will be tested shortly. 
'. . . '_'," ". ,'> :T',,\'l'if,'r'j"f;.,. :; .' . 
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Figure 6.2 CITED} mRNA expression by RT-PCR. Analysis ofa panel ofPTC-derived cell lines; GAPDH 
gene was used as loading control; (N-Thy: N-Thy-Ori 3-1 cell line, N: normal thyrocyte) 
3) We produced CITEDl-myc expression vectors as tools for the proposed functional 
studies. CITED} cDNA has been amplified from HeLa cells and cloned into pcDNA3 or 
pIres vectors, both carrying the myc epitope (details of these plasm ids are reported in 
material and methods section). cDNA constructs have been transiently transfected into 
HEK293T cells and shown to express the expected protein by western blot analysis with 
anti-myc antibody (Figure 6.3). 
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Figure 6.3 Expression of CITEDl-myc protein in HEK293T cells. Cells transiently transfected with 
pcDNA3-CITEDlmyc andplRES-CITEDlmyc constructs were analysed by western blot for the expression of 
CITED 1 myc protein using anti-myc antibody. As a control, empty vector (EV)-transfected HEK293T cells 
were used. ~-tubulin was used as loading control for cell extracts. 
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7.IGFBP7 studies 
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7. Insulin-like growth factor-binding protein 7 ( IGFBP7) 
As anticipated in the aim of the thesis section, our studies were also addressed to the 
investigation of the role of Insulin-like growth factor-binding protein 7 (lGFBP7), one of 
the genes whose expression was differentially regulated in PTC with respect to normal 
thyroid. Even though not strictly related to the PhD project, this analysis is part of a larger 
study conducted by our laboratory, aimed at the dissection of the role of genes 
differentially expressed in thyroid carcinogenesis, in which the candidate collaborated. 
The results are hereafter summarized. 
IGFBP7, also called IGFBP-rPI or MAC25, is a member of the IGFBP superfamily, 
including 16 secreted proteins binding IGFs with variable affinity (Burger et aI., 2005). 
IGFBP7 binds IGFs with low affinity, but in contrast, recognizes insulin with high affinity, 
and thereby modifies its metabolism, distribution, and ability to bind to the insulin receptor 
(Yamanaka et aI., 1997). IGFBP7 has also IGF/insulin-independent actions. 
A large body of evidence suggests that IGFBP7 functions as an oncosuppressor gene 
in human prostate, breast, lung and colorectal cancer, as it regulates cell proliferation, cell 
adhesion, cellular senescence, and angiogenesis (Akaogi et aI., 1996; Burger et aI., 2005; 
Chen et aI., 2007; Ruan et aI., 2006; Sato et aI., 2007; Sprenger et aI., 1999; Wilson et aI., 
2002). IGFBP7 is silenced by promoter hypermethylation in several neoplastic tissues, 
including colorectal and gastric cancers (Ahmed et aI., 2003; Kanemitsu et aI., 2000; Lin et 
aI., 2007). More recently, IGFBP7 has been shown to mediate senescence in melanocytes, 
and to suppress melanoma growth in vivo by inducing apoptosis (Wajapeyee et aI., 2008). 
In our laboratory, we investigate the role of IGFBP7 in PTC. Analysis of expression 
levels in microarray datasets highlighted that IGFBP7 was downregulated in a consistent 
fraction of PTC, with respect to normal thyroid. To address the functional consequences of 
IGFBP7 downregulation we used the PTC-derived NIMI cell line, in which the expression 
of IGFBP7 is lacking. Exposure to soluble IGFBP7 protein or restoration of IGFBP7 
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expression by cDNA transfection reduced growth rate, migration, anchorage independent 
growth and tumourigenicity of NIMl cells. We provide evidence that the effects of 
IGFBP7 are related to apoptosis. We also performed immunohistochemical analysis for 
IGFBP7 expression in thyroid tumour samples including microcarcinomas, PTCs and 
ATCs. We found that microcarcinoma expressed high levels of IGFBP7 whereas PTC 
expressed variable (from low to moderate) levels. Significantly, expression of IGFBP7 was 
not detectable in ATC. These data indicate that IGFBP7 protein expression is progressively 
lost during thyroid tumour progression. 
Overall, our data suggest that IGFBP7 gene exerts an oncosuppressor role in thyroid 
epithelial carcinogenesis. 
Details of the study can be found in the attached reprint of the papers: 
1) MG Vizioli et al. (2010): "IGFBP7: an oncosuppressor gene in thyroid 
carcinogenesis" Oncogene 29(26), 3835-44;); 
2) MG Vizioli et al. (2011) "Evidence of oncogene-induced senescence in thyrOid 
carcinogenesis" Endocr Relat Cancer, Dec 1; 18(6):743-757;) 
141 
8. General discussion and future plans 
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8. General discussion andfuture plans 
Papillary thyroid carcinoma (PTC) is characterized by specific and well known 
alterations, all converging on the activation of the RTKJRASIBRAFIMAPK pathway. Even 
though the identification of these alterations has provided a great contribution to the 
understanding of PTC pathogenesis, the molecular mechanisms underlying the 
development . of these neoplasias are still far from being completely elucidated. In 
particular, the role of tumour suppressor genes in thyroid malignancies is not completely 
understood. 
In the past few years microarray technology has become a powerful tool to analyse 
global gene expression profiles and has provided answers to fundamental questions 
regarding tumour biology, early detection, prognosis and follow-up. Several groups have 
determined the gene expression profile of thyroid tumours. These studies allowed 
discrimination between benign and malignant lesions, and between PTC and FTC. In 
addition to the identification of diagnostic and prognostic markers, gene expression has the 
potential to unveiling genes involved in the pathogenesis of thyroid tumours and possible 
new therapeutic targets. Recent reports highlight the power of gene expression analysis as 
a tool for the identification, among others, of putative oncosuppressor genes. Some genes 
identified as down-regulated in the context of gene expression studies, were classified as 
tumour suppressors by functional studies, as their re-expression modulated transformed 
properties of thyroid carcinoma cell lines. Restoration of MTI G (Ferrario et aI., 2008), 
CBX7 (Pallante et aI., 2008), and ABI3BP (Latini et aI., 2008) in thyroid tumour cell lines 
lacking their expression affected cell growth and transformed properties. On the other 
hand, gene expression analyses of thyroid cancer identified the upregulation of several 
genes, involved in different cellular functions such as adhesion, signal transduction, EMT 
and inflammation, subsequently found to act as tumour promoters. TWISTI and Polo-like 
Kinase 1 were found upregulated in anaplastic thyroid carcinoma (ATC) and shown to 
exert a tumour promoter role. In particular, functional studies revealed that TWIST 1 plays 
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important roles in determining the anaplastic thyroid cancer phenotype, in terms of 
promotion of cell migration, invasion 'and resistance to apoptosis (Salerno et al., 2011), 
whereas functional studies showed that Polo-like Kinase 1 is involved in cell 
transformation and is proposed as a promising target for the molecular therapy of ATe 
(Nappi et aI., 2009). 
Based on the evident importance of functional studies for the discovery of new 
players in thyroid carcinogenesis, we decided to start from a gene expression analysis of 
thyroid tumour samples in order to identify putative tumour suppressor or tumour promoter 
candidates. In this work, we decided to dissect the functional role of Tissue Inhibitor of 
Metalloproteases-3 (JIMP-3), S] OO/calgizzarin and CITED] (CBPlp300-lnteracting 
Transactivators with glutamic acid (E) and aspartic acid (D) rich C-terminal domain ]) 
genes for which a role in the pathogenesis of PTe was also suggested by recently 
published gene and protein expression data. In our micro array analysis, these genes were 
found differentially expressed in PTe compared to normal thyroid tissue. The study of 
these selected genes allowed us to obtain important information about their role in PTe. 
Using an integrated approach, including analysis of gene expression data and 
functional studies, we demonstrated that TIMP3 exerts a negative regulatory role in thyroid 
carcinogenesis. In addition to the inhibitor role on migratory and invasive capabilities of 
the PTe-derived NIMI cells, our data showed that the most striking effect of TIMP3 was 
observed in vivo, as it reduced the NIM 1 tumourigenicity by repressing angiogenesis and 
macrophage infiltration. Our future plans are to better dissect the mechanisms through 
which TIMP3 is able to modulate the inflammatory microenvironment. Even though the 
reduction of inflammation could be generally attributed to the negative role of TIMP3 on 
angiogenesis and on the reduction of the pro-inflammatory TNF-alpha cytokine shedding, 
we think that, in addition to these general mechanisms, TIMP3 might act through the 
involvement of other thyroid specific mediators. To clarify this issue, the characterization 
of soluble molecules produced by NIMl, in the presence or the absence of TIMP3, will be 
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undertaken. In conclusion, some authors reported that TIMP3 overexpression in tumour 
cells suppress primary tumour growth and angiogenesis, indicating its involvement in the 
earliest aspect of tumour development. On the other hand, it has been demonstrated a 
decreased TIMP3 expression at the invasive front of tumour, suggesting that its regional 
loss may facilitate tumour invasion and metastasis. All these data suggest as TIMP3 may 
contribute to all stages of malignant progression. In the context of thyroid tumours the 
dowregulation of TIMP3, concomitant with the BRAF mutation, is associated with several 
aggressive features of PTC, including extrathyroidal invasion, lymph node metastasis, 
multifocality and advanced tumour stages. On the basis these evidences, TIMP3 could be 
considered a good prognostic marker of PTC. 
The second part of the thesis dealt with the dissection of the role of S 1 DDA 11 in PTC. 
Functional studies revealed that S lODAll could have different functions depending on 
cellular context. In K 1 cells, we found the finely tuning of S 1 DDA 11 expression might 
modulate some cellular capabilities such as anchorage-independent growth, whereas no 
effect was observed on cellular proliferation and in vivo tumourigenicity. Our future plans 
are to investigate whether SIDDAll might be involved in other important cellular 
processes such as the remodelling of cytoskeleton and the epithelial to mesenchymal 
transition, features which could be related to cellular invasive and metastatic capabilities. 
Moreover, we plan to perform meta-analysis of publicly available gene expression data 
sets of thyroid tumours in order to investigate a possible association of S 1 DDA 11 
expression with clinical-pathological features, such as presence of metastases. We 
hypothesize that effect of S 1 DDA 11 modulation on K 1 cells could be masked by the 
presence of other members of the S 1 DDA family, such as S lODA4 and S 1 DDA2 which are 
found overexpressed in PTC. In this respect, we plan to investigate whether members of 
S 1 DD family are concomitantly modulated in thyroid tumour and cell lines. On the other 
hand, co-transfection studies in NIH3T3 cells allowed us to observe a cooperation between 
SIDDAll and TRK-T3 oncogene. We plan to carry out more detailed studies in order to 
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investigate how this cooperation occurs. Moreover, we are also interested in understanding 
whether this cooperation is specific for'TRK-T3 oncogene or is common to the other PTC-
associated oncogenes. Since the striking effect of SIDDAll was found in the turnourigenic 
capability of transformed NIH3T3, our aim is to verify whether it could be attributed to the 
secretion-related function of SIDDAll, known to be involved in the regulation of growth 
promotion, inflammation and formation of extracellular matrix. Our plan is to perform 
histopathological analysis of mouse tumour xenografts of transformed NIH3T3 in order to 
validate these hypotheses. Even though from our studies the role of S 1 DDA 11 role has only 
been partially elucidated, some evidences indicate as S 1 DDA 11 could be involved in 
conferring to the cell a transformed phenotype, such as the capability to grow in an 
anchorage-independent manner, thus suggesting a putative role of S 1 DDA 11 in the 
metastatic process. In keeping with this, some authors reported as SlODAll is 
overexpressed in primary tumours with metastatic potential. 
On the whole, our studies contributed to the dissection of the role of these genes in 
thyroid carcinogenesis. In particular, the modulation of TIMP3 and S 1 DDA 11 expression 
was involved in the alteration of important processes such as adhesion, invasion and EMT, 
in keeping with the concept that PTC are characterized by the modulation of genes 
belonging to these onthology classes. So, through different mechanisms, the loss ofTIMP3 
in addition to the overexpression of SIDOAll, could act together to modulate the PTC 
phenotype. We hypothesize that the major contribution of these molecules could reside in 
the stage of progression from primary tumour to distant metastases, even though we can 
not exclude their importance in the promotion of primary tumour onset. From a clinical 
point of view, it would be interesting to investigate whether in PTC samples the TIMP3 
downregulation is associated with the concomitant S 1 OOA 11 overexpression and whether 
they could be considered possible prognostic markers of PTC. 
Many studies reported the involvement of CITEDI in PTC biology. All of them 
analysed the expression level of CITED 1, suggesting a putative tumour promoter role in 
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the context of thyroid cancer. Moreover, some authors proposed it as a powerful diagnostic 
marker of PTC. Our aims are to' better dissect mechanisms leading to CITED 1 
overexpression, to investigate its effect on transforming activity of PTC-associated 
oncogenes and the effect of its silencing on the phenotype of a PTC-derived cellular 
model. 
In conclusion, our studies allowed the identification of specific cellular properties in 
which TIMP3 and S 1 OOA 11 are involved. The function of CITED 1 remains to be 
investigated. Even though more efforts to better elucidate their functional role are needed, 
our studies revealed that they might be considered important players in the complex 
network of alterations of thyroid carcinogenesis. 
The value of this study, from a translational stand point, lies in identifying putative 
biomarkers of PTC. Further studies are needed to evaluate whether these genes could be 
considered a "molecular signature" that could be associated with clinical outcome 
(prognosis), recurrance and survival or putative new targets for thyroid cancer treatment. 
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